{"PMC7351639": [["IntroductionAccording to a recent international observational study, acute respiratory distress syndrome (ARDS) is reported in up to 10% of total intensive care admissions and 20% of all patients who require mechanical ventilation [1].", [["respiratory", "ANATOMY", 75, 86], ["acute respiratory distress syndrome", "DISEASE", 69, 104], ["ARDS", "DISEASE", 106, 110], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["a recent international observational study", "TEST", 25, 67], ["acute respiratory distress syndrome", "PROBLEM", 69, 104], ["ARDS", "PROBLEM", 106, 110], ["mechanical ventilation", "TREATMENT", 208, 230], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["respiratory distress", "OBSERVATION", 75, 95]]], ["Mechanical ventilation remains a cornerstone of ARDS management [2, 3] as it improves the severe hypoxemia and reduces the work of breathing.", [["ARDS", "DISEASE", 48, 52], ["hypoxemia", "DISEASE", 97, 106], ["Mechanical ventilation", "TREATMENT", 0, 22], ["ARDS management", "TREATMENT", 48, 63], ["the severe hypoxemia", "PROBLEM", 86, 106], ["the work of breathing", "PROBLEM", 119, 140], ["ventilation", "OBSERVATION", 11, 22], ["ARDS", "OBSERVATION", 48, 52], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["hypoxemia", "OBSERVATION", 97, 106]]], ["However, the mechanical forces (pressure, volume, and flow) generated by the interactions between the ventilator and the respiratory system can further damage the lung, a process known as ventilator-induced lung injury (VILI) [4].", [["respiratory system", "ANATOMY", 121, 139], ["lung", "ANATOMY", 163, 167], ["lung", "ANATOMY", 207, 211], ["ventilator-induced lung injury", "DISEASE", 188, 218], ["VILI", "DISEASE", 220, 224], ["lung", "ORGAN", 163, 167], ["lung", "ORGAN", 207, 211], ["the mechanical forces (pressure, volume", "TREATMENT", 9, 48], ["the ventilator", "TREATMENT", 98, 112], ["lung injury", "PROBLEM", 207, 218], ["mechanical forces", "OBSERVATION", 13, 30], ["pressure", "OBSERVATION_MODIFIER", 32, 40], ["respiratory system", "ANATOMY", 121, 139], ["lung", "ANATOMY", 163, 167], ["lung", "ANATOMY", 207, 211], ["injury", "OBSERVATION", 212, 218]]], ["To limit VILI, several recommendations based primarily on the tidal volume [5], driving pressure [6], and positive end-expiratory pressure (PEEP) have been put forward [7].", [["the tidal volume", "TREATMENT", 58, 74], ["driving pressure", "TEST", 80, 96], ["positive end-expiratory pressure (PEEP", "TREATMENT", 106, 144], ["expiratory pressure", "OBSERVATION", 119, 138]]], ["More recently, the inspiratory flow [8] and respiratory rate [9] have also been recognized as possible factors promoting VILI.IntroductionTo combine all these elements in a single physical variable, Gattinoni et al. proposed the concept of mechanical power (MP) to estimate the contribution of the various ventilator-related causes of lung injury [10].", [["lung", "ANATOMY", 335, 339], ["lung injury", "DISEASE", 335, 346], ["lung", "ORGAN", 335, 339], ["the inspiratory flow", "TEST", 15, 35], ["respiratory rate", "TEST", 44, 60], ["mechanical power (MP)", "TREATMENT", 240, 261], ["lung injury", "PROBLEM", 335, 346], ["VILI", "OBSERVATION", 121, 125], ["various ventilator", "OBSERVATION", 298, 316], ["lung", "ANATOMY", 335, 339], ["injury", "OBSERVATION", 340, 346]]], ["MP is the energy delivered to the respiratory system over time, which is the product of the absolute proximal airway pressure and related changes in volume and respiratory rate [10].", [["respiratory system", "ANATOMY", 34, 52], ["airway", "ANATOMY", 110, 116], ["respiratory", "ANATOMY", 160, 171], ["MP", "DISEASE", 0, 2], ["MP", "GENE_OR_GENE_PRODUCT", 0, 2], ["airway", "MULTI-TISSUE_STRUCTURE", 110, 116], ["the absolute proximal airway pressure", "TREATMENT", 88, 125], ["related changes in volume", "PROBLEM", 130, 155], ["respiratory rate", "TEST", 160, 176], ["respiratory system", "ANATOMY", 34, 52], ["proximal", "ANATOMY_MODIFIER", 101, 109], ["airway pressure", "OBSERVATION", 110, 125]]], ["Animal data showed that increasing MP was associated with an increase in lung edema and lung damage [11\u201313].", [["lung", "ANATOMY", 73, 77], ["lung", "ANATOMY", 88, 92], ["MP", "DISEASE", 35, 37], ["lung edema", "DISEASE", 73, 83], ["lung damage", "DISEASE", 88, 99], ["MP", "GENE_OR_GENE_PRODUCT", 35, 37], ["lung", "ORGAN", 73, 77], ["lung", "ORGAN", 88, 92], ["Animal data", "TEST", 0, 11], ["increasing MP", "PROBLEM", 24, 37], ["lung edema", "PROBLEM", 73, 83], ["lung damage", "PROBLEM", 88, 99], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["lung", "ANATOMY", 73, 77], ["edema", "OBSERVATION", 78, 83], ["lung", "ANATOMY", 88, 92], ["damage", "OBSERVATION", 93, 99]]], ["Furthermore, two studies in patients with and without ARDS found that MP computed during the first days of mechanical ventilation was independently associated with mortality, which rose significantly above a certain level of MP [14, 15].", [["ARDS", "DISEASE", 54, 58], ["MP", "DISEASE", 70, 72], ["MP", "DISEASE", 225, 227], ["patients", "ORGANISM", 28, 36], ["MP", "GENE_OR_GENE_PRODUCT", 70, 72], ["MP", "GENE_OR_GENE_PRODUCT", 225, 227], ["patients", "SPECIES", 28, 36], ["two studies", "TEST", 13, 24], ["ARDS", "PROBLEM", 54, 58], ["MP", "TEST", 70, 72], ["mechanical ventilation", "TREATMENT", 107, 129]]], ["Nevertheless, although MP can be used at the bedside, it is rather cumbersome to be calculated, a factor that heavily hinders its use in clinical practice [8, 16, 17].IntroductionTwo methods can be employed to calculate MP, a direct measurement, as the dynamic inspiratory area of the airway pressure and volume curve during the respiratory cycle (i.e., the geometric method), or using equations.", [["airway", "ANATOMY", 285, 291], ["respiratory", "ANATOMY", 329, 340], ["MP", "DISEASE", 23, 25], ["MP", "GENE_OR_GENE_PRODUCT", 23, 25], ["MP", "GENE_OR_GENE_PRODUCT", 220, 222], ["airway", "MULTI-TISSUE_STRUCTURE", 285, 291], ["MP", "TEST", 23, 25], ["a direct measurement", "TEST", 224, 244], ["the airway pressure", "TEST", 281, 300], ["volume curve", "TEST", 305, 317], ["the respiratory cycle", "TEST", 325, 346], ["airway pressure", "OBSERVATION", 285, 300]]], ["One of the first equations proposed to compute the MP requires the knowledge of several elements such as the tidal volume, respiratory rate, elastance, resistance, and inspiratory time [10], variables for which an inspiratory hold is necessary in order to adequately distinguish between the resistive and the elastic components of airway pressure.", [["airway", "ANATOMY", 331, 337], ["MP", "DISEASE", 51, 53], ["MP", "GENE_OR_GENE_PRODUCT", 51, 53], ["airway", "MULTI-TISSUE_STRUCTURE", 331, 337], ["the tidal volume", "TEST", 105, 121], ["respiratory rate", "TEST", 123, 139], ["airway pressure", "TEST", 331, 346], ["tidal volume", "OBSERVATION", 109, 121], ["respiratory rate", "OBSERVATION", 123, 139], ["resistive", "OBSERVATION", 291, 300], ["elastic", "OBSERVATION_MODIFIER", 309, 316], ["airway pressure", "OBSERVATION", 331, 346]]], ["In order to facilitate the calculation of MP, the original equation was proposed in a simplified form requiring only the measurement of airway plateau pressure, PEEP, and tidal volume.", [["airway", "ANATOMY", 136, 142], ["MP", "GENE_OR_GENE_PRODUCT", 42, 44], ["airway", "MULTI-TISSUE_STRUCTURE", 136, 142], ["airway plateau pressure", "TEST", 136, 159], ["PEEP", "TREATMENT", 161, 165], ["tidal volume", "TEST", 171, 183], ["airway", "ANATOMY", 136, 142], ["plateau pressure", "OBSERVATION", 143, 159], ["tidal volume", "OBSERVATION", 171, 183]]], ["With the same aim, Giosa et al. [18] described an even simpler equation which did not require an inspiratory hold, trading a small degree of accuracy to allow the continuous display by the ventilator with no action from the clinician.", [["the ventilator", "TREATMENT", 185, 199], ["small degree", "OBSERVATION_MODIFIER", 125, 137]]], ["However, both these equations can be used only during volume-controlled ventilation with constant inspiratory flow in sedated patients with no spontaneous respiratory drive.", [["respiratory", "ANATOMY", 155, 166], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["volume-controlled ventilation", "TREATMENT", 54, 83], ["constant inspiratory flow", "TREATMENT", 89, 114], ["spontaneous respiratory drive", "PROBLEM", 143, 172], ["inspiratory flow", "OBSERVATION", 98, 114], ["respiratory drive", "OBSERVATION", 155, 172]]], ["During pressure-controlled ventilation, in which the airway pressure is held constant, and the flow is decelerated during the mechanical breath, two alternative equations have been suggested [19, 20].IntroductionThe aim of this study was to compare the geometric method to measure MP, considered the reference standard, with the algebraic formulas, both for volume and pressure-controlled ventilation in a group of sedated and paralyzed patients, to understand whether the easier to use surrogate formulas were suitable for the everyday clinical practice.", [["airway", "ANATOMY", 53, 59], ["MP", "DISEASE", 281, 283], ["airway", "MULTI-TISSUE_STRUCTURE", 53, 59], ["MP", "GENE_OR_GENE_PRODUCT", 281, 283], ["patients", "ORGANISM", 437, 445], ["patients", "SPECIES", 437, 445], ["pressure-controlled ventilation", "TREATMENT", 7, 38], ["the airway pressure", "TEST", 49, 68], ["the mechanical breath", "TREATMENT", 122, 143], ["this study", "TEST", 223, 233], ["the algebraic formulas", "TREATMENT", 325, 347], ["volume", "TEST", 358, 364], ["pressure-controlled ventilation", "TREATMENT", 369, 400], ["sedated", "TREATMENT", 415, 422], ["paralyzed", "TREATMENT", 427, 436], ["surrogate formulas", "TREATMENT", 487, 505], ["ventilation", "OBSERVATION", 27, 38], ["airway", "ANATOMY", 53, 59], ["pressure", "OBSERVATION", 60, 68]]], ["This would warrant a more widespread use of mechanical power to promote lung protection.Study population ::: Materials and methodsPatients admitted to the intensive care unit from January to June 2018 after elective surgery (excluding thoracic and cranial surgery) or with medical disease were considered eligible.", [["lung", "ANATOMY", 72, 76], ["thoracic", "ANATOMY", 235, 243], ["cranial", "ANATOMY", 248, 255], ["lung", "ORGAN", 72, 76], ["Patients", "ORGANISM", 130, 138], ["thoracic", "ORGAN", 235, 243], ["Patients", "SPECIES", 130, 138], ["mechanical power", "TREATMENT", 44, 60], ["lung protection", "TREATMENT", 72, 87], ["elective surgery", "TREATMENT", 207, 223], ["thoracic and cranial surgery", "TREATMENT", 235, 263], ["medical disease", "PROBLEM", 273, 288], ["lung", "ANATOMY", 72, 76], ["protection", "OBSERVATION", 77, 87], ["thoracic", "ANATOMY", 235, 243], ["cranial", "ANATOMY", 248, 255], ["surgery", "OBSERVATION", 256, 263]]], ["The study was approved by the institutional review board of our hospital (Comitato Etico Interaziendale Milano Area A 1, n.", [["The study", "TEST", 0, 9]]], ["Exclusion criteria were hemodynamic instability (systolic arterial pressure < 100 mmHg) and COPD (Gold stages 3 and 4).Study design ::: Materials and methodsCritically ill patients with acute respiratory failure, kept in supine position and sedated and paralyzed for clinical reasons, were ventilated in volume-controlled mode with a tidal volume of 6\u20138 mL/kg of predicted body weight with two inspiratory flows (high, 60 L/min, and low, 30 L/min), with a square waveform.", [["arterial", "ANATOMY", 58, 66], ["respiratory", "ANATOMY", 192, 203], ["body", "ANATOMY", 373, 377], ["hemodynamic instability", "DISEASE", 24, 47], ["COPD", "DISEASE", 92, 96], ["Critically ill", "DISEASE", 157, 171], ["acute respiratory failure", "DISEASE", 186, 211], ["arterial", "MULTI-TISSUE_STRUCTURE", 58, 66], ["patients", "ORGANISM", 172, 180], ["body", "ORGANISM_SUBDIVISION", 373, 377], ["patients", "SPECIES", 172, 180], ["hemodynamic instability", "PROBLEM", 24, 47], ["systolic arterial pressure", "TEST", 49, 75], ["COPD", "PROBLEM", 92, 96], ["acute respiratory failure", "PROBLEM", 186, 211], ["sedated", "TREATMENT", 241, 248], ["paralyzed", "TREATMENT", 253, 262], ["a tidal volume", "TEST", 332, 346], ["two inspiratory flows", "TEST", 390, 411], ["hemodynamic instability", "OBSERVATION", 24, 47], ["COPD", "OBSERVATION", 92, 96], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["respiratory failure", "OBSERVATION", 192, 211], ["inspiratory flows", "OBSERVATION", 394, 411]]], ["Subsequently, pressure-controlled ventilation was applied to reach the same tidal volume as volume-controlled ventilation.", [["pressure-controlled ventilation", "TREATMENT", 14, 45], ["volume-controlled ventilation", "TREATMENT", 92, 121], ["pressure", "OBSERVATION_MODIFIER", 14, 22], ["tidal volume", "OBSERVATION", 76, 88]]], ["PEEP and respiratory rates were not changed throughout the study.Measurements ::: Materials and methodsThe inspiratory flow rate was measured with a heated pneumotachograph (Fleisch no. 2, Fleisch, Lausanne, Switzerland).", [["PEEP", "TREATMENT", 0, 4], ["respiratory rates", "TEST", 9, 26], ["the study", "TEST", 55, 64], ["The inspiratory flow rate", "TEST", 103, 128], ["a heated pneumotachograph", "TEST", 147, 172], ["respiratory rates", "OBSERVATION", 9, 26], ["inspiratory flow", "OBSERVATION", 107, 123]]], ["Airway pressure was measured proximally to the endotracheal tube with a dedicated pressure transducer (MPX 2010 DP, Motorola, Solna, Sweden).", [["Airway", "ANATOMY", 0, 6], ["endotracheal tube", "ANATOMY", 47, 64], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["endotracheal tube", "TISSUE", 47, 64], ["Airway pressure", "TEST", 0, 15], ["the endotracheal tube", "TREATMENT", 43, 64], ["a dedicated pressure transducer", "TREATMENT", 70, 101], ["Motorola", "TREATMENT", 116, 124], ["pressure", "OBSERVATION_MODIFIER", 7, 15], ["endotracheal tube", "OBSERVATION", 47, 64]]], ["Flow and airway pressure were collected at a sampling rate of 100 Hz and stored for analysis (Colligo, Elekton, Milan, Italy).Measurements ::: Materials and methodsThe following variables were measured in each condition: tidal volume, inspiratory time, peak airway pressure, plateau airway pressure, and PEEP during an end-inspiratory and expiratory pause.", [["airway", "ANATOMY", 9, 15], ["airway", "ANATOMY", 258, 264], ["airway", "ANATOMY", 283, 289], ["airway", "MULTI-TISSUE_STRUCTURE", 9, 15], ["airway", "MULTI-TISSUE_STRUCTURE", 258, 264], ["airway", "MULTI-TISSUE_STRUCTURE", 283, 289], ["Flow", "TEST", 0, 4], ["airway pressure", "TEST", 9, 24], ["a sampling rate", "TEST", 43, 58], ["analysis", "TEST", 84, 92], ["tidal volume", "TEST", 221, 233], ["inspiratory time", "TEST", 235, 251], ["peak airway pressure", "TEST", 253, 273], ["plateau airway pressure", "TEST", 275, 298], ["PEEP", "TREATMENT", 304, 308], ["an end-inspiratory and expiratory pause", "PROBLEM", 316, 355], ["airway", "ANATOMY", 9, 15], ["pressure", "OBSERVATION_MODIFIER", 16, 24], ["tidal volume", "OBSERVATION", 221, 233], ["airway pressure", "OBSERVATION", 258, 273], ["plateau airway pressure", "OBSERVATION", 275, 298], ["expiratory pause", "OBSERVATION", 339, 355]]], ["Means were computed over five consecutive breaths.Geometric method ::: Computation of mechanical power ::: Materials and methodsDuring volume- and pressure-controlled ventilation, the MP was measured as the energy per breath (the area between the inspiratory limb of the airway pressure curve and the volume (y-axis) (Figure S1), expressed in Joules and multiplied by the respiratory rate (J/min) [10, 21].Comprehensive formula ::: Calculation of MP during volume-controlled ventilation ::: Materials and methodsBy \u201ccomprehensive,\u201d we mean an equation that takes into account both the resistive and elastic components of the mechanical breath, giving a more accurate measurement of MP.", [["inspiratory limb", "ANATOMY", 247, 263], ["airway", "ANATOMY", 271, 277], ["MP", "DISEASE", 184, 186], ["MP", "DISEASE", 447, 449], ["MP", "DISEASE", 682, 684], ["MP", "GENE_OR_GENE_PRODUCT", 184, 186], ["limb", "ORGANISM_SUBDIVISION", 259, 263], ["airway", "MULTI-TISSUE_STRUCTURE", 271, 277], ["MP", "GENE_OR_GENE_PRODUCT", 447, 449], ["MP", "GENE_OR_GENE_PRODUCT", 682, 684], ["volume", "TEST", 135, 141], ["pressure-controlled ventilation", "TREATMENT", 147, 178], ["the MP", "TEST", 180, 186], ["the airway pressure curve", "TEST", 267, 292], ["the respiratory rate", "TEST", 368, 388], ["MP during volume-controlled ventilation", "TREATMENT", 447, 486], ["the mechanical breath", "TREATMENT", 621, 642], ["mechanical power", "OBSERVATION", 86, 102], ["ventilation", "OBSERVATION", 167, 178], ["inspiratory limb", "ANATOMY", 247, 263], ["airway", "ANATOMY", 271, 277], ["resistive", "OBSERVATION", 585, 594], ["elastic", "OBSERVATION_MODIFIER", 599, 606], ["components", "OBSERVATION_MODIFIER", 607, 617]]], ["It requires an inspiratory hold.", [["an inspiratory hold", "TREATMENT", 12, 31]]], ["This equation derives from a mathematical simplification of the original mechanical power formula [10], with the advantage that the calculation starts from the measured peak, plateau, and end-expiratory pressure, allowing a much faster bedside computation.", [["the original mechanical power formula", "TREATMENT", 60, 97], ["the calculation", "TEST", 128, 143], ["plateau", "TEST", 175, 182], ["end-expiratory pressure", "TEST", 188, 211], ["plateau", "OBSERVATION_MODIFIER", 175, 182], ["expiratory pressure", "OBSERVATION", 192, 211]]]], "981bfd4c62eab2456cd404a4715eef434afa575d": [["Dear Editor,We read with great interest the article by Yelamanchi et al. [1] regarding the challenges of exposure to surgical experience in the midst of the COVID-19 pandemic.", [["the COVID", "TEST", 153, 162], ["pandemic", "PROBLEM", 166, 174]]], ["The authors highlight several limitations to residency training including: facilities and equipment, whereby some countries may not have access to adequate animal models, simulations or cadavers to practice first hand; impact on research with reduced sample sizes and less people consenting to research; changes to learning with teaching reduced to case reports and seminars, reduced learning opportunities for junior residents in both the operating theatre and the subsequent management of surgical patients; changes to hospital processes including cancellation of elective procedures, less people attending an operating theatre at one time to reduce risk of transmission, the redeployment of surgical trainees onto COVID-related wards and the difficulties surrounding the use of personal protective equipment (PPE).", [["patients", "ORGANISM", 500, 508], ["people", "ORGANISM", 592, 598], ["people", "SPECIES", 273, 279], ["patients", "SPECIES", 500, 508], ["people", "SPECIES", 592, 598], ["reduced sample sizes", "TREATMENT", 243, 263], ["surgical patients", "TREATMENT", 491, 508], ["elective procedures", "TREATMENT", 566, 585], ["surgical trainees", "TREATMENT", 694, 711], ["personal protective equipment", "TREATMENT", 781, 810]]], ["Whilst this could have detrimental effects to the learning of residents and the uptake of surgical posts in the future, it has also had an impact on those even more junior: such as medical students.Dear Editor,The Medical Schools Council (MSC), who regulate curricula in the UK, have advised that general placements for medical students should be stopped in light of the risk to patients and to students themselves.", [["patients", "ORGANISM", 379, 387], ["patients", "SPECIES", 379, 387], ["general placements", "TREATMENT", 297, 315], ["medical students", "TREATMENT", 320, 336]]], ["This is due to the risk of both symptomatic and asymptomatic transmission [2] .", [["both symptomatic and asymptomatic transmission", "PROBLEM", 27, 73], ["symptomatic", "OBSERVATION_MODIFIER", 32, 43]]], ["This is particularly important in the case of paediatric and obstetrics placementsboth of which have been identified by the MSC as often difficult to arrange and with limited exposure to these patient groups in other clinical specialties.", [["MSC", "ANATOMY", 124, 127], ["MSC", "CELL", 124, 127], ["patient", "ORGANISM", 193, 200], ["patient", "SPECIES", 193, 200], ["paediatric and obstetrics placementsboth", "TREATMENT", 46, 86]]], ["Interaction with these patients is vital for the development of well-rounded medical individuals, and it is these placements that can often be the only experience a medical professional will ever have of, for example, obstetrics [3] .Dear Editor,Furthermore, this has also impacted the education of the most junior medical trainees.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["Additionally, this can impact both trainees with an inclination to expand their portfolio surgically and solidify career choices, as well as those interested in other specialities, where they may have to treat and diagnose surgical problems in later careers.J o u r n a l P r e -p r o o fOverall, we wholeheartedly agree with the authors on the potential negative consequences that the COVID-19 pandemic may have on the surgical speciality and it's trainees and by extension, the repercussions on medical students, as we have identified.", [["the COVID", "TEST", 382, 391]]]], "964ab9720c63e0617198e61b00f1658179e14b38": [["IntroductionThe novel coronavirus (COVID-19) disease has affected over 31.2 million lives, claiming more than 1.02 million fatalities globally, representing an epoch-making global crisis in health care.", [["fatalities", "DISEASE", 123, 133], ["coronavirus", "ORGANISM", 22, 33], ["COVID-19", "ORGANISM", 35, 43], ["The novel coronavirus (COVID", "TREATMENT", 12, 40], ["disease", "PROBLEM", 45, 52], ["global crisis", "OBSERVATION", 173, 186]]], ["At the time of writing, no specific antivirus drugs or vaccines are recommended to control transmission and spread infection.", [["infection", "DISEASE", 115, 124], ["specific antivirus drugs", "TREATMENT", 27, 51], ["vaccines", "TREATMENT", 55, 63], ["spread infection", "PROBLEM", 108, 124], ["spread", "OBSERVATION_MODIFIER", 108, 114], ["infection", "OBSERVATION", 115, 124]]], ["The current diagnosis of COVID-19 is made by Reverse-Transcription Polymer Chain Reaction (RT-PCR) testing, which utilizes several primer-probe sets depending on the assay utilized (Emery et al., 2004) .", [["COVID-19", "DNA", 25, 33], ["COVID", "TEST", 25, 30], ["Reverse-Transcription Polymer Chain Reaction", "TREATMENT", 45, 89], ["RT-PCR) testing", "TEST", 91, 106], ["several primer-probe sets", "TREATMENT", 123, 148], ["the assay", "TEST", 162, 171]]], ["A low-cost, rapid, and an easily accessible testing solution must increase the diagnostic capability and devise a treatment plan.", [["an easily accessible testing solution", "TREATMENT", 23, 60], ["a treatment plan", "TREATMENT", 112, 128], ["low", "OBSERVATION_MODIFIER", 2, 5]]], ["Computed Tomography(CT) helps clinicians perform complete patient assessments and describe the specific characteristic manifestations in the lungs associated with COVID-19 (Li et al., 2020) .", [["lungs", "ANATOMY", 141, 146], ["COVID-19", "CHEMICAL", 163, 171], ["patient", "ORGANISM", 58, 65], ["lungs", "ORGAN", 141, 146], ["patient", "SPECIES", 58, 65], ["Computed Tomography", "TEST", 0, 19], ["complete patient assessments", "TEST", 49, 77], ["the specific characteristic manifestations in the lungs", "PROBLEM", 91, 146], ["COVID", "TEST", 163, 168], ["lungs", "ANATOMY", 141, 146]]], ["Hence, serving as an efficient tool for early screening and diagnosis of COVID-19.", [["early screening", "TEST", 40, 55], ["COVID", "TEST", 73, 78]]], ["In analyzing medical images, AI-based methods have shown great success (Du et al., 2018; Heidari et al., 2018 Heidari et al., , 2020 .", [["medical images", "TEST", 13, 27]]], ["Significant attempts have been made to use x-ray images for automatic diagnosis of COVID-19 (Pereira et al., 2020; Narin et al., 2020; Zhang et al., 2020; Apostolopoulos and Mpesiana, 2020) .", [["x-ray images", "TEST", 43, 55], ["COVID", "TEST", 83, 88]]], ["Studies dealing with the classification of COVID-19 show promising results in this task.IntroductionHowever, in (Cohen et al., 2020) work, the classification limitations of x-ray images are examined since the network may learn more unique features to the dataset than those unique to the disease.", [["COVID-19", "DNA", 43, 51], ["COVID", "TEST", 43, 48], ["x-ray images", "TEST", 173, 185], ["the disease", "PROBLEM", 284, 295], ["disease", "OBSERVATION", 288, 295]]], ["Despite its success, the CT scan displays similar imaging characteristics, making it difficult to distinguish between COVID-19 and other pneumonia types.", [["pneumonia", "DISEASE", 137, 146], ["the CT scan", "TEST", 21, 32], ["COVID", "TEST", 118, 123], ["other pneumonia types", "PROBLEM", 131, 152], ["pneumonia", "OBSERVATION", 137, 146]]], ["Moreover, CT-based methods can be integrated only with the Healthcare system to help clinical doctors, radiologists, and specialists detect COVID-19 patients using chest CT images.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["CT", "TEST", 10, 12], ["chest CT images", "TEST", 164, 179], ["chest", "ANATOMY", 164, 169]]], ["Unfortunately, an individual cannot utilize this method at home.", [["this method", "TREATMENT", 44, 55]]], ["To obtain the CT scan image and report, one must visit a well-equipped clinical facility or diagnostic center, which may increase the risk of exposure to the virus.", [["the CT scan image", "TEST", 10, 27], ["the virus", "PROBLEM", 154, 163]]], ["According to the WHO and CDC official report, the four primary symptoms of the COVID are dry cough, fever, tiredness, and difficulty in breathing.", [["COVID", "DISEASE", 79, 84], ["dry cough", "DISEASE", 89, 98], ["fever", "DISEASE", 100, 105], ["tiredness", "DISEASE", 107, 116], ["the four primary symptoms", "PROBLEM", 46, 71], ["dry cough", "PROBLEM", 89, 98], ["fever", "PROBLEM", 100, 105], ["tiredness", "PROBLEM", 107, 116], ["difficulty in breathing", "PROBLEM", 122, 145], ["dry", "OBSERVATION_MODIFIER", 89, 92], ["cough", "OBSERVATION", 93, 98]]], ["However, cough is more common as it is one of the early symptoms of respiratory tract infections.", [["respiratory tract", "ANATOMY", 68, 85], ["cough", "DISEASE", 9, 14], ["respiratory tract infections", "DISEASE", 68, 96], ["respiratory tract", "ORGANISM_SUBDIVISION", 68, 85], ["cough", "PROBLEM", 9, 14], ["the early symptoms", "PROBLEM", 46, 64], ["respiratory tract infections", "PROBLEM", 68, 96], ["cough", "OBSERVATION", 9, 14], ["respiratory tract", "ANATOMY", 68, 85], ["infections", "OBSERVATION", 86, 96]]], ["Studies show that it occurs in 68% to 83% of the people showing up for the medical examination.", [["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55], ["Studies", "TEST", 0, 7], ["the medical examination", "TEST", 71, 94]]], ["Cough classification is usually carried out manually during a physical examination, and the clinician may listen to several episodes of voluntary or natural coughs to classify them.", [["Cough classification", "PROBLEM", 0, 20], ["a physical examination", "TEST", 60, 82], ["voluntary or natural coughs", "PROBLEM", 136, 163]]], ["This information is crucial in diagnosis and treatment.IntroductionIn previous studies, several methods with speech features have been proposed to automate different cough types classification.", [["cough", "DISEASE", 166, 171], ["treatment", "TREATMENT", 45, 54], ["IntroductionIn previous studies", "TEST", 55, 86]]], ["In the study published by (Knocikova et al., 2008) , the sound of voluntary cough in patients with respiratory diseases was investigated.", [["respiratory", "ANATOMY", 99, 110], ["cough", "DISEASE", 76, 81], ["respiratory diseases", "DISEASE", 99, 119], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["voluntary cough", "PROBLEM", 66, 81], ["respiratory diseases", "PROBLEM", 99, 119], ["voluntary", "OBSERVATION_MODIFIER", 66, 75], ["cough", "OBSERVATION", 76, 81], ["respiratory diseases", "OBSERVATION", 99, 119]]], ["Later, in 2015, (Guclu et al., 2015) published the study on the analysis of asthmatic breathing sounds.", [["the study", "TEST", 47, 56], ["the analysis", "TEST", 60, 72], ["asthmatic breathing sounds", "PROBLEM", 76, 102]]], ["These studies utilized the wavelet transformation, which is a type of signal processing technique, generally used on non-stationary signals.", [["These studies", "TEST", 0, 13]]], ["In a study by (Swarnkar et al., 2012) , a Logistic Regression model was utilized to classify the dry and wet cough from pediatric patients with different respiratory illnesses.", [["respiratory", "ANATOMY", 154, 165], ["cough", "DISEASE", 109, 114], ["respiratory illnesses", "DISEASE", 154, 175], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["a study", "TEST", 3, 10], ["a Logistic Regression model", "TREATMENT", 40, 67], ["the dry and wet cough", "PROBLEM", 93, 114], ["different respiratory illnesses", "PROBLEM", 144, 175], ["dry", "OBSERVATION", 97, 100], ["wet", "OBSERVATION_MODIFIER", 105, 108], ["cough", "OBSERVATION", 109, 114], ["respiratory illnesses", "OBSERVATION", 154, 175]]], ["For pertussis cough classification, three separate classifiers' performance was analyzed in (Parker et al., 2013) research.", [["pertussis cough", "DISEASE", 4, 19], ["pertussis cough classification", "PROBLEM", 4, 34]]], ["Several AIbased approaches, motivated by prior work, have been presented to detect patients with COVID-19 using cough sound analysis.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["COVID", "TEST", 97, 102], ["cough sound analysis", "TEST", 112, 132]]], ["(Deshpande and Schuller, 2020) gives an overview of Audio, Signal, Speech, NLP for COVID-19, (Orlandic et al., 2020; Brown et al., 2020; Sharma et al., 2020) have collected a crowdsourced dataset of respiratory sounds and shared the findings over a subset of the dataset.", [["COVID", "TEST", 83, 88], ["respiratory sounds", "PROBLEM", 199, 217], ["respiratory sounds", "OBSERVATION", 199, 217]]], ["Imran et al. (2020); Furman et al. (2020) performed similar analyses on cough data and achieved good accuracy.", [["cough data", "TEST", 72, 82]]], ["Most studies use short-term magnitude spectrograms transformed from cough sound data to the convolutional neural network (CNN).", [["convolutional neural network", "ANATOMY", 92, 120], ["neural network", "MULTI-TISSUE_STRUCTURE", 106, 120], ["short-term magnitude spectrograms", "TREATMENT", 17, 50], ["cough sound data", "TEST", 68, 84]]], ["However, these methods have the following limitations :Introduction\u2022 Ignoring domain-specific sound information Cough is a non-stationary acoustic event.", [["Cough", "DISEASE", 112, 117], ["Cough", "PROBLEM", 112, 117], ["a non-stationary acoustic event", "PROBLEM", 121, 152]]], ["CNN is based only on a spectrogram input; some domain-specific important characteristics (besides spectrogram) of cough sounds might be overlooked in the feature space.Introduction\u2022 Using cough features only These methods exploit the spectrogram cough features only, ignoring patient characteristics, medical conditions, and symptoms data.", [["cough", "DISEASE", 114, 119], ["patient", "ORGANISM", 276, 283], ["CNN", "PROTEIN", 0, 3], ["patient", "SPECIES", 276, 283], ["a spectrogram input", "TEST", 21, 40], ["cough sounds", "PROBLEM", 114, 126], ["the spectrogram cough features", "PROBLEM", 230, 260], ["symptoms data", "TEST", 325, 338]]], ["Both cough features and other symptoms accompanied by demographic data are responsible for COVID-19 infection.", [["cough", "DISEASE", 5, 10], ["infection", "DISEASE", 100, 109], ["Both cough features", "PROBLEM", 0, 19], ["other symptoms", "PROBLEM", 24, 38], ["demographic data", "TEST", 54, 70], ["COVID-19 infection", "PROBLEM", 91, 109], ["cough", "OBSERVATION", 5, 10], ["infection", "OBSERVATION", 100, 109]]], ["Wherein the prior carries vital information about the respiratory system and the pathologies involved, the latter encodes patient characteristics, signs, and health conditions (fever, chest pain, dyspnea).", [["respiratory system", "ANATOMY", 54, 72], ["chest", "ANATOMY", 184, 189], ["fever", "DISEASE", 177, 182], ["chest pain", "DISEASE", 184, 194], ["dyspnea", "DISEASE", 196, 203], ["patient", "ORGANISM", 122, 129], ["chest", "ORGANISM_SUBDIVISION", 184, 189], ["patient", "SPECIES", 122, 129], ["fever", "PROBLEM", 177, 182], ["chest pain", "PROBLEM", 184, 194], ["dyspnea", "PROBLEM", 196, 203], ["respiratory system", "ANATOMY", 54, 72], ["chest", "ANATOMY", 184, 189]]], ["However, their existence alone is not a precise enough marker of the disease.", [["the disease", "PROBLEM", 65, 76], ["disease", "OBSERVATION", 69, 76]]], ["Therefore, determining the symptoms (besides cough) presented by sus-pected cases, as best predictors of a positive diagnosis would be useful to make rapid decisions on treatment and isolation needs.Introduction\u2022 Lack of interpretability In AI research, the model is not limited to accuracy and sensitivity reports; instead, it is expected to describe the predictions' underlying reasons and enhance medical understanding and knowledge.", [["cough", "DISEASE", 45, 50], ["the symptoms", "PROBLEM", 23, 35], ["cough", "PROBLEM", 45, 50], ["treatment", "TREATMENT", 169, 178], ["isolation needs", "TREATMENT", 183, 198]]], ["Clinical selection of an algorithm depends on two main factors, its clinical usefulness, and trustworthiness.", [["trustworthiness", "PROBLEM", 93, 108]]], ["When the prediction does not directly explain a particular clinical question, its use is limited.IntroductionTo overcome the limitation of the existing methods, a novel interpretable COVID-19 diagnosis AI framework is proposed in this study, which uses symptoms and cough features to classify the COVID-19 cases from non-COVID-19 cases accurately.", [["this study", "TEST", 230, 240], ["symptoms", "PROBLEM", 253, 261], ["cough features", "PROBLEM", 266, 280], ["the COVID", "TEST", 293, 302], ["non-COVID", "TEST", 317, 326]]], ["A three-layer Deep Neural Network model is used to generate cough embeddings from the handcrafted signal processing features and symptoms embeddings are generated by a transformer-based self-attention network called TabNet.", [["TabNet", "PROTEIN", 216, 222], ["A three-layer Deep Neural Network model", "TREATMENT", 0, 39], ["cough embeddings", "PROBLEM", 60, 76], ["symptoms embeddings", "PROBLEM", 129, 148], ["Deep", "ANATOMY_MODIFIER", 14, 18], ["Neural Network", "OBSERVATION", 19, 33]]], ["Arik and Pfister (2020) Finally, the prediction score is obtained by concatenating the Symptoms Embeddings with Cough Embeddings, followed by a Fully Connected layer.", [["Cough", "DISEASE", 112, 117], ["the prediction score", "TEST", 33, 53], ["the Symptoms", "PROBLEM", 83, 95], ["Cough Embeddings", "PROBLEM", 112, 128]]], ["In a sensitive discipline such as healthcare, where any decision comes with an extended and long term responsibility, making wrong predictions can lead to critical judgments in life and death situations.IntroductionIn this study, it is illustrated that this framework is not limited to accurate predictions or projections.", [["death", "DISEASE", 186, 191], ["this study", "TEST", 218, 228]]], ["The contributions of the paper can be summarized as follows:Introduction\u2022 A novel explainable & interpretable COVID-19 diagnosis framework based on deep learning (AI) uses the information from symptoms and cough signal processing features.", [["cough", "DISEASE", 206, 211], ["symptoms", "PROBLEM", 193, 201], ["cough signal processing features", "PROBLEM", 206, 238]]], ["The proposed solution is a low-cost, rapid, and easily accessible testing solution to increase the diagnostic capability and devise a treatment plan in areas where adequate supplies, healthcare facilities, and medical professionals are not available.Introduction\u2022 In this study, an interpretable diagnosis solution is presented, capable of explaining and establishing a dialogue with its endusers about the underlying process.", [["The proposed solution", "TREATMENT", 0, 21], ["easily accessible testing solution", "TREATMENT", 48, 82], ["a treatment plan", "TREATMENT", 132, 148], ["this study", "TEST", 267, 277]]], ["Hence, resulting in transparent human interpretable outputs.Introduction\u2022 In this study, three binary and one multiclass classification tasks are developed; Task 1 uses only cough features to classify between COVID-19 positive and COVID-19 negative.", [["human", "ORGANISM", 32, 37], ["COVID-19", "GENE_OR_GENE_PRODUCT", 231, 239], ["COVID-19 positive and COVID-19", "DNA", 209, 239], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["this study", "TEST", 77, 87], ["cough features", "PROBLEM", 174, 188], ["COVID", "TEST", 209, 214], ["COVID", "TEST", 231, 236]]], ["In Task 2, only demographic and symptoms data is used, and in Task 3, both types of information are used, which helps the model learn deeper relationships between temporal acoustic characteristics of cough sounds and Symptoms' features and hence perform better.", [["cough", "DISEASE", 200, 205], ["symptoms data", "TEST", 32, 45], ["cough sounds", "PROBLEM", 200, 212], ["Symptoms' features", "PROBLEM", 217, 235]]], ["In Task 4, multiclass classification is performed to explain the proposed model's effectiveness in classifying between four cough types, including Bronchitis, Asthma, COVID-19 Positive, and COVID-19 Negative.Introduction\u2022 An in-depth analysis is performed for different cough sounds.", [["cough", "DISEASE", 124, 129], ["Bronchitis", "DISEASE", 147, 157], ["Asthma", "DISEASE", 159, 165], ["cough", "DISEASE", 270, 275], ["four cough types", "PROBLEM", 119, 135], ["Bronchitis", "PROBLEM", 147, 157], ["Asthma", "PROBLEM", 159, 165], ["COVID", "TEST", 167, 172], ["COVID", "TEST", 190, 195], ["An in-depth analysis", "TEST", 222, 242], ["different cough sounds", "PROBLEM", 260, 282], ["Bronchitis", "OBSERVATION", 147, 157], ["Asthma", "OBSERVATION", 159, 165]]], ["The observations and findings are presented, distinguishing COVID-19 cough from other types of cough.Introduction\u2022 A python module was developed to extract better and re-boost cough features from raw cough sounds.", [["cough", "DISEASE", 69, 74], ["cough", "DISEASE", 95, 100], ["cough", "DISEASE", 176, 181], ["cough", "DISEASE", 200, 205], ["COVID", "TEST", 60, 65], ["19 cough", "PROBLEM", 66, 74], ["cough", "PROBLEM", 95, 100], ["A python module", "TREATMENT", 115, 130], ["cough features", "PROBLEM", 176, 190], ["raw cough sounds", "PROBLEM", 196, 212], ["cough", "OBSERVATION", 95, 100]]], ["Those are not necessarily experts in domain-specific cough feature extraction, contributing to real-time cough based research application, and provide better mobile health solutions.Introduction\u2022 This study hence provides a medicallyvetted approach.Model ArchitectureThe model architecture consists of two subnetworks components, including the Symptoms Embedddings component and Cough Embeddings component, that process the data from different modalities.Symptoms EmbeddingsSymptoms Embeddings capture the hidden features of patient characteristics, diagnosis, symptoms.Symptoms EmbeddingsA feature that has been masked a lot has low importance for the model and vice-versa.", [["patient", "ORGANISM", 525, 532], ["patient", "SPECIES", 525, 532], ["specific cough feature extraction", "PROBLEM", 44, 77], ["research application", "TREATMENT", 117, 137], ["This study", "TEST", 196, 206], ["a medicallyvetted approach", "TREATMENT", 222, 248], ["the Symptoms Embedddings component", "PROBLEM", 340, 374], ["Cough Embeddings component", "PROBLEM", 379, 405], ["Symptoms", "PROBLEM", 455, 463], ["Symptoms", "PROBLEM", 474, 482], ["symptoms", "PROBLEM", 561, 569], ["Symptoms", "PROBLEM", 570, 578], ["not necessarily", "UNCERTAINTY", 10, 25], ["Architecture", "OBSERVATION_MODIFIER", 255, 267], ["model", "OBSERVATION_MODIFIER", 271, 276], ["architecture", "OBSERVATION_MODIFIER", 277, 289], ["two", "OBSERVATION_MODIFIER", 302, 305], ["subnetworks", "OBSERVATION_MODIFIER", 306, 317], ["components", "OBSERVATION_MODIFIER", 318, 328], ["component", "OBSERVATION_MODIFIER", 365, 374], ["Cough", "OBSERVATION", 379, 384]]], ["Averaged Attention masks are used to explain the overall importance of symptoms features.DECISION STEP (DS)TabNet stacks the subsequent DS one after the other.", [["Attention masks", "TREATMENT", 9, 24], ["symptoms features", "PROBLEM", 71, 88]]], ["Decision steps are composed of a Feature Transformer(FT) Appendix B.0.2, an Attentive Transformer(AT)Appendix B.0.3 and feature masking.", [["Appendix", "TEST", 57, 65]]], ["Symptoms features are mapped into a D-dimensional trainable embeddings q \u2208 R B\u00d7D , where B is the batch size, and D is the feature dimension.", [["D-dimensional trainable embeddings q", "CELL_LINE", 36, 72], ["Symptoms features", "PROBLEM", 0, 17], ["size", "OBSERVATION_MODIFIER", 104, 108]]], ["A batch normalization (BN) is performed across the whole batch.", [["A batch normalization", "TEST", 0, 21]]], ["For the selection of specific soft features and explain the feature importance TabNet uses a learnable mask M[i] \u2208 R B\u00d7D .", [["a learnable mask", "TREATMENT", 91, 107]]], ["Each decision step has a specific mask and selects its own features; steps are sequential, so the second step needs the first to be finished.DECISION STEP (DS)We obtain the mask(M) output at each decision step by multiplying the mask with Normalised symptoms features q i M[i] \u00b7 q Normalized domain features are passed to FT, and a split block divides the processed representation into two chunks for the next decision step.DECISION STEP (DS)where d[i] \u2208 R B\u00d7n d and a[i] \u2208 R B\u00d7n a . and n d , n a are size of the decision layer and size of the attention bottleneck respectively.", [["FT", "PROTEIN", 322, 324], ["a specific mask", "TREATMENT", 23, 38], ["the mask(M) output", "TREATMENT", 169, 187], ["the mask", "TREATMENT", 225, 233], ["Normalised symptoms features", "PROBLEM", 239, 267], ["Normalized domain features", "PROBLEM", 281, 307], ["a split block", "PROBLEM", 330, 343], ["size", "OBSERVATION_MODIFIER", 533, 537]]], ["After n th step two outputs are produced.DECISION STEP (DS)\u2022 Mask outputs are aggregated from all the decision steps to provide model interpretability result.", [["Mask outputs", "TREATMENT", 61, 73]]], ["Figure 7 and Figure 8 shows the interpretability result.DECISION STEP (DS)\u2022 The final output is a linear combination of the all the summed decision steps, similar to the decision tree result.DECISION STEP (DS)Pairwise dot product was computed between output d out and FC layer to obtain the Symptoms Embeddings S e \u2208 R B\u00d7F where B is the batch size and F is the output dimension.SYMPTOMS EMBEDDING LOSSTabNet uses regularized sparse entropy loss to control the sparsity of attentive features.", [["EMBEDDING LOSSTabNet", "DNA", 388, 408], ["Figure", "TEST", 0, 6], ["the Symptoms", "PROBLEM", 287, 299], ["SYMPTOMS", "PROBLEM", 379, 387], ["regularized sparse entropy loss", "PROBLEM", 414, 445], ["size", "OBSERVATION_MODIFIER", 344, 348]]], ["The regularization factor is a mathematical aggregation of the attention mask.SYMPTOMS EMBEDDING LOSS(3) Where \u03b5 is a small positive value.Cough EmbeddingsCough Embeddigs learn and capture deeper features in temporal acoustic characteristics of cough sounds.Cough Embeddings2.2.1.", [["cough", "DISEASE", 245, 250], ["the attention mask", "TREATMENT", 59, 77], ["a small positive value", "PROBLEM", 116, 138], ["Cough", "PROBLEM", 139, 144], ["cough sounds", "PROBLEM", 245, 257], ["Cough", "PROBLEM", 258, 263], ["small", "OBSERVATION_MODIFIER", 118, 123], ["positive", "OBSERVATION", 124, 132], ["temporal", "OBSERVATION_MODIFIER", 208, 216], ["acoustic", "OBSERVATION_MODIFIER", 217, 225], ["cough sounds", "OBSERVATION", 245, 257]]], ["SIGNAL PREPROCESSING Before extracting cough features and feeding it to Deep Neural Networks(DNN), some preprocessing of raw audio data is needed.", [["SIGNAL PREPROCESSING", "TREATMENT", 0, 20], ["extracting cough features", "PROBLEM", 28, 53], ["Deep", "ANATOMY_MODIFIER", 72, 76], ["Neural Networks", "ANATOMY", 77, 92]]], ["Each cough recording was downsampled to 16 kHz; normalization was applied to the cough signal Normalized features were split into cough segments based on the silence threshold.", [["cough", "DISEASE", 81, 86], ["Each cough", "PROBLEM", 0, 10], ["the cough signal", "TEST", 77, 93], ["split into cough segments", "PROBLEM", 119, 144]]], ["Let s[t] be the discrete-time cough sound recording.", [["cough sound recording", "TEST", 30, 51]]], ["The expression of signal s[t] can be written as: Please see Appendix A for cough features.", [["cough", "DISEASE", 75, 80], ["cough features", "PROBLEM", 75, 89], ["Appendix", "ANATOMY", 60, 68]]], ["Also see Appendix C for detailed information about our data collection process.", [["Appendix", "ANATOMY", 9, 17]]], ["The final feature matrix was grouped by chunks of n Consecutive feature matrix, and A total of 44 cough features were extracted by taking the mean and standard deviation for all the cough features in each chunked matrix.Cough EmbeddingsLater we feed the final feature matrix to 3 layers Deep Neural Network(DNN) with ReLu activation function to get the final Cough.Cough EmbeddingsEmbeddings C e \u2208 R B\u00d7F where B is the batch size and F is the output dimension.COUGH EMBEDDINGS LOSSIn Multi-class classification setting, we use Categorical Crossentropy loss function to calculate the loss of Cough Embeddings where N is the number of classes in dataset,\u0177 i denotes the i-th predicted class in the model output and y i is the corresponding target value.", [["cough", "DISEASE", 98, 103], ["cough", "DISEASE", 182, 187], ["Cough", "DISEASE", 359, 364], ["Cough", "DISEASE", 591, 596], ["matrix", "CELLULAR_COMPONENT", 213, 219], ["ReLu", "PROTEIN", 317, 321], ["44 cough features", "PROBLEM", 95, 112], ["all the cough features", "PROBLEM", 174, 196], ["Cough", "PROBLEM", 220, 225], ["ReLu activation function", "PROBLEM", 317, 341], ["Cough", "PROBLEM", 365, 370], ["COUGH", "PROBLEM", 460, 465], ["Categorical Crossentropy loss function", "TREATMENT", 527, 565], ["Cough", "PROBLEM", 591, 596], ["matrix", "OBSERVATION_MODIFIER", 18, 24], ["cough", "OBSERVATION", 182, 187], ["Deep", "ANATOMY_MODIFIER", 287, 291], ["Neural Network", "ANATOMY", 292, 306], ["Cough", "OBSERVATION", 359, 364], ["size", "OBSERVATION_MODIFIER", 425, 429]]], ["In a binary setting, we use the Binary Cross-Entropy loss function.COUGH EMBEDDINGS LOSS(6) Where y is the label and\u0177 is the predicted label, and N total number of samples.Classification layerWe get the prediction score by concatenating the Symptoms Embeddings with Cough Embeddings followed by a FC layer. y = S e ,C e\u00b7FC(7) Figure 1 shows the overall structure of the proposed architecture.", [["samples", "ANATOMY", 164, 171], ["Cough", "DISEASE", 266, 271], ["the Symptoms", "PROBLEM", 237, 249], ["Cough Embeddings", "PROBLEM", 266, 282], ["y = S e ,C e\u00b7FC", "TEST", 307, 322], ["Cough", "OBSERVATION", 266, 271]]], ["After this, Total loss was calculated as follows\u00b7FCWhere \u03b1 is a small constant value to balance the contribution of the different losses.EvaluationIn this section, a comprehensive evaluation is carried out to investigate the results of four clinical classification tasks.", [["FCWhere \u03b1", "PROTEIN", 49, 58], ["Total loss", "PROBLEM", 12, 22], ["a small constant value", "PROBLEM", 62, 84], ["the different losses", "PROBLEM", 116, 136], ["a comprehensive evaluation", "TEST", 164, 190], ["small", "OBSERVATION_MODIFIER", 64, 69]]], ["Based on the dataset collected, the model was trained on the following combination of features.Evaluation\u2022 Task 1, Using cough data only In this experiment setup, only cough features were utilized from the collected dataset to train the Model and distinguish between COVID-19 positive and negative cases.", [["Evaluation", "TEST", 95, 105], ["cough data", "TEST", 121, 131], ["cough features", "PROBLEM", 168, 182], ["the Model", "TEST", 233, 242], ["COVID", "TEST", 267, 272]]], ["Cough features were extracted using the signal processing pipeline, as described in section 1.Evaluation\u2022 The five standard evaluation metrics (Accuracy, specificity, sensitivity/recall, precision, and F1score) are adopted to evaluate the Model on the test dataset.", [["Cough features", "PROBLEM", 0, 14], ["Evaluation", "TEST", 94, 104], ["The five standard evaluation metrics", "TEST", 106, 142], ["the test dataset", "TEST", 248, 264]]], ["Several iterations were performed, and results were reported.", [["Several iterations", "TEST", 0, 18]]], ["Table 1 and Table 2 represents the classification of results along with the following observations:Evaluation\u2022 The Model achieves Accuracy, Specificity, and Sensitivity of 90.8 \u00b1 0.2%, 90.3 \u00b1 0.3%, 90.1 \u00b1 0.6% respectively.", [["Evaluation", "TEST", 99, 109], ["Accuracy", "TEST", 130, 138], ["Specificity", "TEST", 140, 151], ["Sensitivity", "TEST", 157, 168]]], ["Task 1, using only the cough features.", [["cough", "DISEASE", 23, 28], ["the cough features", "PROBLEM", 19, 37], ["cough", "OBSERVATION", 23, 28]]], ["It demonstrates that Cough provides requisite data about the respiratory system and the pathogenies involved.", [["respiratory system", "ANATOMY", 61, 79], ["Cough", "PROBLEM", 21, 26], ["Cough", "OBSERVATION", 21, 26]]], ["Signal processing characteristics enable the Model to capture the hidden cough sound signatures and diagnose COVID-19 with sufficient sensitivity and specificity.Evaluation\u2022 When using symptoms and demographic data, the Model's performance represents a slight increase in Accuracy, Specificity, and Sensitivity 91.1 \u00b1 0.8%, 90.8 \u00b1 0.3%, and 90.5 \u00b1 0.4%.", [["cough", "DISEASE", 73, 78], ["the hidden cough sound signatures", "PROBLEM", 62, 95], ["diagnose COVID", "TEST", 100, 114], ["Evaluation", "TEST", 162, 172], ["symptoms", "PROBLEM", 185, 193], ["demographic data", "TEST", 198, 214], ["the Model's performance", "TEST", 216, 239], ["Accuracy", "TEST", 272, 280], ["Specificity", "TEST", 282, 293], ["Sensitivity", "TEST", 299, 310], ["slight", "OBSERVATION_MODIFIER", 253, 259], ["increase", "OBSERVATION_MODIFIER", 260, 268]]], ["This increase is attributed to the rich categorical information present in Demographic and Symptoms data about suspected infection cases and Transformer based network; Tab-Net exploits attention mechanism to learn the characteristics, diagnosis automatically, and symptoms based on information in their dataset.Evaluation\u2022 In Task 3, the Model makes better use of available data by combining both types of representation, which complement each other and significantly improve the classification's performance.", [["infection", "DISEASE", 121, 130], ["Tab", "PROTEIN", 168, 171], ["Symptoms data", "TEST", 91, 104], ["suspected infection cases", "PROBLEM", 111, 136], ["symptoms", "PROBLEM", 264, 272], ["Evaluation", "TEST", 311, 321]]], ["It is observed that one data type, either cough features or symptoms' features, is insufficient to capture the features predicting COVID-19 disease diagnosis with reliable results with the Accuracy, Specificity, and Sensitivity of 96.5 \u00b1 0.5%, 96.5 \u00b1 0.3% and 96.2 \u00b1 0.7%.Evaluation\u2022 To further demonstrate the proposed Model's flexibility, the Model was trained with a multi-class classification setting to distinguish between four types of cough classes, including Bronchitis, Asthma, COVID-19 Positive, and COVID-19 Negative.", [["cough", "DISEASE", 442, 447], ["Bronchitis", "DISEASE", 467, 477], ["Asthma", "DISEASE", 479, 485], ["cough features", "PROBLEM", 42, 56], ["symptoms' features", "PROBLEM", 60, 78], ["the Accuracy", "TEST", 185, 197], ["Specificity", "TEST", 199, 210], ["Sensitivity", "TEST", 216, 227], ["Evaluation", "TEST", 272, 282], ["cough classes", "PROBLEM", 442, 455], ["Bronchitis", "PROBLEM", 467, 477], ["Asthma", "PROBLEM", 479, 485], ["COVID", "TEST", 487, 492], ["COVID", "TEST", 510, 515], ["cough", "OBSERVATION", 442, 447], ["Bronchitis", "OBSERVATION", 467, 477], ["Asthma", "OBSERVATION", 479, 485]]], ["Results show that the Model can certainly classify between four types Both types of data enable the Model to learn deeper relationships between temporal acoustic characteristics of cough sounds and Symptoms' features and hence perform better.InterpretabilityIt is demonstrated that the proposed framework benefits from the high accuracy and generality of deep neural networks and TabNet's interpretability, which is crucial for AI-empowered healthcare.", [["neural networks", "ANATOMY", 360, 375], ["cough", "DISEASE", 181, 186], ["neural networks", "MULTI-TISSUE_STRUCTURE", 360, 375], ["cough sounds", "PROBLEM", 181, 193], ["Symptoms' features", "PROBLEM", 198, 216], ["the high accuracy", "PROBLEM", 319, 336], ["deep neural networks", "PROBLEM", 355, 375], ["AI", "PROBLEM", 428, 430], ["cough", "OBSERVATION", 181, 186], ["deep", "ANATOMY_MODIFIER", 355, 359], ["neural networks", "OBSERVATION", 360, 375]]], ["Figure 7 and Figure 8 visualizes the symptoms of a healthy and COVID-19 infected individual.", [["Figure", "TEST", 0, 6], ["the symptoms", "PROBLEM", 33, 45], ["COVID", "TEST", 63, 68], ["infected", "OBSERVATION", 72, 80]]], ["It shows that the model comprehends the hidden pattern in symptoms data and its relationship with cough sounds.", [["cough", "DISEASE", 98, 103], ["symptoms data", "PROBLEM", 58, 71], ["cough sounds", "PROBLEM", 98, 110]]], ["To intuitively show the representation's quality, the cough features using t-sne and symptoms correlation matrix are visualized in Figure 9 and FigureIn Depth Clinical AnalysisAn in-depth analysis is conducted for different cough sounds diagnosed with different diseases based on the collected data.", [["cough", "DISEASE", 54, 59], ["cough sounds", "DISEASE", 224, 236], ["the cough features", "PROBLEM", 50, 68], ["t-sne", "TREATMENT", 75, 80], ["symptoms correlation matrix", "PROBLEM", 85, 112], ["Clinical AnalysisAn in-depth analysis", "TEST", 159, 196], ["different cough sounds", "PROBLEM", 214, 236], ["different diseases", "PROBLEM", 252, 270], ["the collected data", "TEST", 280, 298]]], ["Different types of cough samples are visualized in Figure 6 .", [["cough samples", "ANATOMY", 19, 32], ["cough", "DISEASE", 19, 24], ["cough samples", "CANCER", 19, 32], ["cough samples", "PROBLEM", 19, 32], ["cough", "OBSERVATION", 19, 24]]], ["Based on the analyzed data, the findings are as follows.In Depth Clinical AnalysisThe coughing sound consists of three phases-Phase 1-Initial burst, Phase 2-Noisy airflow, and Phase 3-Glottal closure.", [["Clinical Analysis", "TEST", 65, 82], ["The coughing sound", "TEST", 82, 100], ["Phase", "TEST", 149, 154], ["Noisy airflow", "TEST", 157, 170], ["Phase", "TEST", 176, 181], ["Glottal closure", "TREATMENT", 184, 199], ["coughing", "OBSERVATION", 86, 94], ["airflow", "ANATOMY", 163, 170]]], ["It is observed that in the cough sample of healthy individuals, phase 3 finished with vocal folds activity.", [["vocal folds", "ANATOMY", 86, 97], ["vocal folds activity", "PROBLEM", 86, 106]]], ["Figure 2 shows that after Phase 1, i.e., initial burst, the energy levels are high at higher frequencies.In Depth Clinical AnalysisAsthma & Bronchitis comes under the wet cough (carries mucus and sputum caused by bacteria or viruses, secretion in the lower airways) category.", [["mucus", "ANATOMY", 186, 191], ["sputum", "ANATOMY", 196, 202], ["lower airways", "ANATOMY", 251, 264], ["Bronchitis", "DISEASE", 140, 150], ["cough", "DISEASE", 171, 176], ["mucus", "MULTI-TISSUE_STRUCTURE", 186, 191], ["lower", "ORGANISM_SUBDIVISION", 251, 256], ["airways", "MULTI-TISSUE_STRUCTURE", 257, 264], ["the energy levels", "TEST", 56, 73], ["Bronchitis", "PROBLEM", 140, 150], ["the wet cough", "PROBLEM", 163, 176], ["mucus and sputum", "PROBLEM", 186, 202], ["bacteria", "PROBLEM", 213, 221], ["viruses", "PROBLEM", 225, 232], ["burst", "OBSERVATION_MODIFIER", 49, 54], ["high", "OBSERVATION_MODIFIER", 78, 82], ["Bronchitis", "OBSERVATION", 140, 150], ["lower", "ANATOMY_MODIFIER", 251, 256], ["airways", "ANATOMY", 257, 264]]], ["In particular, vocal fold activity looks random, and the energy is expended over a broader frequency band.", [["vocal fold", "ANATOMY", 15, 25], ["vocal fold activity", "PROBLEM", 15, 34], ["a broader frequency band", "TREATMENT", 81, 105], ["vocal fold", "ANATOMY", 15, 25]]], ["Asthma & Bronchitis Figure 3 and Figure 4 shows these characteristics and the energy level.In Depth Clinical AnalysisIt is observed that COVID-19 cough is continuous; energy distribution is spread across frequencies preceded by a short catch.", [["Asthma", "DISEASE", 0, 6], ["cough", "DISEASE", 146, 151], ["Asthma", "PROBLEM", 0, 6], ["Bronchitis Figure", "PROBLEM", 9, 26], ["Clinical Analysis", "TEST", 100, 117], ["COVID", "TEST", 137, 142], ["cough", "PROBLEM", 146, 151], ["Bronchitis", "OBSERVATION", 9, 19]]], ["By analyzing the mean energy distribution of many COVID-19 cough sounds, Energy distribution was high in Phase 2 and Phase 3.", [["cough", "DISEASE", 59, 64], ["many COVID", "TEST", 45, 55], ["cough sounds", "TEST", 59, 71], ["Energy distribution", "TEST", 73, 92]]], ["The abnormal oscillatory motion in the vocal folds may be produced by altered aerodynamics over the glottis due to respiratory irritation.", [["vocal folds", "ANATOMY", 39, 50], ["glottis", "ANATOMY", 100, 107], ["respiratory", "ANATOMY", 115, 126], ["respiratory irritation", "DISEASE", 115, 137], ["vocal folds", "MULTI-TISSUE_STRUCTURE", 39, 50], ["glottis", "ORGAN", 100, 107], ["The abnormal oscillatory motion in the vocal folds", "PROBLEM", 0, 50], ["altered aerodynamics over the glottis", "PROBLEM", 70, 107], ["respiratory irritation", "PROBLEM", 115, 137], ["abnormal", "OBSERVATION_MODIFIER", 4, 12], ["oscillatory motion", "OBSERVATION", 13, 31], ["vocal folds", "ANATOMY", 39, 50], ["altered", "OBSERVATION_MODIFIER", 70, 77], ["aerodynamics", "OBSERVATION", 78, 90], ["glottis", "ANATOMY", 100, 107], ["respiratory irritation", "OBSERVATION", 115, 137]]], ["Figure 5 shows the resultConclusionThis study brings forth a low cost, accurate and interpretable AI-based diagnostic tool for COVID-19 screening with good Accuracy.", [["This study", "TEST", 35, 45], ["COVID", "TEST", 127, 132], ["screening", "TEST", 136, 145]]], ["Data collection is being performed daily.", [["Data collection", "TEST", 0, 15]]], ["Experiments will be carried out in the future by incorporating different voice data features such as breathing sound, counting sound (natural voice samples), and sustained vowel phonation.", [["breathing sound", "TEST", 101, 116], ["counting sound (natural voice samples", "TEST", 118, 155], ["sustained vowel phonation", "PROBLEM", 162, 187], ["vowel phonation", "OBSERVATION", 172, 187]]], ["The results prove to be transparent, interpretable, and multi-model learning in cough classification research.A.1.", [["cough", "DISEASE", 80, 85]]], ["Mel Frequency Cepstral coefficients (MFCCs)Mel Frequency Cepstral coefficients represent the short-term power spectrum of a signal on the Mel-scale of the frequency.", [["Cepstral coefficients", "TEST", 14, 35], ["Frequency Cepstral coefficients", "TEST", 47, 78], ["short-term power", "OBSERVATION_MODIFIER", 93, 109]]], ["The hearing mechanism of human beings inspires MFCC.", [["MFCC", "ANATOMY", 47, 51], ["MFCC", "DISEASE", 47, 51], ["human", "ORGANISM", 25, 30], ["MFCC", "CANCER", 47, 51], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30]]], ["The coefficients of MEL-frequency that represent this transformation are called MFCCs.", [["MFCCs", "CELL_TYPE", 80, 85]]], ["Mel Frequency Cepstral coefficients (MFCCs)Where N denotes the number of samples in frame, y i [t] is the discrete time domain cough signal, obtained in Section 2.2.1, w(t) is the window function in time domain and Y (k) is the k th harmonic corresponding to the frequency f (k) = kF s /N where F s is the sampling frequency.", [["cough signal", "TEST", 127, 139], ["kF s", "TEST", 281, 285]]], ["MFCCs use Mel filter bank or triangular bandpass filter on each cough signal's DFT output, equally spaced on the Mel-scale.", [["MFCCs", "SIMPLE_CHEMICAL", 0, 5], ["Mel filter bank", "TREATMENT", 10, 25], ["triangular bandpass filter", "TREATMENT", 29, 55], ["each cough signal's DFT output", "TEST", 59, 89], ["triangular", "OBSERVATION_MODIFIER", 29, 39], ["bandpass filter", "OBSERVATION", 40, 55]]], ["At last, we apply the Discrete Cosine Transform(DCT) on the output of the log filter bank in order to get the MFCCs :A.1.", [["the Discrete Cosine Transform(DCT)", "TREATMENT", 18, 52], ["the log filter bank", "TREATMENT", 70, 89]]], ["Mel Frequency Cepstral coefficients (MFCCs)log(E(m)) cos \u03c0i M (m \u2212 0.5) (10) where i = 1, 2, . . . , l, l denotes the cepstrum order, E(m) and M are the filter bank energies and total number of mel-filters respectively.A.2.", [["Mel Frequency Cepstral coefficients", "TEST", 0, 35], ["the filter bank energies", "TREATMENT", 149, 173], ["mel-filters", "TREATMENT", 194, 205], ["filter", "OBSERVATION", 153, 159], ["bank energies", "OBSERVATION", 160, 173]]], ["Log energyTo calculate the log energy of each sub-segment, the following formula was used:A.2.", [["segment", "ANATOMY_MODIFIER", 50, 57]]], ["Log energywhere \u03b5 is a minimal positive value.A.3.", [["a minimal positive value", "PROBLEM", 21, 45], ["minimal", "OBSERVATION_MODIFIER", 23, 30], ["positive", "OBSERVATION", 31, 39]]], ["Zero crossing rate(ZCR)ZCR is used to calculate the number of times a signal crosses the zero axis.", [["ZCR", "TEST", 23, 26], ["zero axis", "OBSERVATION", 89, 98]]], ["To detect the cough signal's periodic nature, we compute the number of zero crossings for each sub-segment.A.3.", [["the cough signal's periodic nature", "PROBLEM", 10, 44], ["segment", "ANATOMY_MODIFIER", 99, 106]]], ["Zero crossing rate(ZCR)Where \u03a0[A] is a indicator function and is defined asA.4.", [["asA", "PROTEIN", 73, 76], ["asA", "TEST", 73, 76]]], ["SkewnessSkewness is the third order moment of a signal, Which measures the symmetry in a probability distribution.A.4.", [["third order moment", "OBSERVATION_MODIFIER", 24, 42]]], ["SkewnessWhere \u00b5 and \u03c3 is mean and stand deviation of the sub-segment y i [t] respectively.A.5.", [["segment", "ANATOMY_MODIFIER", 61, 68]]], ["EntropyWe compute the Entropy for each sub-segment of the cough signal to capture the difference between signal energy distributions.A.5.", [["EntropyWe", "TREATMENT", 0, 9], ["the cough signal", "PROBLEM", 54, 70], ["cough", "OBSERVATION", 58, 63], ["energy distributions", "OBSERVATION", 112, 132]]], ["EntropyIn the analysis of speech signals, Formant frequencies are used to capture a human vocal tract resonance's characteristics.", [["vocal tract", "ANATOMY", 90, 101], ["human", "ORGANISM", 84, 89], ["vocal tract", "ORGANISM_SUBDIVISION", 90, 101], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89]]], ["We used the Levinson-Durbin recursive procedure to select the parameters for the 14th order LPC model.", [["the Levinson", "TREATMENT", 8, 20], ["Durbin recursive procedure", "TREATMENT", 21, 47]]], ["The first four Formant frequencies(F1-F4) are enough to discriminate various acoustic features of airways.A.7.", [["airways", "ANATOMY", 98, 105], ["airways", "MULTI-TISSUE_STRUCTURE", 98, 105], ["airways", "ANATOMY", 98, 105]]], ["KurtosisKurtosis can be defined as the fourth-order moment of a signal, which measures the peakiness or heaviness associated with the cough subsegment probability distribution.A.7.", [["KurtosisKurtosis", "DISEASE", 0, 16], ["peakiness", "DISEASE", 91, 100], ["heaviness", "DISEASE", 104, 113], ["cough", "DISEASE", 134, 139], ["the peakiness", "PROBLEM", 87, 100], ["heaviness", "PROBLEM", 104, 113], ["the cough subsegment probability distribution", "PROBLEM", 130, 175], ["cough", "OBSERVATION", 134, 139]]], ["KurtosisWhere \u00b5 and \u03c3 is mean and stand deviation of the sub-segment y i [t] respectively.A.8.", [["mean", "OBSERVATION_MODIFIER", 25, 29], ["stand deviation", "OBSERVATION", 34, 49], ["sub", "ANATOMY_MODIFIER", 57, 60], ["segment", "ANATOMY_MODIFIER", 61, 68]]], ["Fundamental frequency(F0)To estimate the fundamental frequency (F0) of the cough sub-segment, we used the centerclipped auto-correlation method by removing the formant structure from the auto-correlation of the cough signal.", [["cough", "DISEASE", 211, 216], ["the centerclipped auto-correlation method", "TREATMENT", 102, 143], ["the cough signal", "PROBLEM", 207, 223], ["cough", "OBSERVATION", 211, 216]]], ["(Hoffer et al., 2018) and GLU.", [["GLU", "CHEMICAL", 26, 29], ["GLU", "TEST", 26, 29]]], ["FC layer map the input features to 2(n d + n a ) where n d and n a are size of the decision layer and size of the attention bottleneck respectively.", [["layer", "OBSERVATION_MODIFIER", 3, 8], ["size", "OBSERVATION_MODIFIER", 71, 75], ["size", "OBSERVATION_MODIFIER", 102, 106]]], ["GBN splits each batch in chunks of virtual batch size(BS), standard Batch normalization(BN) applies separately to each of these, and concatenates the results back into the original batch.B.0.2.", [["GBN", "CHEMICAL", 0, 3], ["GBN", "SIMPLE_CHEMICAL", 0, 3], ["GBN", "PROTEIN", 0, 3], ["GBN", "PROBLEM", 0, 3], ["virtual batch size", "TEST", 35, 53], ["BS", "TEST", 54, 56], ["standard Batch normalization(BN)", "TREATMENT", 59, 91], ["size", "OBSERVATION_MODIFIER", 49, 53]]], ["FEATURE TRANSFORMER (FT)The feature transformer is one of the main components of TabNet; it consists of 4 GLU layers, two are shared across the entire network, and two are step-dependent across each decision step allowing for more modeling flexibility.", [["TabNet", "GENE_OR_GENE_PRODUCT", 81, 87], ["TabNet", "PROTEIN", 81, 87], ["main", "OBSERVATION_MODIFIER", 62, 66], ["components", "OBSERVATION_MODIFIER", 67, 77], ["TabNet", "OBSERVATION", 81, 87], ["GLU layers", "OBSERVATION_MODIFIER", 106, 116]]], ["GLU layers are concatenated with each other after being multiplied by a constant scaling factor( \u221a 0.5).", [["GLU layers", "TISSUE", 0, 10], ["a constant scaling factor", "TREATMENT", 70, 95], ["layers", "OBSERVATION_MODIFIER", 4, 10]]], ["Feature Transformer process the filtered features by looking at all the symptoms features assessed and deciding which ones indicate which class.B.0.3.", [["the symptoms features", "PROBLEM", 68, 89]]], ["ATTENTIVE TRANSFORMER (AT)Attention Transformer is another main component of TabNet architecture.", [["TabNet", "GENE_OR_GENE_PRODUCT", 77, 83], ["TabNet", "PROTEIN", 77, 83], ["TabNet architecture", "OBSERVATION", 77, 96]]], ["It utilizes sparse intense wise features selection based on learned symptoms dataset and directs the model's attention by forcing the sparsity into the feature set, focusing on specific symptoms features only.", [["sparse intense wise features selection", "PROBLEM", 12, 50], ["learned symptoms dataset", "PROBLEM", 60, 84], ["specific symptoms features", "PROBLEM", 177, 203], ["sparse", "OBSERVATION_MODIFIER", 12, 18], ["intense", "OBSERVATION_MODIFIER", 19, 26]]], ["The FC handles the learning part of this block.", [["this block", "TREATMENT", 36, 46], ["FC", "OBSERVATION", 4, 6]]], ["TabNet uses the Sparsemax, Martins and Astudillo (2016) an alternative of softmax function for soft feature selection.", [["the Sparsemax", "TREATMENT", 12, 25], ["Martins", "TREATMENT", 27, 34], ["Astudillo", "TREATMENT", 39, 48], ["soft feature selection", "PROBLEM", 95, 117]]], ["Sparsemax activation function is differentiable and has forward and backward propagation.", [["differentiable", "OBSERVATION_MODIFIER", 33, 47], ["backward propagation", "OBSERVATION", 68, 88]]], ["Due to projection and thresholding, sparsemax process sparse probabilities lead to a selective and more compact attention focus on symptoms features.", [["sparsemax process", "PROBLEM", 36, 53], ["symptoms features", "PROBLEM", 131, 148]]]], "d9cdab48a9ee2076476c29fb3112ebb662121be4": [["Canine coronavirus (CCV) has been identified as one of the causative agents of viral enteritis in members of the Canidae.", [["Canine coronavirus", "DISEASE", 0, 18], ["viral enteritis", "DISEASE", 79, 94], ["Canine coronavirus", "ORGANISM", 0, 18], ["CCV", "ORGANISM", 20, 23], ["Canine coronavirus", "SPECIES", 0, 18], ["Canine coronavirus", "SPECIES", 0, 18], ["CCV", "SPECIES", 20, 23], ["Canine coronavirus", "PROBLEM", 0, 18], ["viral enteritis", "PROBLEM", 79, 94], ["coronavirus", "OBSERVATION", 7, 18], ["viral enteritis", "OBSERVATION", 79, 94]]], ["The presence of CCV infection has been reported in many countries.", [["CCV infection", "DISEASE", 16, 29], ["CCV", "ORGANISM", 16, 19], ["CCV", "SPECIES", 16, 19], ["CCV infection", "PROBLEM", 16, 29], ["CCV", "OBSERVATION_MODIFIER", 16, 19], ["infection", "OBSERVATION", 20, 29]]], ["Canine parvovirus, canine rotavirus, and astroviruses may also be responsible for canine viral enteritis (Carmichael and Binn, 1981 ) .", [["Canine parvovirus", "DISEASE", 0, 17], ["canine rotavirus", "DISEASE", 19, 35], ["astroviruses", "DISEASE", 41, 53], ["viral enteritis", "DISEASE", 89, 104], ["Canine parvovirus", "ORGANISM", 0, 17], ["canine rotavirus", "ORGANISM", 19, 35], ["astroviruses", "GENE_OR_GENE_PRODUCT", 41, 53], ["canine", "ORGANISM", 82, 88], ["Canine parvovirus", "SPECIES", 0, 17], ["canine rotavirus", "SPECIES", 19, 35], ["canine", "SPECIES", 82, 88], ["Canine parvovirus", "SPECIES", 0, 17], ["canine", "SPECIES", 19, 25], ["canine viral enteritis (Carmichael and Binn, 1981 )", "SPECIES", 82, 133], ["Canine parvovirus", "PROBLEM", 0, 17], ["canine rotavirus", "PROBLEM", 19, 35], ["astroviruses", "PROBLEM", 41, 53], ["canine viral enteritis", "PROBLEM", 82, 104], ["parvovirus", "OBSERVATION", 7, 17], ["may also be responsible for", "UNCERTAINTY", 54, 81], ["viral", "OBSERVATION_MODIFIER", 89, 94], ["enteritis", "OBSERVATION", 95, 104]]], ["CCV infection and other Present address: Department of Animal Health I, School of Veterinary Medicine, Azabu University, 1-17-71, Fuchinobe, Sagamihara, Kanagawa 229, Japan. viral enteric infections are highly contagious and spread rapidly through dog populations.", [["CCV infection", "DISEASE", 0, 13], ["viral enteric infections", "DISEASE", 174, 198], ["dog", "ORGANISM", 248, 251], ["CCV", "SPECIES", 0, 3], ["CCV infection", "PROBLEM", 0, 13], ["viral enteric infections", "PROBLEM", 174, 198], ["infection", "OBSERVATION", 4, 13], ["enteric", "ANATOMY", 180, 187], ["infections", "OBSERVATION", 188, 198], ["highly", "OBSERVATION_MODIFIER", 203, 209], ["contagious", "OBSERVATION_MODIFIER", 210, 220], ["spread", "OBSERVATION_MODIFIER", 225, 231], ["rapidly", "OBSERVATION_MODIFIER", 232, 239]]], ["Clinical signs of CCV infection vary from inapparent to those of rapidly fatal gastroenteritis.", [["CCV infection", "DISEASE", 18, 31], ["gastroenteritis", "DISEASE", 79, 94], ["CCV", "ORGANISM", 18, 21], ["CCV", "SPECIES", 18, 21], ["CCV infection", "PROBLEM", 18, 31], ["rapidly fatal gastroenteritis", "PROBLEM", 65, 94], ["CCV", "OBSERVATION_MODIFIER", 18, 21], ["infection", "OBSERVATION", 22, 31], ["rapidly", "OBSERVATION_MODIFIER", 65, 72], ["fatal", "OBSERVATION_MODIFIER", 73, 78], ["gastroenteritis", "OBSERVATION", 79, 94]]], ["It is impossible to distinguish between the various causes of gastroenteritis by clinical signs.", [["gastroenteritis", "DISEASE", 62, 77], ["gastroenteritis", "PROBLEM", 62, 77], ["clinical signs", "TEST", 81, 95], ["gastroenteritis", "OBSERVATION", 62, 77]]], ["Mixed infections with two or more agents, including bacteria and parasites, occur in nature, which further complicates the diagnosis of canine enteritis (Vandenberghe et al., 1980; Yasoshima et al., 1983) .Canine coronavirus (CCV) has been identified as one of the causative agents of viral enteritis in members of the Canidae.", [["infections", "DISEASE", 6, 16], ["canine enteritis", "DISEASE", 136, 152], ["Canine coronavirus", "DISEASE", 206, 224], ["viral enteritis", "DISEASE", 285, 300], ["canine", "ORGANISM", 136, 142], ["Canine coronavirus", "ORGANISM", 206, 224], ["CCV", "ORGANISM", 226, 229], ["Canine coronavirus", "SPECIES", 206, 224], ["canine", "SPECIES", 136, 142], ["Canine coronavirus", "SPECIES", 206, 224], ["CCV", "SPECIES", 226, 229], ["Mixed infections", "PROBLEM", 0, 16], ["bacteria", "PROBLEM", 52, 60], ["parasites", "PROBLEM", 65, 74], ["canine enteritis", "PROBLEM", 136, 152], ["Canine coronavirus", "PROBLEM", 206, 224], ["viral enteritis", "PROBLEM", 285, 300], ["infections", "OBSERVATION", 6, 16], ["parasites", "OBSERVATION", 65, 74], ["canine enteritis", "OBSERVATION", 136, 152], ["coronavirus", "OBSERVATION", 213, 224], ["viral enteritis", "OBSERVATION", 285, 300]]], ["The presence of CCV infection has been reported in many countriesIn the diagnosis of CCV infection, electron microscopy, virus isolation by cell culture and the immunofluorescent assay (IFA) have been used for the detection of CCV or its antigen (Binn et al., 1975; Keenan et al., 1976; Williams, 1980) .", [["cell", "ANATOMY", 140, 144], ["CCV infection", "DISEASE", 16, 29], ["CCV infection", "DISEASE", 85, 98], ["CCV", "ORGANISM", 16, 19], ["CCV", "ORGANISM", 85, 88], ["cell", "CELL", 140, 144], ["CCV", "ORGANISM", 227, 230], ["CCV", "SPECIES", 16, 19], ["CCV", "SPECIES", 85, 88], ["CCV", "SPECIES", 227, 230], ["CCV infection", "PROBLEM", 16, 29], ["CCV infection", "PROBLEM", 85, 98], ["electron microscopy", "TEST", 100, 119], ["virus isolation", "TREATMENT", 121, 136], ["cell culture", "TEST", 140, 152], ["the immunofluorescent assay", "TEST", 157, 184], ["CCV", "PROBLEM", 227, 230], ["CCV", "OBSERVATION_MODIFIER", 16, 19], ["infection", "OBSERVATION", 20, 29], ["CCV", "ANATOMY", 85, 88], ["infection", "OBSERVATION", 89, 98]]], ["The virus neutralization test (NT) and indirect IFA have also been used in serodiagnosis and serosurveys (Binn et al., 1975; Keenan et al., 1976; Appel et al., 1980; Heifer-Baker et al., 1980; Foreyt and Evermann, 1985) .", [["The virus neutralization test", "TEST", 0, 29], ["indirect IFA", "TEST", 39, 51]]], ["These procedures take a long time and are not suitable for handling many samples.", [["These procedures", "TREATMENT", 0, 16]]], ["Recently the enzyme-linked immunosorbent assay (ELISA) has been used for the detection of anti-viral antibodies and virus antigens (Voller et al., 1976; Kapikian et al., 1979; Callebaut et al., 1982; Crouch et al., 1984) .", [["anti-viral antibodies", "PROTEIN", 90, 111], ["virus antigens", "PROTEIN", 116, 130], ["the enzyme", "TEST", 9, 19], ["immunosorbent assay", "TEST", 27, 46], ["ELISA", "TEST", 48, 53], ["anti-viral antibodies", "PROBLEM", 90, 111]]], ["In the present report two ELISA procedures for the detection of anti-CCV antibody and CCV antigen are described.Virus and cellsCCV strain 1-71 (Binn et al., 1975 ) was obtained from the American Type Culture Collection (U.S.A.).", [["anti-CCV antibody", "GENE_OR_GENE_PRODUCT", 64, 81], ["CCV antigen", "GENE_OR_GENE_PRODUCT", 86, 97], ["Virus", "ORGANISM", 112, 117], ["cellsCCV strain 1-71", "ORGANISM", 122, 142], ["anti-CCV antibody", "PROTEIN", 64, 81], ["CCV antigen", "PROTEIN", 86, 97], ["anti-CCV", "SPECIES", 64, 72], ["CCV", "SPECIES", 86, 89], ["cellsCCV strain 1-71", "SPECIES", 122, 142], ["the detection", "TEST", 47, 60], ["anti-CCV antibody and CCV antigen", "PROBLEM", 64, 97], ["Virus", "PROBLEM", 112, 117], ["cellsCCV strain", "TEST", 122, 137]]], ["This virus was passaged in primary dog kidney cells and then in CRFK cells, derived from domestic cat kidney by Crandell et al. ( 1973 ) , and was obtained from Dr. J.F. Weaver, Naval Bioscience Laboratory, University of California, U.S.A. The feline cell line fcwf-4 (Horzinek et al., 1982 ) was kindly supplied by Dr. N.C. Pedersen, University of California, U.S.A., and was used for virus isolation experiments.Experimental infection of dogs with CCVOne litter of seven 21-day-old puppies was inoculated with CCV strain 1-17.", [["kidney cells", "ANATOMY", 39, 51], ["CRFK cells", "ANATOMY", 64, 74], ["kidney", "ANATOMY", 102, 108], ["cell line fcwf-4", "ANATOMY", 251, 267], ["infection", "DISEASE", 427, 436], ["dog", "ORGANISM", 35, 38], ["kidney cells", "CELL", 39, 51], ["CRFK cells", "CELL", 64, 74], ["cat", "ORGANISM", 98, 101], ["kidney", "ORGAN", 102, 108], ["feline", "ORGANISM", 244, 250], ["cell line fcwf-4", "CELL", 251, 267], ["dogs", "ORGANISM", 440, 444], ["puppies", "ORGANISM", 484, 491], ["primary dog kidney cells", "CELL_TYPE", 27, 51], ["CRFK cells", "CELL_LINE", 64, 74], ["dog", "SPECIES", 35, 38], ["feline", "SPECIES", 244, 250], ["dogs", "SPECIES", 440, 444], ["dog", "SPECIES", 35, 38], ["CCV", "SPECIES", 512, 515], ["This virus", "PROBLEM", 0, 10], ["The feline cell line fcwf", "TREATMENT", 240, 265], ["virus isolation experiments", "TREATMENT", 386, 413], ["Experimental infection of dogs", "PROBLEM", 414, 444], ["CCVOne litter", "TREATMENT", 450, 463], ["old puppies", "PROBLEM", 480, 491], ["CCV strain", "TEST", 512, 522], ["dog kidney cells", "OBSERVATION", 35, 51], ["kidney", "ANATOMY", 102, 108], ["feline cell line", "OBSERVATION", 244, 260], ["infection", "OBSERVATION", 427, 436]]], ["Three puppies were inoculated orally (dogs D1, D2 and D3; 103~ TCID50 of virus and three intranasally (dogs D4, D5 and D6; 102.2 TCID50); one puppy (dog D7) was kept as a non-inoculated control.", [["intranasally", "ANATOMY", 89, 101], ["puppies", "ORGANISM", 6, 13], ["puppy", "ORGANISM", 142, 147], ["dog", "ORGANISM", 149, 152], ["dogs", "SPECIES", 38, 42], ["dogs", "SPECIES", 103, 107], ["dog", "SPECIES", 149, 152], ["D3", "TEST", 54, 56], ["virus", "TREATMENT", 73, 78], ["D5", "TREATMENT", 112, 114], ["D6", "TREATMENT", 119, 121], ["a non-inoculated control", "TREATMENT", 169, 193]]], ["Serum samples were serially collected from each dog and examined for CCV antibody by ELISA and NT.Experimental infection of dogs with CCVRectal, nasal, and throat swabs were also collected from the dogs.", [["Serum samples", "ANATOMY", 0, 13], ["CCVRectal", "ANATOMY", 134, 143], ["nasal", "ANATOMY", 145, 150], ["throat swabs", "ANATOMY", 156, 168], ["infection", "DISEASE", 111, 120], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["dog", "ORGANISM", 48, 51], ["CCV", "ORGANISM", 69, 72], ["dogs", "ORGANISM", 124, 128], ["nasal", "ORGANISM_SUBDIVISION", 145, 150], ["throat swabs", "ORGANISM_SUBSTANCE", 156, 168], ["dogs", "ORGANISM", 198, 202], ["CCV antibody", "PROTEIN", 69, 81], ["dog", "SPECIES", 48, 51], ["dogs", "SPECIES", 124, 128], ["dogs", "SPECIES", 198, 202], ["CCV", "SPECIES", 69, 72], ["Serum samples", "TEST", 0, 13], ["CCV antibody", "TEST", 69, 81], ["NT", "PROBLEM", 95, 97], ["Experimental infection of dogs", "PROBLEM", 98, 128], ["CCVRectal, nasal", "TREATMENT", 134, 150], [", and throat swabs", "TEST", 150, 168], ["infection", "OBSERVATION", 111, 120], ["nasal", "ANATOMY", 145, 150], ["throat", "ANATOMY", 156, 162]]], ["These specimens were suspended in 3 ml of Eagle's minimum essential medium containing 10% tryptose phosphate broth, 1% fetal calf serum, 10 mM N-2hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) and antibiotics, and the suspensions were clarified by low-speed centrifugation.", [["specimens", "ANATOMY", 6, 15], ["fetal calf serum", "ANATOMY", 119, 135], ["tryptose phosphate", "CHEMICAL", 90, 108], ["N-2hydroxyethylpiperazine-N'-2-ethanesulfonic acid", "CHEMICAL", 143, 193], ["HEPES", "CHEMICAL", 195, 200], ["tryptose phosphate", "CHEMICAL", 90, 108], ["N-2hydroxyethylpiperazine-N'-2-ethanesulfonic acid", "CHEMICAL", 143, 193], ["HEPES", "CHEMICAL", 195, 200], ["tryptose", "SIMPLE_CHEMICAL", 90, 98], ["calf", "ORGANISM", 125, 129], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["N-2hydroxyethylpiperazine-N'-2-ethanesulfonic acid", "SIMPLE_CHEMICAL", 143, 193], ["HEPES", "SIMPLE_CHEMICAL", 195, 200], ["calf", "SPECIES", 125, 129], ["These specimens", "TEST", 0, 15], ["10% tryptose phosphate broth", "TREATMENT", 86, 114], ["fetal calf serum", "TEST", 119, 135], ["2hydroxyethylpiperazine", "TREATMENT", 145, 168], ["ethanesulfonic acid (HEPES", "TREATMENT", 174, 200], ["antibiotics", "TREATMENT", 206, 217], ["the suspensions", "TREATMENT", 223, 238], ["calf", "ANATOMY", 125, 129]]], ["The supernatants were stored at -20 \u00b0C until examined.", [["supernatants", "ANATOMY", 4, 16]]], ["Some dogs were killed at post-inoculation day (PID) 5 (dogs D3 and D6) or PID 11 (dogs D2 and D5) and necropsied.", [["dogs", "ORGANISM", 5, 9], ["dogs", "SPECIES", 5, 9], ["dogs", "SPECIES", 55, 59], ["dogs", "SPECIES", 82, 86], ["Some dogs", "PROBLEM", 0, 9], ["dogs D3 and D6)", "TREATMENT", 55, 70], ["PID", "PROBLEM", 74, 77]]], ["Each organ was divided into two parts; one part was quenched in n-hexane at -70\u00b0C for viral antigen detection by IFA, and the other was stored at -20 \u00b0 C for virus isolation by cell culture and viral antigen detection by the F~LISA developed in this study.", [["organ", "ANATOMY", 5, 10], ["cell", "ANATOMY", 177, 181], ["n-hexane", "CHEMICAL", 64, 72], ["n-hexane", "CHEMICAL", 64, 72], ["organ", "ORGAN", 5, 10], ["n-hexane", "SIMPLE_CHEMICAL", 64, 72], ["C", "GENE_OR_GENE_PRODUCT", 80, 81], ["cell", "CELL", 177, 181], ["viral antigen detection", "TEST", 86, 109], ["IFA", "TEST", 113, 116], ["virus isolation", "TREATMENT", 158, 173], ["cell culture", "TEST", 177, 189], ["viral antigen detection", "TEST", 194, 217], ["this study", "TEST", 245, 255]]], ["For these assays frozen materials were thawed and 10% homogenates were prepared in the medium used for the swab specimens.Antisera against coronavirusesAntisera against CCV strain 1-17 were prepared in rabbits.", [["homogenates", "ANATOMY", 54, 65], ["swab specimens", "ANATOMY", 107, 121], ["coronaviruses", "DISEASE", 139, 152], ["Antisera", "ORGANISM_SUBSTANCE", 122, 130], ["coronaviruses", "ORGANISM", 139, 152], ["Antisera", "ORGANISM_SUBSTANCE", 152, 160], ["CCV strain 1-17", "ORGANISM", 169, 184], ["rabbits", "ORGANISM", 202, 209], ["coronaviruses", "SPECIES", 139, 152], ["rabbits", "SPECIES", 202, 209], ["CCV", "SPECIES", 169, 172], ["rabbits", "SPECIES", 202, 209], ["these assays frozen materials", "TEST", 4, 33], ["the swab specimens", "TEST", 103, 121], ["Antisera", "TREATMENT", 122, 130], ["coronaviruses", "PROBLEM", 139, 152], ["Antisera", "TREATMENT", 152, 160], ["CCV strain", "TEST", 169, 179]]], ["Virus antigens purified by the method of Makino et al. (1983 Makino et al. ( , 1984 were mixed with Freund's complete adjuvant, and injected into the foot pad.", [["foot pad", "ANATOMY", 150, 158], ["Virus", "ORGANISM", 0, 5], ["foot", "ORGANISM_SUBDIVISION", 150, 154], ["pad", "ORGANISM_SUBDIVISION", 155, 158], ["Virus antigens", "PROTEIN", 0, 14], ["Virus antigens", "PROBLEM", 0, 14], ["Freund's complete adjuvant", "TREATMENT", 100, 126], ["foot", "ANATOMY", 150, 154]]], ["Three weeks later each rabbit received a similar injection, and sera were obtained 1 week after this booster inoculation.", [["sera", "ANATOMY", 64, 68], ["rabbit", "ORGANISM", 23, 29], ["sera", "ORGANISM_SUBSTANCE", 64, 68], ["rabbit", "SPECIES", 23, 29], ["rabbit", "SPECIES", 23, 29], ["a similar injection", "TREATMENT", 39, 58], ["this booster inoculation", "TREATMENT", 96, 120]]], ["Serum from a cat experimentally infected with feline infectious peritonitis virus (FIPV) was kindly supplied by Dr. R. Goitsuka (Department of Veterinary Medicine, University of Tokyo, Japan).", [["Serum", "ANATOMY", 0, 5], ["feline infectious peritonitis", "DISEASE", 46, 75], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cat", "ORGANISM", 13, 16], ["feline infectious peritonitis virus", "ORGANISM", 46, 81], ["cat", "SPECIES", 13, 16], ["feline infectious peritonitis virus", "SPECIES", 46, 81], ["feline infectious peritonitis virus", "SPECIES", 46, 81], ["FIPV", "SPECIES", 83, 87], ["Serum", "TEST", 0, 5], ["feline infectious peritonitis virus", "PROBLEM", 46, 81], ["feline", "OBSERVATION_MODIFIER", 46, 52], ["infectious", "OBSERVATION_MODIFIER", 53, 63], ["peritonitis", "OBSERVATION", 64, 75]]], ["This serum had a neutralizing titer of 600 000 against CCV strain 1-71.Antisera against coronavirusesELISA procedure for the detection of antibody to CCV CRFK cells, which were inoculated with CCV strain 1-71 at a multiplicity of infection of 0.1, were incubated at 37 \u00b0C for 24 h.", [["serum", "ANATOMY", 5, 10], ["CCV CRFK cells", "ANATOMY", 150, 164], ["infection", "DISEASE", 230, 239], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["Antisera", "ORGANISM_SUBSTANCE", 71, 79], ["CCV CRFK cells", "CELL", 150, 164], ["CCV strain 1-71", "ORGANISM", 193, 208], ["CCV CRFK cells", "CELL_LINE", 150, 164], ["CCV strain 1-71", "SPECIES", 55, 70], ["CCV", "SPECIES", 150, 153], ["CCV strain 1-71", "SPECIES", 193, 208], ["This serum", "TEST", 0, 10], ["a neutralizing titer", "TEST", 15, 35], ["CCV strain", "TEST", 55, 65], ["Antisera", "TREATMENT", 71, 79], ["coronavirusesELISA procedure", "TREATMENT", 88, 116], ["the detection", "TEST", 121, 134], ["antibody to CCV CRFK cells", "PROBLEM", 138, 164], ["CCV strain", "TEST", 193, 203], ["infection", "PROBLEM", 230, 239], ["infection", "OBSERVATION", 230, 239]]], ["The infected cells were scraped off using a rubber policeman and washed three times with phosphate buffered saline (PBS), and 108 cells were resuspended in 5.5 ml of PBS containing 0.3% sodium deoxycholate (Difco, U.S.A.).", [["cells", "ANATOMY", 13, 18], ["cells", "ANATOMY", 130, 135], ["phosphate", "CHEMICAL", 89, 98], ["sodium deoxycholate", "CHEMICAL", 186, 205], ["phosphate", "CHEMICAL", 89, 98], ["sodium deoxycholate", "CHEMICAL", 186, 205], ["cells", "CELL", 13, 18], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 89, 114], ["cells", "CELL", 130, 135], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 186, 205], ["infected cells", "CELL_TYPE", 4, 18], ["The infected cells", "PROBLEM", 0, 18], ["a rubber policeman", "TREATMENT", 42, 60], ["phosphate buffered saline (PBS", "TREATMENT", 89, 119], ["PBS", "TREATMENT", 166, 169], ["0.3% sodium deoxycholate", "TREATMENT", 181, 205], ["infected cells", "OBSERVATION", 4, 18]]], ["The suspension was incubated on ice for 30 min, centrifuged at 90 000\u00d7g for 30 min, and the supernatant was used as the ELISA antigen.", [["supernatant", "ANATOMY", 92, 103], ["ELISA antigen", "PROTEIN", 120, 133], ["The suspension", "TREATMENT", 0, 14], ["ice", "TREATMENT", 32, 35], ["the supernatant", "TREATMENT", 88, 103], ["the ELISA antigen", "TEST", 116, 133], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["Mock infected cells were treated in the same manner and used as the control antigen.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["Mock infected cells", "TREATMENT", 0, 19], ["infected cells", "OBSERVATION", 5, 19]]], ["The protein contents of these antigens were measured by the method of Lowry et al. (1951 ) .", [["antigens", "PROTEIN", 30, 38], ["these antigens", "TEST", 24, 38]]], ["These antigens were stored at -70 \u00b0 C until use.Antisera against coronavirusesFor the ELISA, virus antigen and control antigen were diluted to an appropriate concentration in PBS, and 100-#1 volumes of the dilutions were dispensed into the wells of 96-well flat-bottomed Immunoplates (Nunc, Denmark).", [["coronaviruses", "DISEASE", 65, 78], ["Antisera", "ORGANISM_SUBSTANCE", 48, 56], ["coronaviruses", "ORGANISM", 65, 78], ["antigens", "PROTEIN", 6, 14], ["virus antigen", "PROTEIN", 93, 106], ["coronaviruses", "SPECIES", 65, 78], ["These antigens", "TEST", 0, 14], ["Antisera", "TREATMENT", 48, 56], ["coronaviruses", "PROBLEM", 65, 78], ["the ELISA", "TEST", 82, 91], ["virus antigen", "TEST", 93, 106], ["control antigen", "TEST", 111, 126], ["the dilutions", "TEST", 202, 215]]], ["After overnight incubation at 4\u00b0C, the solutions were decanted and the sensitized wells were preincubated with 100 #l/well of PBS containing 0.1% bovine serum albumin (Armour, U.S.A.) for 1 h at 37\u00b0C, followed by a single wash with PBS containing 0.05% Tween 20 (PT).", [["serum", "ANATOMY", 153, 158], ["Tween 20", "CHEMICAL", 253, 261], ["bovine", "ORGANISM", 146, 152], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["albumin", "ORGANISM_SUBSTANCE", 159, 166], ["bovine", "SPECIES", 146, 152], ["bovine", "SPECIES", 146, 152], ["the solutions", "TREATMENT", 35, 48], ["the sensitized wells", "TREATMENT", 67, 87], ["PBS", "TREATMENT", 126, 129], ["0.1% bovine serum albumin", "TREATMENT", 141, 166], ["a single wash with PBS", "TREATMENT", 213, 235]]], ["Test and control sera were serially diluted two-fold in PT containing 10% calf serum (PTCS), and 50-/~1 aliquots were dispensed into each well of virus antigen-coated and control antigen-coated plates.", [["sera", "ANATOMY", 17, 21], ["calf serum", "ANATOMY", 74, 84], ["PTCS", "ANATOMY", 86, 90], ["sera", "ORGANISM_SUBSTANCE", 17, 21], ["calf", "ORGANISM", 74, 78], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["calf", "SPECIES", 74, 78], ["Test and control sera", "TEST", 0, 21], ["PT", "TEST", 56, 58], ["PTCS", "TEST", 86, 90], ["virus antigen", "TREATMENT", 146, 159], ["control antigen-coated plates", "TREATMENT", 171, 200]]], ["After incubation for 1 h at room temperature, wells were washed three times with PT and again incubated with 50-/~1 volumes of peroxidase-conjugated goat anti-dog IgG (Cappel, U.S.A.) for another hour at room temperature.", [["peroxidase", "GENE_OR_GENE_PRODUCT", 127, 137], ["goat", "ORGANISM", 149, 153], ["anti-dog IgG", "SIMPLE_CHEMICAL", 154, 166], ["peroxidase", "PROTEIN", 127, 137], ["conjugated goat anti-dog IgG", "PROTEIN", 138, 166], ["goat", "SPECIES", 149, 153], ["goat", "SPECIES", 149, 153], ["PT", "TREATMENT", 81, 83], ["peroxidase", "TREATMENT", 127, 137]]], ["The wells were again washed, and 100/~1 of substrate solution was placed in each well.", [["substrate solution", "TREATMENT", 43, 61]]], ["The solution consisted of 50 ml 0.1 M citric acid, 50 ml 0.2 M disodium hydrogen phosphate, 30 mg 2,2azino-di-[ 3-ethylbenzthiazoline sulfonate ] diammonium salt (ABTS, Boehringer Mannheim GmbH, West Germany), and 10 #1 30% hydrogen peroxide.", [["citric acid", "CHEMICAL", 38, 49], ["disodium hydrogen phosphate", "CHEMICAL", 63, 90], ["2,2azino-di-[ 3-ethylbenzthiazoline sulfonate", "CHEMICAL", 98, 143], ["diammonium salt", "CHEMICAL", 146, 161], ["ABTS", "CHEMICAL", 163, 167], ["hydrogen peroxide", "CHEMICAL", 224, 241], ["citric acid", "CHEMICAL", 38, 49], ["disodium hydrogen phosphate", "CHEMICAL", 63, 90], ["2,2azino-di-[ 3-ethylbenzthiazoline sulfonate ] diammonium salt", "CHEMICAL", 98, 161], ["ABTS", "CHEMICAL", 163, 167], ["hydrogen peroxide", "CHEMICAL", 224, 241], ["citric acid", "SIMPLE_CHEMICAL", 38, 49], ["disodium hydrogen phosphate", "SIMPLE_CHEMICAL", 63, 90], ["2,2azino-di-[ 3-ethylbenzthiazoline sulfonate ] diammonium salt", "SIMPLE_CHEMICAL", 98, 161], ["ABTS", "SIMPLE_CHEMICAL", 163, 167], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 224, 241], ["The solution", "TREATMENT", 0, 12], ["citric acid", "TREATMENT", 38, 49], ["disodium hydrogen phosphate", "TREATMENT", 63, 90], ["ethylbenzthiazoline sulfonate ] diammonium salt", "TREATMENT", 114, 161]]], ["After 1 h of incubation at room temperature, optical density was measured at 405 nm with a Titertek Multiskan (Flow Laboratories, U.S.A. ).", [["density", "OBSERVATION", 53, 60]]], ["The ELISA value of each sample was obtained by subtracting the absorbance of the control antigen-coated well from that of the virus antigen-coated well; an ELISA value greater than 0.1 was considered to be positive for the reaction.", [["sample", "ANATOMY", 24, 30], ["virus antigen", "PROTEIN", 126, 139], ["The ELISA value", "TEST", 0, 15], ["the control antigen", "TEST", 77, 96], ["the virus antigen", "TEST", 122, 139], ["an ELISA value", "TEST", 153, 167], ["the reaction", "PROBLEM", 219, 231]]], ["The ELISA antibody titer was expressed as the reciprocal of the highest positive serum dilution.Virus neutralization testTest serum was heated at 56\u00b0C for 30 min, then serially diluted two-fold and mixed with an equal volume of virus solution containing 200 plaqueforming units/0.2 ml of CCV strain 1-71 and was incubated at 37\u00b0C for 1 h.", [["serum", "ANATOMY", 81, 86], ["serum", "ANATOMY", 126, 131], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["Virus", "ORGANISM", 96, 101], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["The ELISA antibody titer", "TEST", 0, 24], ["the highest positive serum dilution", "PROBLEM", 60, 95], ["Virus neutralization test", "TEST", 96, 121], ["Test serum", "TEST", 121, 131], ["an equal volume of virus solution", "TREATMENT", 209, 242], ["CCV strain", "TEST", 288, 298]]], ["The mixture was assayed by the plaque-counting method (Tuchiya et al., 1987 ) , and the neutralization titer was expressed as the reciprocal of the serum dilution that reduced the plaque count to 50% of the control value.ELISA procedure for the detection of CCV antigenThe double antibody sandwich method was used with anti-FIPV cat serum as the capture antibody.", [["plaque", "ANATOMY", 31, 37], ["serum", "ANATOMY", 148, 153], ["plaque", "ANATOMY", 180, 186], ["serum", "ANATOMY", 333, 338], ["CCV antigen", "CHEMICAL", 258, 269], ["serum", "ORGANISM_SUBSTANCE", 148, 153], ["plaque", "PATHOLOGICAL_FORMATION", 180, 186], ["CCV antigen", "GENE_OR_GENE_PRODUCT", 258, 269], ["cat", "ORGANISM", 329, 332], ["serum", "ORGANISM_SUBSTANCE", 333, 338], ["CCV antigen", "PROTEIN", 258, 269], ["anti-FIPV", "PROTEIN", 319, 328], ["CCV", "SPECIES", 258, 261], ["anti-FIPV", "SPECIES", 319, 328], ["cat", "SPECIES", 329, 332], ["the neutralization titer", "TEST", 84, 108], ["the serum dilution", "TEST", 144, 162], ["the plaque count", "TEST", 176, 192], ["ELISA procedure", "TREATMENT", 221, 236], ["the detection", "TEST", 241, 254], ["CCV antigen", "TEST", 258, 269], ["The double antibody sandwich method", "TREATMENT", 269, 304], ["anti-FIPV cat serum", "TEST", 319, 338], ["the capture antibody", "TEST", 342, 362], ["plaque", "OBSERVATION_MODIFIER", 180, 186]]], ["Cat anti-FIPV serum and anti-CCV antibody-free serum were diluted at an optimal concentration in 50 mM carbonate buffer, pH 9.6, and 100/~1 of each serum was dispensed into individual wells of 96well Immunoplates.", [["serum", "ANATOMY", 14, 19], ["serum", "ANATOMY", 47, 52], ["serum", "ANATOMY", 148, 153], ["carbonate", "CHEMICAL", 103, 112], ["carbonate", "CHEMICAL", 103, 112], ["Cat", "GENE_OR_GENE_PRODUCT", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["anti-CCV antibody", "GENE_OR_GENE_PRODUCT", 24, 41], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["carbonate", "SIMPLE_CHEMICAL", 103, 112], ["serum", "ORGANISM_SUBSTANCE", 148, 153], ["Cat anti-FIPV serum", "PROTEIN", 0, 19], ["anti-CCV antibody", "PROTEIN", 24, 41], ["anti-FIPV", "SPECIES", 4, 13], ["anti-CCV", "SPECIES", 24, 32], ["Cat anti-FIPV serum", "TEST", 0, 19], ["anti-CCV antibody", "TEST", 24, 41], ["free serum", "TEST", 42, 52], ["50 mM carbonate buffer", "TREATMENT", 97, 119], ["pH", "TEST", 121, 123], ["each serum", "TEST", 143, 153]]], ["After overnight incubation at 4 \u00b0 C, serum solutions were decanted and wells were preincubated with 100 ~l/well of PBS containing 0.1% bovine serum albumin for 1 h at 37\u00b0C followed by one wash with PT.", [["serum", "ANATOMY", 37, 42], ["serum", "ANATOMY", 142, 147], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["bovine", "ORGANISM", 135, 141], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["albumin", "GENE_OR_GENE_PRODUCT", 148, 155], ["bovine", "SPECIES", 135, 141], ["bovine", "SPECIES", 135, 141], ["serum solutions", "TREATMENT", 37, 52], ["PBS", "TREATMENT", 115, 118], ["0.1% bovine serum albumin", "TREATMENT", 130, 155], ["PT", "TREATMENT", 198, 200]]], ["Specimen solutions were diluted 1 : 2 in PBS containing 0. i % Tween 20, and 100-/zl aliquots were distributed into each well of the anti-FIPV, serum-coated and anti-CCV antibody-free, serum-coated wells.", [["serum", "ANATOMY", 144, 149], ["serum", "ANATOMY", 185, 190], ["Tween", "CHEMICAL", 63, 68], ["anti-FIPV", "SIMPLE_CHEMICAL", 133, 142], ["serum", "ORGANISM_SUBSTANCE", 144, 149], ["anti-CCV antibody", "SIMPLE_CHEMICAL", 161, 178], ["serum", "ORGANISM_SUBSTANCE", 185, 190], ["anti-FIPV", "PROTEIN", 133, 142], ["serum-coated and anti-CCV antibody", "PROTEIN", 144, 178], ["Specimen solutions", "TREATMENT", 0, 18], ["/zl aliquots", "TREATMENT", 81, 93], ["the anti-FIPV", "TEST", 129, 142], ["serum", "TEST", 144, 149], ["anti-CCV antibody", "TEST", 161, 178], ["serum", "TEST", 185, 190]]], ["After overnight incubation at 4\u00b0C, wells were washed with PT three times and incubated with 50-/~1 volumes of rabbit anti-CCV serum in PTCS for 1 h at room temperature.", [["serum", "ANATOMY", 126, 131], ["PTCS", "CHEMICAL", 135, 139], ["rabbit", "ORGANISM", 110, 116], ["anti-CCV", "ORGANISM_SUBSTANCE", 117, 125], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["rabbit", "SPECIES", 110, 116], ["rabbit", "SPECIES", 110, 116], ["anti-CCV", "SPECIES", 117, 125], ["PT", "TREATMENT", 58, 60]]], ["The wells were washed and again incubated with goat anti-rabbit IgG peroxidase conjugate (Miles-Yada Ltd., Israel) in PTCS for another hour at room temperature.", [["goat", "ORGANISM", 47, 51], ["peroxidase conjugate", "SIMPLE_CHEMICAL", 68, 88], ["goat anti-rabbit IgG peroxidase", "PROTEIN", 47, 78], ["goat", "SPECIES", 47, 51], ["anti-rabbit", "SPECIES", 52, 63], ["goat", "SPECIES", 47, 51], ["anti-rabbit", "SPECIES", 52, 63], ["goat anti-rabbit IgG peroxidase conjugate", "TREATMENT", 47, 88]]], ["The wells were then washed, and the amount of conjugate bound to each well was determined as described above.", [["conjugate bound", "PROBLEM", 46, 61]]], ["The ELISA value of each specimen was obtained by subtracting the absorbance of the anti-CCV antibodyfree, serum-coated well from that of anti-FIPV serum-coated well.", [["specimen", "ANATOMY", 24, 32], ["serum", "ANATOMY", 106, 111], ["serum", "ANATOMY", 147, 152], ["anti-CCV", "SIMPLE_CHEMICAL", 83, 91], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["anti-FIPV", "SIMPLE_CHEMICAL", 137, 146], ["serum", "ORGANISM_SUBSTANCE", 147, 152], ["anti-CCV antibodyfree", "PROTEIN", 83, 104], ["anti-FIPV", "PROTEIN", 137, 146], ["anti-CCV", "SPECIES", 83, 91], ["The ELISA value", "TEST", 0, 15], ["the anti-CCV antibodyfree", "TREATMENT", 79, 104], ["serum", "TEST", 106, 111], ["anti-FIPV serum", "TEST", 137, 152]]], ["The cutoff value was calculated by the method of Smirnov ( 1941 ) .Antigen absorption testThe specificity of the antigen-detection ELISA was examined using the absorption test.", [["The cutoff value", "TEST", 0, 16], ["Antigen absorption test", "TEST", 67, 90], ["the antigen-detection ELISA", "TEST", 109, 136], ["the absorption test", "TEST", 156, 175]]], ["Rectal swab specimens with a high ELISA value from dogs D 1 and D4 were mixed with equal volumes ofcoronavirus antibody-negative and -positive dog serum, and the mixtures were incubated at 4 \u00b0C overnight.", [["Rectal swab specimens", "ANATOMY", 0, 21], ["serum", "ANATOMY", 147, 152], ["Rectal swab specimens", "CANCER", 0, 21], ["dog", "ORGANISM", 143, 146], ["serum", "ORGANISM_SUBSTANCE", 147, 152], ["dogs", "SPECIES", 51, 55], ["dog", "SPECIES", 143, 146], ["dog", "SPECIES", 143, 146], ["Rectal swab specimens", "TEST", 0, 21], ["a high ELISA value", "TEST", 27, 45], ["dogs D 1 and D4", "TEST", 51, 66], ["antibody", "TEST", 111, 119], ["positive dog serum", "PROBLEM", 134, 152], ["the mixtures", "TEST", 158, 170]]], ["The reduction of the ELISA value by treatment with anti-CCV serum and the lack of reduction with antibody-free serum indicated the specificity of the procedure.Virus isolationSpecimens from experimental dogs were inoculated with CRFK and fcwf-4 cells, and each culture medium was blindly passaged three times.", [["anti-CCV serum", "ANATOMY", 51, 65], ["serum", "ANATOMY", 111, 116], ["CRFK", "ANATOMY", 229, 233], ["fcwf-4 cells", "ANATOMY", 238, 250], ["anti-CCV", "ORGANISM", 51, 59], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["Virus", "ORGANISM", 160, 165], ["dogs", "ORGANISM", 203, 207], ["CRFK", "CELL", 229, 233], ["fcwf-4 cells", "CELL", 238, 250], ["antibody", "PROTEIN", 97, 105], ["CRFK and fcwf-4 cells", "CELL_LINE", 229, 250], ["dogs", "SPECIES", 203, 207], ["anti-CCV", "SPECIES", 51, 59], ["the ELISA value", "TEST", 17, 32], ["treatment", "TREATMENT", 36, 45], ["anti-CCV serum", "TEST", 51, 65], ["antibody-free serum", "TEST", 97, 116], ["the procedure", "TREATMENT", 146, 159], ["Virus isolationSpecimens", "PROBLEM", 160, 184], ["experimental dogs", "TEST", 190, 207], ["CRFK", "TEST", 229, 233], ["fcwf", "TEST", 238, 242], ["each culture medium", "TEST", 256, 275], ["reduction", "OBSERVATION_MODIFIER", 4, 13]]], ["Isolated cytopathic agents were identified as CCV by the IFA technique described below.IFAThe localization of viral antigens in the frozen sections of organs from experimental dogs was demonstrated by an indirect IFA technique using rabbit anti-CCV serum and fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (Miles-Yada Ltd., Israel).Determination of optimal antigen concentration for antibody-detection ELISAAntigen concentrations ranging from 4 to 0.125 #g/well were coated onto Immunoplates and the optimal antigen concentration for the procedure was determined.", [["sections", "ANATOMY", 139, 147], ["organs", "ANATOMY", 151, 157], ["serum", "ANATOMY", 249, 254], ["fluorescein isothiocyanate", "CHEMICAL", 259, 285], ["fluorescein isothiocyanate", "CHEMICAL", 259, 285], ["organs", "ORGAN", 151, 157], ["dogs", "ORGANISM", 176, 180], ["rabbit", "ORGANISM", 233, 239], ["anti-CCV", "ORGANISM", 240, 248], ["serum", "ORGANISM_SUBSTANCE", 249, 254], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 259, 285], ["goat", "ORGANISM", 297, 301], ["ELISAAntigen", "SIMPLE_CHEMICAL", 414, 426], ["viral antigens", "PROTEIN", 110, 124], ["fluorescein isothiocyanate-conjugated goat anti-rabbit IgG", "PROTEIN", 259, 317], ["dogs", "SPECIES", 176, 180], ["rabbit", "SPECIES", 233, 239], ["goat", "SPECIES", 297, 301], ["anti-rabbit", "SPECIES", 302, 313], ["CCV", "SPECIES", 46, 49], ["rabbit", "SPECIES", 233, 239], ["anti-CCV", "SPECIES", 240, 248], ["goat", "SPECIES", 297, 301], ["Isolated cytopathic agents", "TREATMENT", 0, 26], ["viral antigens", "PROBLEM", 110, 124], ["experimental dogs", "PROBLEM", 163, 180], ["an indirect IFA technique", "TEST", 201, 226], ["rabbit anti-CCV serum", "TEST", 233, 254], ["fluorescein isothiocyanate", "TEST", 259, 285], ["conjugated goat anti-rabbit IgG", "TREATMENT", 286, 317], ["optimal antigen concentration", "TEST", 361, 390], ["antibody", "TEST", 395, 403], ["Immunoplates", "TREATMENT", 491, 503], ["the procedure", "TREATMENT", 546, 559], ["cytopathic agents", "OBSERVATION", 9, 26], ["viral antigens", "OBSERVATION", 110, 124], ["organs", "ANATOMY", 151, 157]]], ["As shown in Fig. 1 , antigen protein concentrations from 4 to 1 /~g/well reacted similarly with CCV antibody-positive canine serum, whereas the ELISA value decreased at concentrations below 1 /zg/well.", [["serum", "ANATOMY", 125, 130], ["CCV", "ORGANISM", 96, 99], ["canine", "ORGANISM", 118, 124], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["antigen protein", "PROTEIN", 21, 36], ["CCV antibody", "PROTEIN", 96, 108], ["CCV", "SPECIES", 96, 99], ["canine", "SPECIES", 118, 124], ["antigen protein concentrations", "TEST", 21, 51], ["CCV antibody", "TEST", 96, 108], ["positive canine serum", "PROBLEM", 109, 130], ["the ELISA value", "TEST", 140, 155]]], ["An antigen concentration of 1/tg/well was therefore used for subsequent experiments.Determination of optimal dilution of capture antibody for antigen-detection ELISAThe optimal concentration of anti-FIPV serum used as the capture antibody was determined by checker-board titration.", [["serum", "ANATOMY", 204, 209], ["anti-FIPV", "ORGANISM", 194, 203], ["serum", "ORGANISM_SUBSTANCE", 204, 209], ["anti-FIPV", "PROTEIN", 194, 203], ["anti-FIPV", "SPECIES", 194, 203], ["An antigen concentration", "TREATMENT", 0, 24], ["capture antibody", "TEST", 121, 137], ["antigen", "TEST", 142, 149], ["anti-FIPV serum", "TREATMENT", 194, 209], ["the capture antibody", "TEST", 218, 238]]], ["Serially diluted anti-FIPV serum was coated onto wells, and each of the dilutions of CCV antigen that had been prepared from CCV-infected CRFK cells was reacted to the wells.", [["serum", "ANATOMY", 27, 32], ["CRFK cells", "ANATOMY", 138, 148], ["anti-FIPV", "ORGANISM_SUBSTANCE", 17, 26], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["CCV", "ORGANISM", 85, 88], ["CCV", "ORGANISM", 125, 128], ["CRFK cells", "CELL", 138, 148], ["CCV antigen", "PROTEIN", 85, 96], ["CCV-infected CRFK cells", "CELL_LINE", 125, 148], ["anti-FIPV", "SPECIES", 17, 26], ["CCV", "SPECIES", 85, 88], ["CCV", "SPECIES", 125, 128], ["Serially diluted anti-FIPV serum", "TEST", 0, 32], ["the dilutions", "TEST", 68, 81], ["CCV antigen", "PROBLEM", 85, 96], ["infected CRFK cells", "PROBLEM", 129, 148], ["infected", "OBSERVATION_MODIFIER", 129, 137], ["CRFK cells", "OBSERVATION", 138, 148]]], ["The amount of antigen captured by each well was determined as described in Materials and Methods.", [["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["As shown in Fig. 2 , antibody diluted 1:5000 to 1 : 40 000 reacted similarly with respective dilutions of CCV antigen, and there was a sharp decrease in the ELISA value at dilutions below 1 : 80 000.", [["CCV antigen", "GENE_OR_GENE_PRODUCT", 106, 117], ["CCV antigen", "PROTEIN", 106, 117], ["CCV", "SPECIES", 106, 109], ["Fig.", "TEST", 12, 16], ["antibody", "TEST", 21, 29], ["CCV antigen", "TEST", 106, 117], ["a sharp decrease", "PROBLEM", 133, 149], ["the ELISA value", "TEST", 153, 168], ["sharp", "OBSERVATION_MODIFIER", 135, 140], ["decrease", "OBSERVATION_MODIFIER", 141, 149]]], ["Anti-FIPV serum was therefore diluted 1 : 20 000 to 1 : 40 000 for the subsequent experiments.Antibody responses in experimentally infected dogs measured by ELISA and NTELISA and NT antibody responses of two experimental dogs are shown in Fig. 3 .", [["serum", "ANATOMY", 10, 15], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["dogs", "ORGANISM", 140, 144], ["NT antibody", "GENE_OR_GENE_PRODUCT", 179, 190], ["dogs", "ORGANISM", 221, 225], ["dogs", "SPECIES", 140, 144], ["dogs", "SPECIES", 221, 225], ["Anti-FIPV serum", "TEST", 0, 15], ["Antibody responses", "TEST", 94, 112], ["experimentally infected dogs", "PROBLEM", 116, 144], ["ELISA", "TEST", 157, 162], ["NTELISA", "TEST", 167, 174], ["NT antibody responses", "TEST", 179, 200], ["infected", "OBSERVATION_MODIFIER", 131, 139]]], ["Dog D 1, inoculated orally with CCV, produced detectable NT antibody at PID 7, and the titer reached its maximum level at PID 14.", [["Dog D 1", "GENE_OR_GENE_PRODUCT", 0, 7], ["CCV", "ORGANISM", 32, 35], ["NT antibody", "GENE_OR_GENE_PRODUCT", 57, 68], ["NT antibody", "PROTEIN", 57, 68], ["CCV", "SPECIES", 32, 35], ["CCV", "PROBLEM", 32, 35], ["detectable NT antibody", "PROBLEM", 46, 68], ["the titer", "TEST", 83, 92]]], ["On the other hand, ELISA antibody was first detected at PID 11 and reached its maximum level at PID 22.", [["ELISA antibody", "PROTEIN", 19, 33], ["ELISA antibody", "TEST", 19, 33]]], ["Subsequently, ELISA titers were slightly lower that NT titers.", [["ELISA titers", "TEST", 14, 26], ["NT titers", "TEST", 52, 61]]], ["The intranasally inoculated dog D4 also produced NT and ELISA an- tibody; as in dog D 1, ELISA antibody was first detected later than NT antibody, and the ELISA titer was slightly lower than the NT titer.", [["dog", "ORGANISM", 28, 31], ["D4", "ORGANISM", 32, 34], ["NT", "GENE_OR_GENE_PRODUCT", 49, 51], ["dog D 1", "ORGANISM", 80, 87], ["ELISA antibody", "PROTEIN", 89, 103], ["NT antibody", "PROTEIN", 134, 145], ["intranasally", "SPECIES", 4, 16], ["dog", "SPECIES", 28, 31], ["dog", "SPECIES", 28, 31], ["dog D 1", "SPECIES", 80, 87], ["NT", "PROBLEM", 49, 51], ["ELISA", "TEST", 56, 61], ["ELISA antibody", "TEST", 89, 103], ["NT antibody", "TEST", 134, 145], ["the ELISA titer", "TEST", 151, 166]]], ["The non-inoculated control dog D7 produced neither NT or ELISA antibody.Detection of CCV and its antigen in experimentally infected dogsELISA values of rectal swab specimens collected from dogs D 1, D4 and D7 are shown in Fig. 4 .", [["rectal swab specimens", "ANATOMY", 152, 173], ["dog", "ORGANISM", 27, 30], ["D7", "ORGANISM", 31, 33], ["NT", "GENE_OR_GENE_PRODUCT", 51, 53], ["CCV", "GENE_OR_GENE_PRODUCT", 85, 88], ["dogsELISA", "CANCER", 132, 141], ["rectal swab specimens", "MULTI-TISSUE_STRUCTURE", 152, 173], ["NT", "PROTEIN", 51, 53], ["ELISA antibody", "PROTEIN", 57, 71], ["CCV", "PROTEIN", 85, 88], ["dog", "SPECIES", 27, 30], ["dogs", "SPECIES", 189, 193], ["dog D7", "SPECIES", 27, 33], ["CCV", "SPECIES", 85, 88], ["ELISA antibody", "TEST", 57, 71], ["CCV", "PROBLEM", 85, 88], ["its antigen", "TEST", 93, 104], ["rectal swab specimens", "TEST", 152, 173], ["rectal", "ANATOMY", 152, 158]]], ["The values for uninfected control dog D7 remained below 0.1 throughout the test period, and had a mean value of 0.033 and a standard deviation of 0.016 (n = 12 ).", [["dog", "ORGANISM", 34, 37], ["D7", "ORGANISM", 38, 40], ["dog", "SPECIES", 34, 37], ["dog", "SPECIES", 34, 37], ["The values", "TEST", 0, 10], ["a mean value", "TEST", 96, 108]]], ["The cut-off value was 0.101.", [["The cut-off value", "TEST", 0, 17]]], ["Fig. 4 therefore shows that CCV was excreted in the feces of dog D 1 from PID 3 to PID 11, and of dog D4 from PID 5 to PID 11.", [["feces", "ANATOMY", 52, 57], ["CCV", "ORGANISM", 28, 31], ["feces", "ORGANISM_SUBDIVISION", 52, 57], ["dog", "ORGANISM", 98, 101], ["CCV", "SPECIES", 28, 31], ["dog D", "TREATMENT", 61, 66], ["dog D4 from PID", "TREATMENT", 98, 113]]], ["The specificity of the ELISA was examined by the absorption test.", [["the ELISA", "TEST", 19, 28], ["the absorption test", "TEST", 45, 64]]], ["After incubation of the ELISA-positive specimens with CCV antibody-positive serum, ELISA values were all reduced below 0.1; values were not reduced after incubation with CCV antibody-free serum.Detection of CCV and its antigen in experimentally infected dogsCCV excretion in the feces of experimentally infected dogs is shown in Table 1.", [["specimens", "ANATOMY", 39, 48], ["serum", "ANATOMY", 76, 81], ["serum", "ANATOMY", 188, 193], ["feces", "ANATOMY", 279, 284], ["CCV", "ORGANISM", 54, 57], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["serum", "ORGANISM_SUBSTANCE", 188, 193], ["CCV", "GENE_OR_GENE_PRODUCT", 207, 210], ["dogsCCV", "ORGANISM", 254, 261], ["feces", "ORGANISM_SUBDIVISION", 279, 284], ["dogs", "ORGANISM", 312, 316], ["CCV antibody", "PROTEIN", 54, 66], ["CCV antibody", "PROTEIN", 170, 182], ["dogs", "SPECIES", 312, 316], ["CCV", "SPECIES", 54, 57], ["CCV", "SPECIES", 170, 173], ["CCV", "SPECIES", 207, 210], ["the ELISA", "TEST", 20, 29], ["CCV antibody", "TEST", 54, 66], ["ELISA values", "TEST", 83, 95], ["CCV antibody", "TEST", 170, 182], ["CCV", "PROBLEM", 207, 210], ["its antigen", "PROBLEM", 215, 226], ["experimentally infected dogsCCV excretion", "PROBLEM", 230, 271], ["experimentally infected dogs", "PROBLEM", 288, 316], ["CCV", "ANATOMY", 207, 210], ["infected", "OBSERVATION_MODIFIER", 245, 253], ["feces", "OBSERVATION_MODIFIER", 279, 284], ["experimentally", "OBSERVATION_MODIFIER", 288, 302], ["infected", "OBSERVATION", 303, 311]]], ["In orally infected dogs, CCV was first detected at PID 3-4, whereas intranasally infected dogs began to excrete at PID 4-6.", [["dogs", "ORGANISM", 19, 23], ["CCV", "ORGANISM", 25, 28], ["dogs", "ORGANISM", 90, 94], ["dogs", "SPECIES", 19, 23], ["dogs", "SPECIES", 90, 94], ["CCV", "SPECIES", 25, 28], ["orally infected dogs", "PROBLEM", 3, 23], ["CCV", "PROBLEM", 25, 28], ["intranasally infected dogs", "PROBLEM", 68, 94], ["infected", "OBSERVATION_MODIFIER", 10, 18], ["dogs", "OBSERVATION", 19, 23]]], ["Excretion of CCV occurred until PID 11 in all dogs examined.", [["dogs", "ORGANISM", 46, 50], ["dogs", "SPECIES", 46, 50], ["CCV", "SPECIES", 13, 16], ["Excretion of CCV", "PROBLEM", 0, 16], ["PID", "PROBLEM", 32, 35], ["CCV", "OBSERVATION", 13, 16]]], ["No CCV excretion was detected by ELISA in nasal and throat swabs in any dog.", [["nasal", "ANATOMY", 42, 47], ["throat swabs", "ANATOMY", 52, 64], ["CCV", "GENE_OR_GENE_PRODUCT", 3, 6], ["nasal", "ORGANISM_SUBDIVISION", 42, 47], ["throat swabs", "ORGANISM_SUBSTANCE", 52, 64], ["dog", "ORGANISM", 72, 75], ["dog", "SPECIES", 72, 75], ["CCV", "SPECIES", 3, 6], ["CCV excretion", "PROBLEM", 3, 16], ["ELISA", "TEST", 33, 38], ["CCV", "OBSERVATION_MODIFIER", 3, 6], ["excretion", "OBSERVATION", 7, 16], ["nasal", "ANATOMY", 42, 47], ["throat", "ANATOMY", 52, 58]]], ["Although virus isolation was attempted using CRFK and fcwf-4 cells, both of which are known to be susceptible to CCV, no CCV was isolated, even from ELISA-positive specimens.Detection of CCV and its antigen in experimentally infected dogsSome dogs were killed at PID 5 or PID 11, and their organs were subjected to virus isolation and antigen detection.", [["fcwf-4 cells", "ANATOMY", 54, 66], ["specimens", "ANATOMY", 164, 173], ["organs", "ANATOMY", 290, 296], ["CRFK", "CELL", 45, 49], ["fcwf-4 cells", "CELL", 54, 66], ["CCV", "ORGANISM", 113, 116], ["CCV", "GENE_OR_GENE_PRODUCT", 121, 124], ["CCV", "GENE_OR_GENE_PRODUCT", 187, 190], ["dogs", "ORGANISM", 234, 238], ["dogs", "ORGANISM", 243, 247], ["organs", "ORGAN", 290, 296], ["CRFK and fcwf-4 cells", "CELL_LINE", 45, 66], ["dogs", "SPECIES", 234, 238], ["dogs", "SPECIES", 243, 247], ["CCV", "SPECIES", 113, 116], ["CCV", "SPECIES", 121, 124], ["CCV", "SPECIES", 187, 190], ["virus isolation", "TREATMENT", 9, 24], ["CRFK", "TEST", 45, 49], ["fcwf-4 cells", "PROBLEM", 54, 66], ["CCV", "PROBLEM", 113, 116], ["CCV", "PROBLEM", 121, 124], ["ELISA", "TEST", 149, 154], ["CCV", "PROBLEM", 187, 190], ["its antigen", "PROBLEM", 195, 206], ["experimentally infected dogs", "PROBLEM", 210, 238], ["virus isolation", "TREATMENT", 315, 330], ["antigen detection", "TEST", 335, 352], ["organs", "ANATOMY", 290, 296]]], ["As shown in Table 2 , cytopathic agents were isolated only from the kidney and mesenteric lymph node of dog D3, and were identified as CCV by IFA.", [["kidney", "ANATOMY", 68, 74], ["mesenteric lymph node", "ANATOMY", 79, 100], ["kidney", "ORGAN", 68, 74], ["mesenteric lymph node", "MULTI-TISSUE_STRUCTURE", 79, 100], ["dog", "ORGANISM", 104, 107], ["D3", "SIMPLE_CHEMICAL", 108, 110], ["CCV", "ORGANISM", 135, 138], ["dog", "SPECIES", 104, 107], ["dog", "SPECIES", 104, 107], ["CCV", "SPECIES", 135, 138], ["cytopathic agents", "TREATMENT", 22, 39], ["kidney", "ANATOMY", 68, 74], ["mesenteric", "ANATOMY", 79, 89], ["lymph node", "OBSERVATION", 90, 100]]], ["However, CCV antigen could not be detected in the kidney of dog D3, either by ELISA or by IFA.", [["kidney", "ANATOMY", 50, 56], ["CCV antigen", "GENE_OR_GENE_PRODUCT", 9, 20], ["kidney", "ORGAN", 50, 56], ["dog", "ORGANISM", 60, 63], ["D3", "SIMPLE_CHEMICAL", 64, 66], ["CCV antigen", "PROTEIN", 9, 20], ["dog", "SPECIES", 60, 63], ["CCV", "SPECIES", 9, 12], ["dog", "SPECIES", 60, 63], ["CCV antigen", "TEST", 9, 20], ["kidney", "ANATOMY", 50, 56]]], ["CCV antigens were detected in almost all parts of the small intestine of infected dogs by both ELISA and IFA.", [["small intestine", "ANATOMY", 54, 69], ["CCV antigens", "GENE_OR_GENE_PRODUCT", 0, 12], ["small intestine", "ORGAN", 54, 69], ["dogs", "ORGANISM", 82, 86], ["CCV antigens", "PROTEIN", 0, 12], ["dogs", "SPECIES", 82, 86], ["CCV", "SPECIES", 0, 3], ["CCV antigens", "TEST", 0, 12], ["infected dogs", "PROBLEM", 73, 86], ["small intestine", "ANATOMY", 54, 69], ["infected dogs", "OBSERVATION", 73, 86]]], ["Of four mesenteric lymph nodes, two (including one from dog D3) were ELISA-positive for CCV antigens, but were IFA-negative.", [["mesenteric lymph nodes", "ANATOMY", 8, 30], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 8, 30], ["dog", "ORGANISM", 56, 59], ["CCV", "ORGANISM", 88, 91], ["IFA", "GENE_OR_GENE_PRODUCT", 111, 114], ["CCV antigens", "PROTEIN", 88, 100], ["IFA", "PROTEIN", 111, 114], ["CCV", "SPECIES", 88, 91], ["four mesenteric lymph nodes", "PROBLEM", 3, 30], ["ELISA", "TEST", 69, 74], ["CCV antigens", "TEST", 88, 100], ["IFA", "TEST", 111, 114], ["four", "OBSERVATION_MODIFIER", 3, 7], ["mesenteric", "ANATOMY", 8, 18], ["lymph nodes", "OBSERVATION", 19, 30], ["negative", "OBSERVATION", 115, 123]]], ["No CCV was detected in other organs by ELISA, IFA, or virus isolation experiments.DISCUSSIONIn the present study, an ELISA method using detergent-solubilized antigen from CCV-infected cells was developed for the detection of antibody against the virus in canine serum.", [["organs", "ANATOMY", 29, 35], ["cells", "ANATOMY", 184, 189], ["serum", "ANATOMY", 262, 267], ["organs", "ORGAN", 29, 35], ["CCV", "ORGANISM", 171, 174], ["cells", "CELL", 184, 189], ["canine", "ORGANISM", 255, 261], ["serum", "ORGANISM_SUBSTANCE", 262, 267], ["detergent-solubilized antigen", "PROTEIN", 136, 165], ["CCV-infected cells", "CELL_LINE", 171, 189], ["canine", "SPECIES", 255, 261], ["CCV", "SPECIES", 3, 6], ["CCV", "SPECIES", 171, 174], ["canine", "SPECIES", 255, 261], ["CCV", "PROBLEM", 3, 6], ["ELISA", "TEST", 39, 44], ["IFA", "TEST", 46, 49], ["virus isolation experiments", "PROBLEM", 54, 81], ["the present study", "TEST", 95, 112], ["an ELISA method", "TEST", 114, 129], ["detergent-solubilized antigen", "TREATMENT", 136, 165], ["infected cells", "PROBLEM", 175, 189], ["the detection", "TEST", 208, 221], ["antibody", "PROBLEM", 225, 233], ["the virus in canine serum", "PROBLEM", 242, 267], ["CCV", "OBSERVATION", 3, 6], ["infected cells", "OBSERVATION", 175, 189]]], ["Enveloped viruses are commonly inactivated by treatment with detergents, and solubilized antigens have therefore been widely used as non-infectious antigens in ELISA.", [["solubilized antigens", "PROTEIN", 77, 97], ["non-infectious antigens", "PROTEIN", 133, 156], ["Enveloped viruses", "PROBLEM", 0, 17], ["detergents", "TREATMENT", 61, 71], ["solubilized antigens", "TREATMENT", 77, 97], ["non-infectious antigens in ELISA", "PROBLEM", 133, 165], ["viruses", "OBSERVATION", 10, 17]]], ["We chose sodium deoxycholate for antigen solubilization because it is reported that the presence of the detergent, whatever the concentration, does not interfere with the adsorption of antigens to the solid phase (Jeansson et al., 1982) .", [["sodium deoxycholate", "CHEMICAL", 9, 28], ["sodium deoxycholate", "CHEMICAL", 9, 28], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 9, 28], ["antigens", "PROTEIN", 185, 193], ["sodium deoxycholate", "TREATMENT", 9, 28], ["antigen solubilization", "TREATMENT", 33, 55]]], ["The original solubilized antigen solution contains about 2 mg/ml of protein, so 1 ml of antigen would be sufficient for 20 antigen-coated plates.", [["The original solubilized antigen solution", "TREATMENT", 0, 41], ["protein", "TREATMENT", 68, 75], ["antigen", "TREATMENT", 88, 95], ["20 antigen-coated plates", "TREATMENT", 120, 144]]], ["The antigen preparation and assay procedures developed in this study are simple, so that this ELISA method will be useful in large-scale epidemiological surveys of CCV infection in the field.", [["CCV infection", "DISEASE", 164, 177], ["CCV", "ORGANISM", 164, 167], ["CCV", "SPECIES", 164, 167], ["The antigen preparation", "TREATMENT", 0, 23], ["assay procedures", "TEST", 28, 44], ["this study", "TEST", 58, 68], ["this ELISA method", "TEST", 89, 106], ["CCV infection", "PROBLEM", 164, 177], ["CCV", "OBSERVATION_MODIFIER", 164, 167], ["infection", "OBSERVATION", 168, 177]]], ["In the experimental infection, ELISA antibody was first detected about 3 days after the appearance of NT antibody.", [["infection", "DISEASE", 20, 29], ["NT antibody", "GENE_OR_GENE_PRODUCT", 102, 113], ["ELISA antibody", "PROTEIN", 31, 45], ["NT antibody", "PROTEIN", 102, 113], ["the experimental infection", "PROBLEM", 3, 29], ["ELISA antibody", "TEST", 31, 45], ["NT antibody", "PROBLEM", 102, 113], ["experimental", "OBSERVATION_MODIFIER", 7, 19], ["infection", "OBSERVATION", 20, 29]]], ["We suspect that this was because our ELISA procedure detects only IgG subclass antibodies and does not detect antibodies of other classes -probably IgM -that may be produced during the early stage of infection and detected by NT.DISCUSSIONAn ELISA procedure for the detection of CCV antigens was also developed in this study.", [["infection", "DISEASE", 200, 209], ["IgM", "GENE_OR_GENE_PRODUCT", 148, 151], ["CCV", "ORGANISM", 279, 282], ["IgG subclass antibodies", "PROTEIN", 66, 89], ["antibodies", "PROTEIN", 110, 120], ["IgM", "PROTEIN", 148, 151], ["CCV antigens", "PROTEIN", 279, 291], ["CCV", "SPECIES", 279, 282], ["our ELISA procedure", "TEST", 33, 52], ["IgG subclass antibodies", "PROBLEM", 66, 89], ["antibodies of other classes", "PROBLEM", 110, 137], ["IgM", "TEST", 148, 151], ["infection", "PROBLEM", 200, 209], ["ELISA procedure", "TREATMENT", 242, 257], ["CCV antigens", "PROBLEM", 279, 291], ["this study", "TEST", 314, 324], ["probably", "UNCERTAINTY", 139, 147], ["IgM", "OBSERVATION", 148, 151], ["infection", "OBSERVATION", 200, 209]]], ["Anti-FIPV serum was used as the capture antibody because FIPV is antigenically related to CCV (Pedersen et al., 1978; Horzinek et al., 1982 ) , and FIPV-infected cats produce high antibody titers.", [["serum", "ANATOMY", 10, 15], ["Anti-FIPV", "ORGANISM_SUBSTANCE", 0, 9], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["FIPV", "GENE_OR_GENE_PRODUCT", 57, 61], ["CCV", "ORGANISM", 90, 93], ["FIPV", "ORGANISM", 148, 152], ["cats", "ORGANISM", 162, 166], ["FIPV", "PROTEIN", 57, 61], ["cats", "SPECIES", 162, 166], ["FIPV", "SPECIES", 57, 61], ["CCV", "SPECIES", 90, 93], ["Anti-FIPV serum", "TEST", 0, 15], ["the capture antibody", "TEST", 28, 48], ["FIPV", "PROBLEM", 57, 61], ["FIPV", "TEST", 148, 152], ["high antibody titers", "PROBLEM", 175, 195], ["antibody titers", "OBSERVATION", 180, 195]]], ["The anti-FIPV serum used in this study did not need purification of Ig or specific antibody fraction, and could be used at 1 : 40 000 dilution.DISCUSSIONAlthough CCV was not isolated from feces in experimental infections, high ELISA values were observed in specimens from inoculated dogs for a limited period of time, but were not found in specimens from the non-inoculated dog at any time.", [["serum", "ANATOMY", 14, 19], ["feces", "ANATOMY", 188, 193], ["specimens", "ANATOMY", 257, 266], ["specimens", "ANATOMY", 340, 349], ["infections", "DISEASE", 210, 220], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["Ig", "GENE_OR_GENE_PRODUCT", 68, 70], ["feces", "ORGANISM_SUBSTANCE", 188, 193], ["dogs", "ORGANISM", 283, 287], ["specimens", "CANCER", 340, 349], ["dog", "ORGANISM", 374, 377], ["Ig", "PROTEIN", 68, 70], ["dogs", "SPECIES", 283, 287], ["dog", "SPECIES", 374, 377], ["CCV", "SPECIES", 162, 165], ["dog", "SPECIES", 374, 377], ["The anti-FIPV serum", "TEST", 0, 19], ["this study", "TEST", 28, 38], ["Ig", "TREATMENT", 68, 70], ["specific antibody fraction", "TEST", 74, 100], ["experimental infections", "PROBLEM", 197, 220], ["high ELISA values", "PROBLEM", 222, 239], ["infections", "OBSERVATION", 210, 220]]], ["Conclusive diagnosis requires isolation of the virus from feces, but attempts to isolate the virus have been unsuccessful in many previous reports (Cartwright and Lucas, 1972; Williams, 1980; Marshall et al., 1984) as well as in the present work.", [["feces", "ANATOMY", 58, 63], ["feces", "ORGANISM_SUBSTANCE", 58, 63], ["the virus", "PROBLEM", 43, 52], ["feces", "PROBLEM", 58, 63], ["the virus", "PROBLEM", 89, 98], ["virus", "OBSERVATION", 47, 52]]], ["As shown in Table 2 , we also failed to isolate virus from necropsied samples of ELISApositive organs; however, the results of ELISA were correlated with those of IFA for almost all specimens.", [["samples", "ANATOMY", 70, 77], ["organs", "ANATOMY", 95, 101], ["specimens", "ANATOMY", 182, 191], ["organs", "ORGAN", 95, 101], ["isolate virus", "PROBLEM", 40, 53], ["ELISApositive organs", "PROBLEM", 81, 101], ["ELISA", "TEST", 127, 132], ["IFA", "TEST", 163, 166]]], ["The high ELISA values observed for fecal specimens were reduced after incubation of the specimen with dog serum containing anti-CCV antibody, but was not reduced by incubation with antibody-free serum.", [["fecal specimens", "ANATOMY", 35, 50], ["specimen", "ANATOMY", 88, 96], ["serum", "ANATOMY", 106, 111], ["serum", "ANATOMY", 195, 200], ["fecal specimens", "ORGANISM_SUBSTANCE", 35, 50], ["dog", "ORGANISM", 102, 105], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["anti-CCV antibody", "PROTEIN", 123, 140], ["antibody", "PROTEIN", 181, 189], ["dog", "SPECIES", 102, 105], ["dog", "SPECIES", 102, 105], ["anti-CCV", "SPECIES", 123, 131], ["The high ELISA values", "TEST", 0, 21], ["fecal specimens", "TEST", 35, 50], ["the specimen", "TEST", 84, 96], ["dog serum containing anti-CCV antibody", "TEST", 102, 140], ["antibody", "TEST", 181, 189]]], ["These observations indicate the specificity of our ELISA procedure for the detection of CCV antigen in feces and organ homogenates; it is important that any ELISA method used in the field detects only CCV antigens and not other antigens such as canine parvovirus, canine rotavirus, food antigens etc. Although we were unable to examine the reactivity of the two antisera (capture and detector antibodies) with antigens other than CCV, these antisera were prepared from healthy animals of species other than the dog (cat and rabbit), so it seems unlikely that both sera simultaneously possess the same antibodies against other canine pathogens and food antigens.", [["feces", "ANATOMY", 103, 108], ["organ homogenates", "ANATOMY", 113, 130], ["sera", "ANATOMY", 564, 568], ["canine parvovirus", "DISEASE", 245, 262], ["CCV antigen", "GENE_OR_GENE_PRODUCT", 88, 99], ["feces", "ORGANISM_SUBSTANCE", 103, 108], ["organ homogenates", "TISSUE", 113, 130], ["canine parvovirus", "ORGANISM", 245, 262], ["canine rotavirus", "ORGANISM", 264, 280], ["CCV", "ORGANISM", 430, 433], ["dog", "ORGANISM", 511, 514], ["cat", "ORGANISM", 516, 519], ["rabbit", "ORGANISM", 524, 530], ["sera", "ORGANISM_SUBSTANCE", 564, 568], ["canine", "ORGANISM", 626, 632], ["CCV antigen", "PROTEIN", 88, 99], ["CCV antigens", "PROTEIN", 201, 213], ["antigens", "PROTEIN", 228, 236], ["detector antibodies", "PROTEIN", 384, 403], ["antigens", "PROTEIN", 410, 418], ["antibodies", "PROTEIN", 601, 611], ["food antigens", "PROTEIN", 647, 660], ["canine parvovirus", "SPECIES", 245, 262], ["canine", "SPECIES", 264, 270], ["dog", "SPECIES", 511, 514], ["cat", "SPECIES", 516, 519], ["rabbit", "SPECIES", 524, 530], ["canine", "SPECIES", 626, 632], ["CCV", "SPECIES", 88, 91], ["CCV", "SPECIES", 201, 204], ["canine parvovirus", "SPECIES", 245, 262], ["canine", "SPECIES", 264, 270], ["rotavirus", "SPECIES", 271, 280], ["CCV", "SPECIES", 430, 433], ["dog", "SPECIES", 511, 514], ["cat", "SPECIES", 516, 519], ["rabbit", "SPECIES", 524, 530], ["canine", "SPECIES", 626, 632], ["our ELISA procedure", "TREATMENT", 47, 66], ["the detection", "TEST", 71, 84], ["CCV antigen in feces", "PROBLEM", 88, 108], ["organ homogenates", "PROBLEM", 113, 130], ["any ELISA method", "TREATMENT", 153, 169], ["CCV antigens", "PROBLEM", 201, 213], ["canine parvovirus", "PROBLEM", 245, 262], ["detector antibodies", "TEST", 384, 403], ["antigens", "PROBLEM", 410, 418], ["other canine pathogens", "PROBLEM", 620, 642]]], ["We used polyclonal antisera in this study, but it is likely that the use of monoclonal antibody as the detector will improve specificity.DISCUSSIONIn conclusion, our method was more simple, rapid and reliable for the de-tection of CCV than virus isolation, electron microscopic examination and the IFA technique, and was able to detect antigen in specimens as small as rectal swabs.", [["specimens", "ANATOMY", 347, 356], ["rectal swabs", "ANATOMY", 369, 381], ["CCV", "ORGANISM", 231, 234], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 369, 381], ["monoclonal antibody", "PROTEIN", 76, 95], ["CCV", "SPECIES", 231, 234], ["polyclonal antisera", "TREATMENT", 8, 27], ["this study", "TEST", 31, 41], ["monoclonal antibody", "TREATMENT", 76, 95], ["virus isolation", "TREATMENT", 240, 255], ["electron microscopic examination", "TEST", 257, 289], ["the IFA technique", "TEST", 294, 311], ["antigen in specimens", "TEST", 336, 356], ["rectal swabs", "TEST", 369, 381]]]], "2a95ce38ae354de809fba1577100199c6e39b98a": [["INTRODUCTIONThere are increasing calls to collect data to better understand the inequities populations of color are facing in the U.S. with regard to coronavirus disease 2019 .", [["coronavirus disease", "DISEASE", 150, 169], ["coronavirus", "ORGANISM", 150, 161], ["coronavirus disease", "PROBLEM", 150, 169]]], ["Recent reports suggest that racial and ethnic minorities in the U.S. are at increased risk of acquiring COVID-19, of experiencing greater severity of infection, and are at excess risk of death.", [["infection", "DISEASE", 150, 159], ["death", "DISEASE", 187, 192], ["racial and ethnic minorities", "PROBLEM", 28, 56], ["infection", "PROBLEM", 150, 159], ["death", "PROBLEM", 187, 192], ["racial", "OBSERVATION_MODIFIER", 28, 34], ["infection", "OBSERVATION", 150, 159]]], ["Although efforts to collect data stratified by race on COVID-19 tests administered, confirmed cases, and deaths are necessary to understand the needs of populations of color, the public health community must recognize that not all health inequities will be captured.", [["deaths", "DISEASE", 105, 111], ["COVID", "TEST", 55, 60], ["tests", "TEST", 64, 69]]], ["One ethnic group likely at increased risk of COVID-19 complications that will not be captured with stratified racial reporting is Arab Americans.INTRODUCTIONArab Americans are individuals with ethnic, linguistic, or cultural origins to Arabic speaking countries in the Middle East and North Africa that live in the U.S. Although activist groups worked hard to lobby for the 2020 Census to capture Arab Americans through a distinct racial/ethnic category (i.e., Middle Eastern and North African), and testing found the additional identifier properly captured Arab Americans, 1 this category was not adopted in the 2020 Census.", [["COVID", "DISEASE", 45, 50], ["COVID-19 complications", "PROBLEM", 45, 67], ["testing", "TEST", 500, 507], ["Middle", "ANATOMY_MODIFIER", 269, 275]]], ["There are a number of reasons why Arab Americans may be at increased risk of COVID-19 infection, complications, and death including exposure to xenophobia and stigma, pre-existing conditions, crowded living conditions, lack of social support for new immigrants, and poor adoption of prevention behavior.XENOPHOBIA AND DISCRIMINATIONArab Americans have faced substantial xenophobia and discrimination since they first started to immigrate to this country in the late 1800s 8 and continue to face a growing risk of hate crimes following the events of September 11, 2001.", [["infection", "DISEASE", 86, 95], ["death", "DISEASE", 116, 121], ["xenophobia", "DISEASE", 144, 154], ["xenophobia", "DISEASE", 370, 380], ["Arab Americans", "ORGANISM", 34, 48], ["COVID-19 infection", "PROBLEM", 77, 95], ["complications", "PROBLEM", 97, 110], ["death", "PROBLEM", 116, 121], ["xenophobia", "PROBLEM", 144, 154], ["stigma", "PROBLEM", 159, 165], ["pre-existing conditions", "PROBLEM", 167, 190], ["social support", "TREATMENT", 227, 241], ["faced substantial xenophobia", "PROBLEM", 352, 380], ["infection", "OBSERVATION", 86, 95], ["substantial", "OBSERVATION_MODIFIER", 358, 369], ["xenophobia", "OBSERVATION", 370, 380]]], ["9 Progressively greater negative rhetoric and adverse public policies have increased the vulnerability of this ethnic group in the U.S. 10 For example, perceived discrimination among Arab Americans after September 11th was found to heighten psychological distress, 11 reduce levels of happiness, 12 contribute to more adverse birth outcomes, 13 and enhance feelings of isolation and stigmatization in this group.", [["psychological distress", "DISEASE", 241, 263], ["stigmatization", "DISEASE", 383, 397], ["psychological distress", "PROBLEM", 241, 263], ["stigmatization", "PROBLEM", 383, 397], ["greater", "OBSERVATION_MODIFIER", 16, 23], ["negative", "OBSERVATION_MODIFIER", 24, 32], ["rhetoric", "OBSERVATION_MODIFIER", 33, 41], ["increased", "OBSERVATION_MODIFIER", 75, 84]]], ["14UNDERLYING HEALTH CONDITIONSThere is a high prevalence of underlying health conditions and comorbidities among Arab American populations in the U.S. that places them at increased risk of COVID-19 complications.UNDERLYING HEALTH CONDITIONSSome known risk factors for COVID-19 include diabetes, cardiovascular disease, hypertension, and obesity.", [["cardiovascular", "ANATOMY", 295, 309], ["COVID", "DISEASE", 189, 194], ["diabetes", "DISEASE", 285, 293], ["cardiovascular disease", "DISEASE", 295, 317], ["hypertension", "DISEASE", 319, 331], ["obesity", "DISEASE", 337, 344], ["cardiovascular", "ANATOMICAL_SYSTEM", 295, 309], ["underlying health conditions", "PROBLEM", 60, 88], ["COVID-19 complications", "PROBLEM", 189, 211], ["COVID", "TEST", 268, 273], ["diabetes", "PROBLEM", 285, 293], ["cardiovascular disease", "PROBLEM", 295, 317], ["hypertension", "PROBLEM", 319, 331], ["obesity", "PROBLEM", 337, 344], ["high prevalence", "OBSERVATION_MODIFIER", 41, 56], ["diabetes", "OBSERVATION", 285, 293], ["cardiovascular", "ANATOMY", 295, 309], ["disease", "OBSERVATION", 310, 317], ["hypertension", "OBSERVATION", 319, 331], ["obesity", "OBSERVATION", 337, 344]]], ["Diabetes prevalence among Arab Americans has been found to be greater than that of white populations in the U.S., with estimates as high as 23% in some samples.", [["samples", "ANATOMY", 152, 159], ["Diabetes", "DISEASE", 0, 8], ["Diabetes prevalence", "PROBLEM", 0, 19], ["greater", "OBSERVATION_MODIFIER", 62, 69]]], ["18 A study of self-reported heart disease in Michigan found that Arab American women were four times more likely to report a heart disease diagnosis than black American women.", [["heart", "ANATOMY", 28, 33], ["heart", "ANATOMY", 125, 130], ["heart disease", "DISEASE", 28, 41], ["heart disease", "DISEASE", 125, 138], ["heart", "ORGAN", 28, 33], ["women", "ORGANISM", 79, 84], ["heart", "ORGAN", 125, 130], ["women", "ORGANISM", 169, 174], ["women", "SPECIES", 79, 84], ["women", "SPECIES", 169, 174], ["A study", "TEST", 3, 10], ["heart disease", "PROBLEM", 28, 41], ["a heart disease diagnosis", "PROBLEM", 123, 148], ["heart", "ANATOMY", 28, 33], ["disease", "OBSERVATION", 34, 41], ["heart", "ANATOMY", 125, 130], ["disease", "OBSERVATION", 131, 138]]], ["19 In another hospitalbased study in Michigan found that the prevalence of hypertension among Arab Americans was higher for both men and women than for non-Hispanic whites.", [["hypertension", "DISEASE", 75, 87], ["men", "ORGANISM", 129, 132], ["women", "ORGANISM", 137, 142], ["men", "SPECIES", 129, 132], ["women", "SPECIES", 137, 142], ["hypertension", "PROBLEM", 75, 87], ["non-Hispanic whites", "PROBLEM", 152, 171], ["hypertension", "OBSERVATION", 75, 87]]], ["5 Researchers also found in a study among Arab Americans in California that the proportion of respondents who were overweight or obese was 55.2%.", [["overweight", "DISEASE", 115, 125], ["obese", "PROBLEM", 129, 134]]], ["4 families in the U.S. is higher than the national average (2.6).", [["higher", "OBSERVATION_MODIFIER", 26, 32]]], ["21 Arab American homes are more 5 likely to be multigenerational (59%), 22 and this may lead to greater transmission risk within households to older individuals, increasing vulnerability to infection.SOCIAL SUPPORTMany recent immigrants with Arab heritage are refugees and immigrants with fragile social networks and limited social support.", [["infection", "DISEASE", 190, 199], ["fragile social networks", "DISEASE", 289, 312], ["increasing vulnerability to infection", "PROBLEM", 162, 199], ["infection", "OBSERVATION", 190, 199]]], ["23 The ability of refugees and immigrants to access quality health care and information about health risks in the Arabic language may be an important impediment to receiving information about COVID-19 risk and prevention.", [["COVID", "TREATMENT", 192, 197]]], ["A recent study in California showed that Arab immigrants (first generation Arab Americans) had worse health outcomes than second and third generation immigrants, supporting the need for dedicated outreach.", [["A recent study", "TEST", 0, 14]]], ["4 Although many organizations and groups have used Arabic language messaging, more work can be done to effectively reach out to these vulnerable subgroups.PREVENTIVE BEHAVIORPreventive behavior among Arab Americans may be poor, especially for reducing infectious disease risk.", [["infectious disease", "DISEASE", 252, 270], ["Arabic language messaging", "TREATMENT", 51, 76], ["reducing infectious disease risk", "PROBLEM", 243, 275]]], ["Arab Americans are less likely to be vaccinated than the average American and studies have found that they receive the influenza vaccine less frequently in the past year in California than white Americans, 4 which is corroborated by national data for influenza and pneumonia vaccinations.", [["influenza", "DISEASE", 251, 260], ["pneumonia", "DISEASE", 265, 274], ["the influenza vaccine", "TREATMENT", 115, 136], ["influenza", "PROBLEM", 251, 260], ["pneumonia vaccinations", "PROBLEM", 265, 287], ["less likely", "UNCERTAINTY", 19, 30], ["pneumonia", "OBSERVATION", 265, 274]]], ["24 This suggests the need for more targeted education about the risks of infectious diseases for this vulnerable subgroup with a goal of positively influencing vaccination uptake.CONCLUSIONSA call for health equity must support the needs of all populations of color in the U.S. Arab Americans have often been \"invisible\" in these efforts in the past, but advancing their health needs will contribute importantly to the larger efforts to reduce health disparities in the U.S.CONCLUSIONSWithout dedicated data on testing, confirmed cases, and deaths among Arab Americans, potential health disparities may be masked and ignored, leading to worse health outcomes for this population during the COVID-19 crisis and beyond.ACKNOWLEDGMENTSNo financial disclosures were reported by the author of this paper.", [["infectious diseases", "DISEASE", 73, 92], ["deaths", "DISEASE", 541, 547], ["infectious diseases", "PROBLEM", 73, 92], ["testing", "TEST", 511, 518], ["this population", "PROBLEM", 663, 678], ["the COVID", "TEST", 686, 695]]]], "PMC4605412": [["IntroductionRecruitment into the military and congregation of recruits in training camps brings together many people from geographically diverse areas into close living conditions.", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116]]], ["Similar to other settings, such as college dormitories, sports teams, and cruise ships, the close physical proximity of individuals in military barracks enhances the risk of the transmission of respiratory and enteric pathogens.", [["respiratory", "ANATOMY", 194, 205], ["respiratory and enteric pathogens", "DISEASE", 194, 227], ["respiratory and enteric pathogens", "PROBLEM", 194, 227], ["respiratory", "ANATOMY", 194, 205], ["enteric", "ANATOMY", 210, 217], ["pathogens", "OBSERVATION", 218, 227]]], ["The congregation of diverse individuals can lead to the introduction of one or more pathogens into a confined population, leading to an outbreak of infections.", [["infections", "DISEASE", 148, 158], ["diverse individuals", "PROBLEM", 20, 39], ["an outbreak of infections", "PROBLEM", 133, 158], ["outbreak", "OBSERVATION_MODIFIER", 136, 144], ["infections", "OBSERVATION", 148, 158]]], ["Institutions that permit frequent, longer term, and intimate contacts among individuals generally can be expected to have higher attack rates.1 Other factors such as physical exertion and the prevalence of immunologically na\u00efve individuals can contribute to the unique vulnerability of military recruits.2IntroductionMilitaries are a unique subset of institutions that potentially have higher attack rates than other societal groupings.", [["higher attack rates", "PROBLEM", 122, 141], ["Other factors", "PROBLEM", 144, 157], ["physical exertion", "PROBLEM", 166, 183], ["immunologically na\u00efve individuals", "PROBLEM", 206, 239]]], ["Military personnel and children may be at greater risk of infection than other groups.1 The effect of school closures during epidemics have demonstrated that environments with high people density can function as amplifying arenas for influenza and other respiratory diseases.3 The large-scale mobilization of military forces during World War I was a contributing factor to the global influenza pandemic of 1918\u20131919.4,5 In the years since then, much research has been done to study respiratory illness among U.S. military recruits.", [["respiratory", "ANATOMY", 254, 265], ["infection", "DISEASE", 58, 67], ["influenza", "DISEASE", 234, 243], ["respiratory diseases", "DISEASE", 254, 274], ["influenza", "DISEASE", 384, 393], ["1918\u20131919.4,5", "CHEMICAL", 406, 419], ["respiratory illness", "DISEASE", 482, 501], ["children", "ORGANISM", 23, 31], ["people", "ORGANISM", 181, 187], ["children", "SPECIES", 23, 31], ["people", "SPECIES", 181, 187], ["infection", "PROBLEM", 58, 67], ["school closures", "TREATMENT", 102, 117], ["influenza", "PROBLEM", 234, 243], ["other respiratory diseases", "PROBLEM", 248, 274], ["The large-scale mobilization", "TREATMENT", 277, 305], ["infection", "OBSERVATION", 58, 67], ["respiratory diseases", "OBSERVATION", 254, 274], ["large", "OBSERVATION_MODIFIER", 281, 286], ["-scale", "OBSERVATION_MODIFIER", 286, 292], ["mobilization", "OBSERVATION_MODIFIER", 293, 305]]], ["The Commission on Acute Respiratory Diseases conducted studies at United States recruiting camps documenting that rates of respiratory disease among recruits were higher than other \u2018seasoned\u2019 military groups.6 Miller et al. noted a direct correlation between changes in rates of pneumonia and respiratory illness with the number of recruits in training.", [["respiratory", "ANATOMY", 123, 134], ["respiratory", "ANATOMY", 293, 304], ["Respiratory Diseases", "DISEASE", 24, 44], ["respiratory disease", "DISEASE", 123, 142], ["pneumonia", "DISEASE", 279, 288], ["respiratory illness", "DISEASE", 293, 312], ["Acute Respiratory Diseases", "PROBLEM", 18, 44], ["respiratory disease", "PROBLEM", 123, 142], ["pneumonia", "PROBLEM", 279, 288], ["respiratory illness", "PROBLEM", 293, 312], ["Acute", "OBSERVATION_MODIFIER", 18, 23], ["Respiratory Diseases", "OBSERVATION", 24, 44], ["respiratory disease", "OBSERVATION", 123, 142], ["pneumonia", "OBSERVATION", 279, 288], ["respiratory illness", "OBSERVATION", 293, 312]]], ["The number of recruits proved to be an even stronger determinant of infection rates than seasonal factors.7 In a more recent study examining influenza vaccine, rates of influenza-like illness (ILI) among recruits were found to be 2\u201316 times higher than non-recruit service members.8 In spite of widespread immunization among U.S. military personnel, influenza outbreaks continue to occur in crowded military settings.9,10 More recently, human adenovirus (H-AdV) has been a predominant cause of febrile respiratory illness in the U.S. military.11IntroductionWhile more is known about the respiratory illness experience of U.S. military personnel, little is known about the experience of military populations of other countries in the tropics and Asia, an area that is very important in the global ecology of influenza.12 Vaccination uptake in developing nations is considerably less than it is in developed countries and is not mandatory in the militaries of many countries including Thailand.", [["respiratory", "ANATOMY", 502, 513], ["infection", "DISEASE", 68, 77], ["influenza", "DISEASE", 141, 150], ["influenza-like illness", "DISEASE", 169, 191], ["ILI", "DISEASE", 193, 196], ["influenza outbreaks", "DISEASE", 350, 369], ["febrile respiratory illness", "DISEASE", 494, 521], ["respiratory illness", "DISEASE", 587, 606], ["influenza", "DISEASE", 807, 816], ["human adenovirus", "ORGANISM", 437, 453], ["H-AdV", "ORGANISM", 455, 460], ["seasonal factors", "PROTEIN", 89, 105], ["influenza-", "SPECIES", 169, 179], ["human", "SPECIES", 437, 442], ["human", "SPECIES", 437, 442], ["H-AdV", "SPECIES", 455, 460], ["infection rates", "PROBLEM", 68, 83], ["a more recent study", "TEST", 111, 130], ["influenza vaccine", "TREATMENT", 141, 158], ["influenza", "PROBLEM", 169, 178], ["influenza outbreaks", "PROBLEM", 350, 369], ["febrile respiratory illness", "PROBLEM", 494, 521], ["influenza", "PROBLEM", 807, 816], ["infection", "OBSERVATION", 68, 77], ["predominant cause of", "UNCERTAINTY", 473, 493], ["febrile", "OBSERVATION_MODIFIER", 494, 501], ["respiratory illness", "OBSERVATION", 502, 521], ["influenza", "OBSERVATION", 807, 816], ["considerably", "OBSERVATION_MODIFIER", 864, 876], ["less", "OBSERVATION_MODIFIER", 877, 881]]], ["Furthermore, the prevailing circulating viruses are unknown.", [["the prevailing circulating viruses", "PROBLEM", 13, 47], ["circulating viruses", "OBSERVATION", 28, 47]]], ["Influenza which has well defined seasonality in temperate climates is far more difficult to characterize in the middle latitudes of the tropics.13IntroductionWe report the results of a respiratory illness study among new military recruits at a Royal Thai Army (RTA) barracks in Bangkok, Thailand.", [["Influenza", "DISEASE", 0, 9], ["respiratory illness", "DISEASE", 185, 204], ["Influenza", "SPECIES", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["a respiratory illness study", "TEST", 183, 210], ["well defined", "OBSERVATION_MODIFIER", 20, 32], ["seasonality", "OBSERVATION_MODIFIER", 33, 44], ["temperate climates", "OBSERVATION_MODIFIER", 48, 66], ["far more difficult to characterize", "OBSERVATION_MODIFIER", 70, 104], ["middle", "ANATOMY_MODIFIER", 112, 118]]], ["These results were complemented by laboratory testing to confirm infection including multiplex PCR.Laboratory ::: MethodsNasal and throat swabs were tested for influenza viruses using real-time reverse transcriptase polymerase chain reaction (rRT-PCR) using the U.S. CDC protocol.14,15 In addition, acute samples collected during basic training of class 1 were tested by multiplex real-time PCR using Fast Track Diagnostics (FTD) respiratory pathogens 33 kit (FTD, Esch-sur-Alzette, Luxembourg) according to the manufacturer's instruction to identify a broader spectrum of pathogens present in the class.", [["throat swabs", "ANATOMY", 131, 143], ["samples", "ANATOMY", 305, 312], ["infection", "DISEASE", 65, 74], ["influenza viruses", "DISEASE", 160, 177], ["FTD", "DISEASE", 425, 428], ["FTD", "DISEASE", 460, 463], ["throat swabs", "ORGANISM_SUBSTANCE", 131, 143], ["reverse transcriptase", "PROTEIN", 194, 215], ["laboratory testing", "TEST", 35, 53], ["infection", "PROBLEM", 65, 74], ["multiplex PCR", "TEST", 85, 98], ["MethodsNasal", "TREATMENT", 114, 126], ["throat swabs", "TEST", 131, 143], ["influenza viruses", "PROBLEM", 160, 177], ["the U.S. CDC protocol", "TEST", 258, 279], ["acute samples", "PROBLEM", 299, 312], ["Fast Track Diagnostics", "TEST", 401, 423], ["respiratory pathogens", "TEST", 430, 451], ["FTD", "TEST", 460, 463], ["Esch", "TEST", 465, 469], ["pathogens", "PROBLEM", 573, 582], ["throat", "ANATOMY", 131, 137], ["acute", "OBSERVATION_MODIFIER", 299, 304], ["pathogens", "OBSERVATION", 573, 582]]], ["Resource limitations permitted multiplex PCR testing only on the one class.Statistical analysis ::: MethodsIncidence rates for respiratory illness during basic training were calculated using the reported number of URI or ILIs divided by the recruit-weeks observed over the time period between enrollment and the date the recruits were allowed to go on leave.", [["respiratory", "ANATOMY", 127, 138], ["respiratory illness", "DISEASE", 127, 146], ["multiplex PCR testing", "TEST", 31, 52], ["respiratory illness", "PROBLEM", 127, 146], ["basic training", "TREATMENT", 154, 168], ["URI", "PROBLEM", 214, 217], ["ILIs", "TREATMENT", 221, 225]]], ["For classes 1 and 2, incidence rates were also calculated for time periods after the end of basic training.", [["incidence rates", "TEST", 21, 36], ["basic training", "TREATMENT", 92, 106]]], ["Post-basic training was defined as the period beginning with the first full week after recruits returned from leave following basic training (see Appendix S1 for specific time intervals for the class surveillance periods).", [["basic training", "TREATMENT", 126, 140]]], ["Confidence intervals for incidence rates and ratios were calculated using formulae from Rothman and Greenland (using the epiR package in r).16 All analyses were performed using r version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).Statistical analysis ::: MethodsThe Cochrane\u2013Mantel\u2013Haenszel test was used for linear trend of differences in row means (vcdExtra package in r) to evaluate trend over the weeks between enrollment and the leave after basic training.", [["Confidence intervals", "TEST", 0, 20], ["incidence rates", "TEST", 25, 40], ["ratios", "TEST", 45, 51], ["the epiR package", "TREATMENT", 117, 133], ["All analyses", "TEST", 143, 155], ["r version", "TEST", 177, 186], ["Statistical analysis", "TEST", 251, 271], ["Haenszel test", "TEST", 303, 316], ["vcdExtra package", "TREATMENT", 372, 388], ["basic training", "TREATMENT", 467, 481]]], ["While rates of infections in sequestered recruits may be expected to increase initially, then decrease as susceptible individuals are depleted, given that enrollment occurred after basic training was initiated (up to 3 weeks for some classes), we used the Mantel-Haenszel chi-square test to evaluate the P-for-trend to demonstrate a preponderance of a decrease in the rate over time as evidence that infections came from within the recruit class (i.e. seeded from entry).", [["infections", "DISEASE", 15, 25], ["infections", "DISEASE", 400, 410], ["infections", "PROBLEM", 15, 25], ["basic training", "TREATMENT", 181, 195], ["Haenszel chi-square test", "TEST", 263, 287], ["the P", "TEST", 300, 305], ["a decrease in the rate", "PROBLEM", 350, 372], ["infections", "PROBLEM", 400, 410], ["infections", "OBSERVATION", 15, 25], ["may be", "UNCERTAINTY", 50, 56], ["decrease", "OBSERVATION_MODIFIER", 352, 360], ["infections", "OBSERVATION", 400, 410]]], ["One-week intervals were used beginning with the week that enrollment occurred, and ending with the week in which recruits went on post-basic training leave.", [["post-basic training", "TREATMENT", 130, 149]]], ["The P-for-trend during this last week, however, included some amount of time when the camp was largely unpopulated.", [["P", "DNA", 4, 5], ["The P", "TEST", 0, 5]]], ["For this reason, we included a P-for-trend from the enrollment week to the last full week prior to dismissal for post-basic training leave.Statistical analysis ::: MethodsTo evaluate the transmissibility of infections by close contact (i.e. from droplet transmission), we evaluated whether the bed location, available only for class 1, of those with URI/ILI were clustered using the \u03c4(d) method adapted from Salje et al.17 Using this method, we compared the probability that two individuals had beds within distance d meters apart given they had a respiratory illness within a week of each other relative to the probability that any two individuals had beds d meters apart.", [["infections", "DISEASE", 207, 217], ["ILI", "DISEASE", 354, 357], ["respiratory illness", "DISEASE", 548, 567], ["MethodsTo", "TREATMENT", 164, 173], ["infections", "PROBLEM", 207, 217], ["URI/ILI", "PROBLEM", 350, 357], ["the \u03c4(d) method", "TREATMENT", 379, 394], ["a respiratory illness", "PROBLEM", 546, 567], ["infections", "OBSERVATION", 207, 217]]], ["Values of \u03c4(d) > 1 indicate spatial clustering of cases at that distance.", [["Values", "TEST", 0, 6], ["\u03c4(d)", "TEST", 10, 14]]], ["The estimator we used for \u03c4(d) can be found in the Appendix S1.", [["\u03c4(d)", "TREATMENT", 26, 30], ["Appendix S1", "ANATOMY", 51, 62]]], ["Confidence intervals were calculated using a bootstrap method where all individuals were resampled with replacement and \u03c4(d) recalculated over 500 iterations.", [["a bootstrap method", "TREATMENT", 43, 61], ["replacement and \u03c4(d)", "TREATMENT", 104, 124]]], ["Ninety-five per cent confidence intervals were calculated from the 2\u00b75 and 97\u00b75 percentiles of the resultant distribution.Recruits ::: ResultsRecruits came from 28 of the 77 provinces of Thailand (including Bangkok) ranging in age between 20 and 31 years, with a median of 21 years (Table1).", [["resultant", "OBSERVATION_MODIFIER", 99, 108], ["distribution", "OBSERVATION_MODIFIER", 109, 121]]], ["Smoking was very prevalent with 60% reporting being current smokers with 186 (70%) smoking half a pack per day or less.", [["Smoking", "DISEASE", 0, 7]]], ["Only 2% had been vaccinated for influenza in the previous 12 months.", [["influenza", "DISEASE", 32, 41], ["influenza", "PROBLEM", 32, 41]]], ["Approximately 16% reported a medical condition at enrollment.", [["a medical condition", "PROBLEM", 27, 46]]], ["The most common conditions were allergy (5%) and asthma (4%).Single barracks/basic training (closed cohort) ::: ResultsSixty-six URIs and 11 ILIs occurred in 56 class 1 recruits between weeks 2 and 10 of basic training (Table2).", [["allergy", "DISEASE", 32, 39], ["asthma", "DISEASE", 49, 55], ["ILIs", "DISEASE", 141, 145], ["allergy", "PROBLEM", 32, 39], ["asthma", "PROBLEM", 49, 55], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["asthma", "OBSERVATION", 49, 55]]], ["The rate was 6\u00b79 per 100 recruit-weeks (95% CI: 5\u00b75\u20138\u00b76).", [["The rate", "TEST", 0, 8]]], ["The P-for-trend for the decrease in the weekly rate of illness over the course of basic training was 0\u00b717.", [["illness", "DISEASE", 55, 62], ["P", "DNA", 4, 5], ["The P", "TEST", 0, 5], ["the decrease", "PROBLEM", 20, 32], ["decrease", "OBSERVATION_MODIFIER", 24, 32]]], ["Fifty-five URIs among 48 class 2 recruits occurred between weeks 3 and 10 of basic training.", [["basic training", "TREATMENT", 77, 91]]], ["The infection rate was 5\u00b76 per 100 recruit-weeks (95% CI: 4\u00b73\u20137\u00b72).", [["infection", "DISEASE", 4, 13], ["The infection rate", "TEST", 0, 18], ["infection", "OBSERVATION", 4, 13]]], ["The P-for-trend for the decrease in the rate of illness during basic training was <0\u00b70001.", [["illness", "DISEASE", 48, 55], ["P", "DNA", 4, 5], ["The P", "TEST", 0, 5], ["the decrease", "PROBLEM", 20, 32], ["illness", "PROBLEM", 48, 55], ["decrease", "OBSERVATION_MODIFIER", 24, 32]]], ["Twenty-eight URIs and 1 ILI among 29 class 3 recruits occurred between weeks 4 and 11 of basic training.", [["ILI", "DISEASE", 24, 27], ["basic training", "TREATMENT", 89, 103]]], ["The infection rate was 4\u00b77 respiratory illnesses per 100 recruit-weeks (95% CI: 3\u00b72\u20136\u00b77).", [["infection", "DISEASE", 4, 13], ["respiratory illnesses", "DISEASE", 27, 48], ["The infection rate", "TEST", 0, 18], ["respiratory illnesses", "PROBLEM", 27, 48], ["infection", "OBSERVATION", 4, 13]]], ["The P-for-trend for the decrease in the rate of illness during basic training was 0\u00b701.", [["illness", "DISEASE", 48, 55], ["P", "DNA", 4, 5], ["The P", "TEST", 0, 5], ["the decrease", "PROBLEM", 20, 32], ["illness", "PROBLEM", 48, 55], ["basic training", "TREATMENT", 63, 77], ["decrease", "OBSERVATION_MODIFIER", 24, 32]]], ["Forty URIs and 3 ILIs among 41 class 4 recruits occurred between weeks 4 and 11 of basic training.", [["ILIs", "DISEASE", 17, 21], ["basic training", "TREATMENT", 83, 97]]], ["The infection rate was 5\u00b71 respiratory illnesses per 100 recruit-weeks (95% CI: 3\u00b78\u20136\u00b78).", [["infection", "DISEASE", 4, 13], ["respiratory illnesses", "DISEASE", 27, 48], ["The infection rate", "TEST", 0, 18], ["respiratory illnesses", "PROBLEM", 27, 48], ["infection", "OBSERVATION", 4, 13]]], ["The P-for-trend for the decrease in the rate of illness during basic training was <0\u00b701.Post-basic training ::: ResultsThe rate of respiratory illness among class 1 recruits upon their return to camp after basic training was 4\u00b70 per 100 recruit-weeks (95% CI: 3\u00b71\u20135\u00b71).", [["respiratory", "ANATOMY", 131, 142], ["illness", "DISEASE", 48, 55], ["respiratory illness", "DISEASE", 131, 150], ["P", "DNA", 4, 5], ["The P", "TEST", 0, 5], ["the decrease", "PROBLEM", 20, 32], ["illness", "PROBLEM", 48, 55], ["basic training", "TEST", 63, 77], ["respiratory illness", "PROBLEM", 131, 150], ["decrease", "OBSERVATION_MODIFIER", 24, 32]]], ["The rate ratio of respiratory illness during basic training relative to after basic training was 1\u00b77 (95% CI: 1\u00b729\u20132\u00b729).", [["respiratory", "ANATOMY", 18, 29], ["respiratory illness", "DISEASE", 18, 37], ["The rate ratio", "TEST", 0, 14], ["respiratory illness", "PROBLEM", 18, 37], ["basic training", "TEST", 78, 92], ["respiratory illness", "OBSERVATION", 18, 37]]], ["The rate or respiratory illness among class 2 recruits upon their return after basic training was 2\u00b73 (95% CI: 1\u00b74\u20137\u00b72).", [["respiratory", "ANATOMY", 12, 23], ["respiratory illness", "DISEASE", 12, 31], ["respiratory illness", "PROBLEM", 12, 31], ["respiratory illness", "OBSERVATION", 12, 31]]], ["The rate ratio during basic training relative to after basic training was 2\u00b746 (95% CI: 1\u00b75\u20134\u00b71).Laboratory-confirmed illness \u2013 influenza RT-PCR and multiplex PCR ::: ResultsInfluenza RT-PCR was performed on all nasal/throat swab samples in the four classes.", [["nasal", "ANATOMY", 212, 217], ["throat swab samples", "ANATOMY", 218, 237], ["nasal", "ORGANISM_SUBDIVISION", 212, 217], ["The rate ratio", "TEST", 0, 14], ["basic training", "TEST", 55, 69], ["CI", "TEST", 84, 86], ["illness", "PROBLEM", 118, 125], ["influenza RT", "TEST", 128, 140], ["PCR", "TEST", 141, 144], ["multiplex PCR", "TEST", 149, 162], ["Influenza RT-PCR", "TEST", 174, 190], ["all nasal/throat swab samples", "TEST", 208, 237], ["throat", "ANATOMY", 218, 224]]], ["Only one sample (in class 3) was found to be positive for influenza virus (type B).", [["sample", "ANATOMY", 9, 15], ["influenza virus", "DISEASE", 58, 73], ["influenza virus", "ORGANISM", 58, 73], ["influenza virus", "SPECIES", 58, 73], ["influenza virus", "SPECIES", 58, 73], ["one sample", "TEST", 5, 15], ["influenza virus", "PROBLEM", 58, 73], ["influenza virus", "OBSERVATION", 58, 73]]], ["Multiplex PCR was performed on 76 of the 77 nasal/throat swab specimens collected during basic training from class 1.", [["nasal", "ANATOMY", 44, 49], ["throat swab specimens", "ANATOMY", 50, 71], ["Multiplex PCR", "TEST", 0, 13], ["nasal/throat swab specimens", "TEST", 44, 71], ["throat", "ANATOMY", 50, 56]]], ["Of 18 viral pathogens in the panel (including influenza A, B and C), three pathogens were detected among 31 (40\u00b78%) of 76 specimens (Figure1).", [["specimens", "ANATOMY", 122, 131], ["B", "GENE_OR_GENE_PRODUCT", 59, 60], ["specimens", "CANCER", 122, 131], ["18 viral pathogens", "PROBLEM", 3, 21], ["the panel", "TEST", 25, 34], ["influenza A", "TEST", 46, 57], ["three pathogens", "TEST", 69, 84], ["Figure1", "TEST", 133, 140], ["viral pathogens", "OBSERVATION", 6, 21]]], ["Rhinovirus was detected in 22 specimens, coronavirus 229 in eight specimens and parainfluenza 4 virus in four.", [["specimens", "ANATOMY", 30, 39], ["specimens", "ANATOMY", 66, 75], ["parainfluenza 4 virus", "DISEASE", 80, 101], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 0, 10], ["coronavirus 229", "ORGANISM", 41, 56], ["specimens", "CANCER", 66, 75], ["parainfluenza 4 virus", "ORGANISM", 80, 101], ["parainfluenza 4 virus", "SPECIES", 80, 101], ["Rhinovirus", "SPECIES", 0, 10], ["coronavirus 229", "SPECIES", 41, 56], ["parainfluenza 4 virus", "SPECIES", 80, 101], ["Rhinovirus", "PROBLEM", 0, 10], ["coronavirus", "TEST", 41, 52], ["parainfluenza", "PROBLEM", 80, 93]]], ["Three recruits with rhinovirus had co-infections (two with coronavirus 229 and one with parainfluenza).Bed location ::: ResultsFigure2 shows the \u03c4(d) clustering statistic over distances between 0 and 20 m between beds for class 1.", [["rhinovirus had co-infections", "DISEASE", 20, 48], ["parainfluenza", "DISEASE", 88, 101], ["rhinovirus", "ORGANISM", 20, 30], ["parainfluenza", "ORGANISM", 88, 101], ["parainfluenza", "SPECIES", 88, 101], ["rhinovirus", "PROBLEM", 20, 30], ["co-infections", "PROBLEM", 35, 48], ["coronavirus", "PROBLEM", 59, 70], ["parainfluenza", "PROBLEM", 88, 101]]], ["We found some evidence of spatial dependence at very small spatial scales.", [["spatial dependence at very small spatial scales", "PROBLEM", 26, 73], ["some evidence of", "UNCERTAINTY", 9, 25], ["spatial dependence", "OBSERVATION", 26, 44], ["very", "OBSERVATION_MODIFIER", 48, 52], ["small", "OBSERVATION_MODIFIER", 53, 58], ["spatial scales", "OBSERVATION", 59, 73]]], ["Individuals were 1\u00b72 times more likely to have a bed within 3 m of another case given they had a respiratory illness within a week of each other, relative to the probability that any two individuals had beds within 3 m of each other.", [["respiratory", "ANATOMY", 97, 108], ["respiratory illness", "DISEASE", 97, 116], ["a respiratory illness", "PROBLEM", 95, 116]]], ["However, the uncertainty in these estimates was wide (95% confidence intervals of 0\u00b78\u20131\u00b75).", [["wide", "OBSERVATION_MODIFIER", 48, 52]]], ["This value dropped to 1\u00b70 at 5 m (95% confidence intervals of 0\u00b78\u20131\u00b73).DiscussionIn this report on respiratory illness surveillance among new conscripts in a military barracks in the tropics, we found a high incidence of respiratory illness.", [["respiratory", "ANATOMY", 221, 232], ["respiratory illness", "DISEASE", 99, 118], ["respiratory illness", "DISEASE", 221, 240], ["This value", "TEST", 0, 10], ["respiratory illness", "PROBLEM", 221, 240], ["respiratory illness", "OBSERVATION", 221, 240]]], ["Between 39% (class 4) and 46% (class 1) of recruits reported respiratory illness with incidence rates ranging from 4\u00b77 to 6\u00b79 per 100 recruit-weeks.", [["respiratory", "ANATOMY", 61, 72], ["respiratory illness", "DISEASE", 61, 80], ["respiratory illness", "PROBLEM", 61, 80], ["incidence rates", "TEST", 86, 101], ["respiratory illness", "OBSERVATION", 61, 80]]], ["The viral pathogens identified, rhinovirus, coronavirus, and parainfluenza virus, were compatible with URI symptoms prevalent in this study.", [["rhinovirus, coronavirus, and parainfluenza virus", "DISEASE", 32, 80], ["rhinovirus", "ORGANISM", 32, 42], ["coronavirus", "ORGANISM", 44, 55], ["parainfluenza virus", "ORGANISM", 61, 80], ["rhinovirus", "SPECIES", 32, 42], ["coronavirus", "SPECIES", 44, 55], ["parainfluenza virus", "SPECIES", 61, 80], ["parainfluenza virus", "SPECIES", 61, 80], ["The viral pathogens", "PROBLEM", 0, 19], ["rhinovirus", "PROBLEM", 32, 42], ["coronavirus", "PROBLEM", 44, 55], ["parainfluenza virus", "PROBLEM", 61, 80], ["URI symptoms", "PROBLEM", 103, 115], ["this study", "TEST", 129, 139], ["viral pathogens", "OBSERVATION", 4, 19], ["rhinovirus", "OBSERVATION", 32, 42], ["parainfluenza virus", "OBSERVATION", 61, 80]]], ["At least one of these three pathogens was present in 40% of the samples collected.", [["samples", "ANATOMY", 64, 71], ["these three pathogens", "PROBLEM", 16, 37], ["three", "OBSERVATION_MODIFIER", 22, 27], ["pathogens", "OBSERVATION", 28, 37]]], ["We found little febrile respiratory illness (i.e. ILI) and only one laboratory-confirmed influenza case even though influenza immunization was seldom reported among the recruits.", [["respiratory", "ANATOMY", 24, 35], ["febrile respiratory illness", "DISEASE", 16, 43], ["ILI", "DISEASE", 50, 53], ["influenza", "DISEASE", 89, 98], ["influenza", "DISEASE", 116, 125], ["little febrile respiratory illness", "PROBLEM", 9, 43], ["influenza case", "PROBLEM", 89, 103], ["influenza immunization", "TREATMENT", 116, 138], ["little", "OBSERVATION_MODIFIER", 9, 15], ["febrile", "OBSERVATION_MODIFIER", 16, 23], ["respiratory illness", "OBSERVATION", 24, 43], ["influenza", "OBSERVATION", 89, 98]]], ["Notably, at the time the first recruit class entered the barracks (May 2012), there was very little Influenza virus transmission.18 Thereafter, influenza circulated almost continuously throughout the study period in Thailand until December of 2013.", [["Influenza virus transmission", "DISEASE", 100, 128], ["influenza", "DISEASE", 144, 153], ["Influenza virus", "ORGANISM", 100, 115], ["Influenza virus", "SPECIES", 100, 115], ["very little Influenza virus transmission", "PROBLEM", 88, 128], ["influenza", "PROBLEM", 144, 153], ["little", "OBSERVATION_MODIFIER", 93, 99], ["Influenza virus", "OBSERVATION", 100, 115]]], ["However, at the time the last three recruit classes entered training, influenza transmission in Thailand was moderate (November 2012) to low (May and November 2013).", [["influenza", "DISEASE", 70, 79], ["influenza transmission", "PROBLEM", 70, 92]]], ["Influenza activity in Thailand tends to peak after the beginning of the rainy season between July and September.19DiscussionAdenovirus, a pathogen that is recognized as the most common viral pathogen found in military barracks and responsible for a great proportion of respiratory illnesses among the U.S. military, was not identified among those specimens that underwent multiplex PCR.20 The paucity of influenza virus and adenovirus infections was most likely due to the fact that outbreaks of these pathogens were, simply by chance, not captured among the relatively small number of recruits in our study.", [["respiratory", "ANATOMY", 269, 280], ["specimens", "ANATOMY", 347, 356], ["Influenza", "DISEASE", 0, 9], ["respiratory illnesses", "DISEASE", 269, 290], ["influenza virus and adenovirus infections", "DISEASE", 404, 445], ["19DiscussionAdenovirus", "ORGANISM", 112, 134], ["influenza virus", "ORGANISM", 404, 419], ["adenovirus", "ORGANISM", 424, 434], ["influenza virus", "SPECIES", 404, 419], ["influenza virus", "SPECIES", 404, 419], ["adenovirus", "SPECIES", 424, 434], ["Influenza activity", "PROBLEM", 0, 18], ["Adenovirus", "PROBLEM", 124, 134], ["a pathogen", "PROBLEM", 136, 146], ["respiratory illnesses", "PROBLEM", 269, 290], ["multiplex PCR", "TEST", 372, 385], ["influenza virus", "PROBLEM", 404, 419], ["adenovirus infections", "PROBLEM", 424, 445], ["these pathogens", "PROBLEM", 496, 511], ["our study", "TEST", 598, 607], ["respiratory illnesses", "OBSERVATION", 269, 290], ["paucity", "OBSERVATION_MODIFIER", 393, 400], ["influenza virus", "OBSERVATION", 404, 419], ["pathogens", "OBSERVATION", 502, 511], ["relatively", "OBSERVATION_MODIFIER", 559, 569], ["small", "OBSERVATION_MODIFIER", 570, 575], ["number", "OBSERVATION_MODIFIER", 576, 582]]], ["With respect to influenza, the time the recruits came together in the camps did not happen to correspond to significant virus transmission in Thailand.", [["influenza", "DISEASE", 16, 25], ["influenza", "PROBLEM", 16, 25], ["significant virus transmission in Thailand", "PROBLEM", 108, 150], ["influenza", "OBSERVATION", 16, 25], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["virus", "OBSERVATION", 120, 125]]], ["A larger study involving thousands of individuals, particularly after the beginning of the rainy season, would be more likely to capture such outbreaks.", [["A larger study", "TEST", 0, 14], ["larger", "OBSERVATION_MODIFIER", 2, 8]]], ["However, it is also possible that the conditions within military barracks in the tropics may be less favorable for transmission of these viruses compared with more temperate climates, perhaps related to higher humidity and temperature.", [["the conditions", "PROBLEM", 34, 48], ["these viruses", "PROBLEM", 131, 144], ["is also possible", "UNCERTAINTY", 12, 28], ["viruses", "OBSERVATION", 137, 144], ["higher humidity", "OBSERVATION", 203, 218]]], ["Larger studies among military recruits would need to be performed to clarify the burden of influenza and adenovirus among recruits in the tropics.DiscussionIn this barracks setting during basic training, our results indicate the presence of infection dynamics typical of crowded conditions consistent with those seen in military barracks in the United States.", [["influenza", "DISEASE", 91, 100], ["infection", "DISEASE", 241, 250], ["adenovirus", "ORGANISM", 105, 115], ["adenovirus", "SPECIES", 105, 115], ["Larger studies", "TEST", 0, 14], ["influenza", "PROBLEM", 91, 100], ["adenovirus", "PROBLEM", 105, 115], ["basic training", "TREATMENT", 188, 202], ["infection dynamics", "PROBLEM", 241, 259], ["crowded conditions", "PROBLEM", 271, 289], ["influenza", "OBSERVATION", 91, 100], ["infection", "OBSERVATION", 241, 250], ["crowded conditions", "OBSERVATION", 271, 289], ["consistent with", "UNCERTAINTY", 290, 305]]], ["In the U.S. military, the evidence suggests that most cases arise from internal transmission in which recruits infect one another rather than repeatedly being infected from outside the barracks.21 In one study in a U.S. barracks, the incidence of acute respiratory illness rose rapidly in the first few weeks, peaked in week 5, then declined by week 7 to below week 1 levels toward the end of training.22 The trend in our study of decreasing rates of infection over the course of basic training in three of the four classes supports the notion of initial seeding by new recruits infected from the outside with subsequent internal transmission leading to high initial rates followed by a decline due to depletion of susceptibles.", [["respiratory", "ANATOMY", 253, 264], ["respiratory illness", "DISEASE", 253, 272], ["infection", "DISEASE", 451, 460], ["acute respiratory illness", "PROBLEM", 247, 272], ["our study", "TEST", 418, 427], ["decreasing rates of infection", "PROBLEM", 431, 460], ["basic training", "TREATMENT", 480, 494], ["initial seeding", "PROBLEM", 547, 562], ["high initial rates", "PROBLEM", 654, 672], ["a decline", "PROBLEM", 685, 694], ["depletion of susceptibles", "PROBLEM", 702, 727], ["infected", "OBSERVATION", 159, 167], ["acute", "OBSERVATION_MODIFIER", 247, 252], ["respiratory illness", "OBSERVATION", 253, 272], ["trend", "OBSERVATION_MODIFIER", 409, 414], ["decreasing", "OBSERVATION_MODIFIER", 431, 441], ["rates", "OBSERVATION_MODIFIER", 442, 447], ["infection", "OBSERVATION", 451, 460], ["seeding", "OBSERVATION", 555, 562], ["new", "OBSERVATION_MODIFIER", 566, 569], ["infected", "OBSERVATION", 579, 587]]], ["Further support comes from the pattern of infections relative to bed location in the barracks.", [["infections", "DISEASE", 42, 52], ["Further support", "TREATMENT", 0, 15], ["infections", "PROBLEM", 42, 52], ["infections", "OBSERVATION", 42, 52]]], ["Though not significant, the likelihood of having a respiratory infection tended to increase with proximity to the bed of someone with URI/ILI.", [["respiratory", "ANATOMY", 51, 62], ["respiratory infection", "DISEASE", 51, 72], ["ILI", "DISEASE", 138, 141], ["a respiratory infection", "PROBLEM", 49, 72], ["URI", "PROBLEM", 134, 137], ["ILI", "PROBLEM", 138, 141], ["not", "UNCERTAINTY", 7, 10], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["respiratory", "ANATOMY", 51, 62], ["infection", "OBSERVATION", 63, 72]]], ["It should also be noted that recruits from each class were effectively sequestered from the outside during basic training.", [["basic training", "TREATMENT", 107, 121]]], ["Though it is possible that the training instructors were allowed to come and go from the camp and, therefore, may have offered an opportunity for pathogens to be introduced from the outside, the instructors also slept in the barracks.", [["pathogens", "PROBLEM", 146, 155]]], ["Thus, it is likely that the infection dynamics reflected the seeding of infectious pathogens from recruits upon entering the class.DiscussionIn the current study, soldiers in basic training were more likely to experience URI/ILI than soldiers who had already completed basic training in the same camps.", [["infection", "DISEASE", 28, 37], ["ILI", "DISEASE", 225, 228], ["the infection dynamics", "PROBLEM", 24, 46], ["infectious pathogens", "PROBLEM", 72, 92], ["the current study", "TEST", 144, 161], ["URI", "PROBLEM", 221, 224], ["basic training", "TREATMENT", 269, 283], ["is likely", "UNCERTAINTY", 9, 18], ["infection", "OBSERVATION", 28, 37], ["infectious", "OBSERVATION_MODIFIER", 72, 82]]], ["This higher infection rate among recruits during basic training relative to more seasoned soldiers, those that have completed basic training, provides evidence that recruits in the RTA are particularly vulnerable to infectious respiratory diseases similar to what is seen in the U.S. military.8 The approximately twofold higher infection rates observed in RTA recruits in basic training is, however, at the lower end of the 2- to 16-fold higher rates seen in U.S. soldiers.", [["respiratory", "ANATOMY", 227, 238], ["infection", "DISEASE", 12, 21], ["respiratory diseases", "DISEASE", 227, 247], ["infection", "DISEASE", 328, 337], ["RTA", "GENE_OR_GENE_PRODUCT", 181, 184], ["This higher infection rate", "PROBLEM", 0, 26], ["basic training", "TREATMENT", 49, 63], ["basic training", "TREATMENT", 126, 140], ["infectious respiratory diseases", "PROBLEM", 216, 247], ["The approximately twofold higher infection rates", "PROBLEM", 295, 343], ["higher", "OBSERVATION_MODIFIER", 5, 11], ["infection", "OBSERVATION", 12, 21], ["infectious", "OBSERVATION_MODIFIER", 216, 226], ["approximately", "OBSERVATION_MODIFIER", 299, 312], ["twofold", "OBSERVATION_MODIFIER", 313, 320], ["higher", "OBSERVATION_MODIFIER", 321, 327], ["infection", "OBSERVATION", 328, 337], ["RTA", "OBSERVATION_MODIFIER", 356, 359]]], ["The fact that these soldiers were conscripted may make our findings more generally applicable than had they gone through the self-selection that occurs among volunteer armies.DiscussionA few limitations of our study may have impacted the reliable inference regarding the infection dynamics in RTA training camps.", [["infection", "DISEASE", 271, 280], ["our study", "TEST", 206, 215], ["the infection dynamics", "PROBLEM", 267, 289], ["RTA training camps", "TREATMENT", 293, 311], ["infection", "OBSERVATION", 271, 280]]], ["For logistical reasons, we were unable to begin illness surveillance until 2\u20133 weeks had elapsed after initiation of basic training.", [["illness", "DISEASE", 48, 55], ["basic training", "TREATMENT", 117, 131]]], ["Therefore, the first generations of infectious transmission were not observed to effectively characterize the possible initial increase in infection rates as may be expected under the conditions of internal transmission alone.", [["infection", "DISEASE", 139, 148], ["infectious transmission", "TEST", 36, 59], ["initial increase in infection rates", "PROBLEM", 119, 154], ["infectious", "OBSERVATION", 36, 46], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["infection", "OBSERVATION", 139, 148]]], ["The clustering statistic for distance between beds may be diluted due to other recruit activities done in close proximity such as eating, common toilets and instruction.", [["distance between beds", "TREATMENT", 29, 50], ["other recruit activities", "PROBLEM", 73, 97]]], ["Another limitation was that our study relied on syndromic surveillance.", [["our study", "TEST", 28, 37], ["syndromic surveillance", "TEST", 48, 70]]], ["Thus, we had little opportunity to observe asymptomatic cases.", [["asymptomatic cases", "PROBLEM", 43, 61]]], ["Also, we could not be certain that pathogen exposure from the outside did not occur over the course of training.", [["pathogen exposure", "PROBLEM", 35, 52]]], ["Furthermore, while a corpsman did routinely remind soldiers that they were to report any illnesses, some illnesses may have been missed.", [["any illnesses", "PROBLEM", 85, 98], ["some illnesses", "PROBLEM", 100, 114]]], ["When illnesses were reported, they occurred in temporal clusters, suggesting that other, perhaps social factors, may have precipitated reporting.", [["illnesses", "PROBLEM", 5, 14]]], ["Finally, due to resource constraints, we were unable to perform multiplex PCR for all recruit classes.DiscussionWhile there are other settings with intense population mixing, such as schools, sports teams, prisons, and monasteries, the situation of new recruits in a military barracks represents a unique combination of sudden convergence of geographically diverse individuals, extended and continuous duration of mixing, and extreme physical exertion not seen in most other settings.", [["multiplex PCR", "TEST", 64, 77], ["extreme physical exertion", "PROBLEM", 426, 451]]], ["The conditions for enhanced disease transmission in the RTA barracks may also have been different from barracks in more temperate climates such as the United States.", [["enhanced disease transmission", "PROBLEM", 19, 48]]], ["For example, the RTA barracks were very well ventilated with wide open windows in the sleeping quarters.", [["the RTA barracks", "PROBLEM", 13, 29], ["wide open windows", "TREATMENT", 61, 78]]], ["Also, other activities such as classroom training and eating occurred in the open air or under a roof only.", [["classroom training", "TREATMENT", 31, 49]]], ["It is possible that these factors could have potentially dampened intense internal transmission.", [["dampened", "OBSERVATION_MODIFIER", 57, 65], ["intense", "OBSERVATION_MODIFIER", 66, 73], ["internal", "OBSERVATION_MODIFIER", 74, 82], ["transmission", "OBSERVATION_MODIFIER", 83, 95]]], ["Other simple interventions could also potentially be considered to mitigate transmission such as arranging sleeping cots foot to foot instead of head to head or organizing training activities and sleeping arrangements into discrete clusters.DiscussionOur findings are consistent with the dynamic of infections harbored by a few individuals upon entry into a military barracks and spreading over successive generations of transmission until susceptible individuals are depleted.", [["head", "ANATOMY", 145, 149], ["head", "ANATOMY", 153, 157], ["infections", "DISEASE", 299, 309], ["foot", "ORGANISM_SUBDIVISION", 121, 125], ["foot", "ORGANISM_SUBDIVISION", 129, 133], ["head", "ORGANISM_SUBDIVISION", 145, 149], ["head", "ORGANISM_SUBDIVISION", 153, 157], ["individuals", "ORGANISM", 452, 463], ["Other simple interventions", "TREATMENT", 0, 26], ["sleeping cots foot", "TREATMENT", 107, 125], ["organizing training activities", "TREATMENT", 161, 191], ["infections", "PROBLEM", 299, 309], ["susceptible individuals", "PROBLEM", 440, 463], ["foot", "ANATOMY", 129, 133], ["head", "ANATOMY", 145, 149], ["head", "ANATOMY", 153, 157], ["consistent with", "UNCERTAINTY", 268, 283], ["infections", "OBSERVATION", 299, 309]]], ["Our study is effectively a random selection of an event that frequently takes place both in and out of the military.", [["Our study", "TEST", 0, 9]]], ["In this instance, the pathogens that caused infections produced mild disease.", [["infections", "DISEASE", 44, 54], ["the pathogens", "PROBLEM", 18, 31], ["infections", "PROBLEM", 44, 54], ["mild disease", "PROBLEM", 64, 76], ["infections", "OBSERVATION", 44, 54], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["disease", "OBSERVATION", 69, 76]]], ["What is significant is that such congregations of people await the chance introduction of more virulent and/or communicable infections such as measles, mumps, norovirus, SARS-CoV, MERS-CoV, influenza, or emerging infections with significant potential for more debilitating disease or mortality.Author contributionsJWL and IKY contributed to study design, data analysis/interpretation, and manuscript writing.", [["infections", "DISEASE", 124, 134], ["measles, mumps, norovirus", "DISEASE", 143, 168], ["SARS-CoV", "DISEASE", 170, 178], ["influenza", "DISEASE", 190, 199], ["infections", "DISEASE", 213, 223], ["people", "ORGANISM", 50, 56], ["SARS-CoV", "ORGANISM", 170, 178], ["MERS-CoV", "ORGANISM", 180, 188], ["IKY", "DNA", 322, 325], ["people", "SPECIES", 50, 56], ["MERS-CoV", "SPECIES", 180, 188], ["SARS-CoV", "SPECIES", 170, 178], ["MERS-CoV", "SPECIES", 180, 188], ["communicable infections", "PROBLEM", 111, 134], ["measles", "PROBLEM", 143, 150], ["mumps", "PROBLEM", 152, 157], ["norovirus", "PROBLEM", 159, 168], ["SARS", "PROBLEM", 170, 174], ["CoV", "PROBLEM", 175, 178], ["MERS", "PROBLEM", 180, 184], ["CoV", "PROBLEM", 185, 188], ["influenza", "PROBLEM", 190, 199], ["emerging infections", "PROBLEM", 204, 223], ["more debilitating disease", "PROBLEM", 255, 280], ["data analysis", "TEST", 355, 368], ["significant", "OBSERVATION_MODIFIER", 8, 19]]], ["PB and HA contributed to study design, data acquisition, data analysis/interpretation, and manuscript writing.", [["HA", "PROBLEM", 7, 9], ["study design", "TEST", 25, 37], ["data acquisition", "TEST", 39, 55], ["data analysis", "TEST", 57, 70]]], ["SS and KH contributed to data acquisition and manuscript writing.", [["data acquisition", "TEST", 25, 41]]], ["HS contributed to data analysis/interpretation and manuscript writing.", [["data analysis", "TEST", 18, 31]]], ["RR, RGJ and RVG contributed to study design and manuscript writing.", [["RR", "TEST", 0, 2], ["RGJ", "PROBLEM", 4, 7], ["RVG", "PROBLEM", 12, 15]]], ["SF and CK contributed to data acquisition, data analysis/interpretation, and manuscript writing.", [["CK", "GENE_OR_GENE_PRODUCT", 7, 9], ["SF", "PROTEIN", 0, 2], ["CK", "PROTEIN", 7, 9], ["CK", "TEST", 7, 9], ["data acquisition", "TEST", 25, 41], ["data analysis", "TEST", 43, 56]]]], "PMC7465880": [["IntroductionSince the advent of the COVID-19 pandemic and the rapid spread of the disease across the globe, the practice of rheumatology has found itself in the middle of crucial decision making and widespread service disruption.", [["the COVID", "TEST", 32, 41], ["pandemic", "PROBLEM", 45, 53], ["the disease across the globe", "PROBLEM", 78, 106], ["rapid", "OBSERVATION_MODIFIER", 62, 67], ["spread", "OBSERVATION_MODIFIER", 68, 74], ["disease", "OBSERVATION", 82, 89], ["globe", "ANATOMY", 101, 106], ["middle", "ANATOMY_MODIFIER", 161, 167], ["widespread", "OBSERVATION_MODIFIER", 199, 209], ["service disruption", "OBSERVATION", 210, 228]]], ["Across Africa, the impact of the pandemic is even more noticeable as there is a wide disparity in the availability and quality of healthcare services in the different countries and regions of the continent [1].", [["healthcare services", "TREATMENT", 130, 149], ["wide", "OBSERVATION_MODIFIER", 80, 84], ["disparity", "OBSERVATION_MODIFIER", 85, 94]]], ["Recommendations and practice standards have changed rapidly in the face of the pandemic, and the potential roles of a number of disease-modifying anti-rheumatic drugs (DMARDs) in the management of COVID-19 have come to the fore.IntroductionThe leadership of the African League Against Rheumatism (AFLAR) commissioned a task force to develop recommendations for the management of rheumatic and musculoskeletal diseases (RMDs) in the unprecedented situation of a continent faced with COVID-19.", [["musculoskeletal", "ANATOMY", 393, 408], ["rheumatic and musculoskeletal diseases", "DISEASE", 379, 417], ["RMDs", "DISEASE", 419, 423], ["COVID-19", "CHEMICAL", 197, 205], ["COVID-19", "CHEMICAL", 482, 490], ["disease", "PROBLEM", 128, 135], ["modifying anti-rheumatic drugs", "TREATMENT", 136, 166], ["DMARDs", "TREATMENT", 168, 174], ["COVID", "TEST", 197, 202], ["the management", "TREATMENT", 361, 375], ["rheumatic and musculoskeletal diseases", "PROBLEM", 379, 417], ["COVID", "TEST", 482, 487], ["pandemic", "OBSERVATION", 79, 87], ["Rheumatism", "OBSERVATION", 285, 295], ["rheumatic", "OBSERVATION", 379, 388], ["musculoskeletal", "ANATOMY", 393, 408], ["diseases", "OBSERVATION", 409, 417]]], ["However, the relatively delayed spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the continent a while after other continents such as Asia, North America and Europe allowed for some body of evidence to have been developed and recommendations made by other international rheumatology bodies which became available for the appraisal of the African team.Mandate ::: MethodsThe scope of the proposed recommendations was to address clinical questions encountered on a daily basis by the practicing rheumatologists in Africa in the complex situation where COVID-19 redefines clinical needs and standards.", [["acute respiratory syndrome coronavirus", "DISEASE", 53, 91], ["severe acute respiratory syndrome coronavirus", "SPECIES", 46, 91], ["SARS-CoV-2", "SPECIES", 95, 105], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 42, 91], ["SARS", "TEST", 95, 99], ["CoV", "TEST", 100, 103], ["Methods", "TREATMENT", 396, 403], ["relatively", "OBSERVATION_MODIFIER", 13, 23], ["delayed", "OBSERVATION_MODIFIER", 24, 31], ["spread", "OBSERVATION_MODIFIER", 32, 38], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["respiratory syndrome coronavirus", "OBSERVATION", 59, 91]]], ["Recommendations were proposed to cover the management of RMDs among adult and paediatric patients in the context of COVID-19.", [["RMDs", "DISEASE", 57, 61], ["RMDs", "CANCER", 57, 61], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["COVID", "TEST", 116, 121]]], ["The task excludes recommendations for the management of individual RMDs or the treatment of COVID-19.", [["RMDs", "DISEASE", 67, 71], ["COVID-19", "CHEMICAL", 92, 100], ["RMDs", "CANCER", 67, 71], ["the management", "TREATMENT", 38, 52], ["individual RMDs", "TREATMENT", 56, 71], ["COVID", "TEST", 92, 97]]], ["The lead and membership of the central working committee (CWC) and subsequently the full membership list of the larger task force were commissioned by the president of AFLAR to produce the recommendations within predefined deadlines.Structure of the task force ::: MethodsA hub-and-spoke model was adopted with the task force spreading out from the CWC formed by the leads of the four subgroups as well as the AFLAR president, an executive of the Pediatric African League Against Rheumatism (PAFLAR) and 2 members of the COVID-19 African Rheumatology Research Group.", [["Rheumatism", "DISEASE", 480, 490], ["CWC", "CANCER", 349, 352], ["central", "OBSERVATION_MODIFIER", 31, 38]]], ["The leads of the subgroups were assigned and delegated with the tasks and the broad themes of each subgroup were as follows: subgroup 1, risk assessment and prevention of SARS-CoV-2 infection among patients with RMDs; subgroup 2, use of usual rheumatological treatments in patients at risk of SARS-CoV-2 infection; subgroup 3, treatment of patients with RMDs after exposure to known case of COVID-19; and subgroup 4, management of RMDs in patients infected with SARS-CoV-2.", [["SARS-CoV-2 infection", "DISEASE", 171, 191], ["RMDs", "DISEASE", 212, 216], ["SARS-CoV-2 infection", "DISEASE", 293, 313], ["RMDs", "DISEASE", 354, 358], ["RMDs", "DISEASE", 431, 435], ["SARS", "DISEASE", 462, 466], ["SARS-CoV-2", "ORGANISM", 171, 181], ["patients", "ORGANISM", 198, 206], ["patients", "ORGANISM", 273, 281], ["patients", "ORGANISM", 340, 348], ["patients", "ORGANISM", 439, 447], ["SARS-CoV-2", "ORGANISM", 462, 472], ["patients", "SPECIES", 198, 206], ["patients", "SPECIES", 273, 281], ["patients", "SPECIES", 340, 348], ["patients", "SPECIES", 439, 447], ["SARS-CoV", "SPECIES", 171, 179], ["SARS-CoV", "SPECIES", 462, 470], ["risk assessment", "TEST", 137, 152], ["SARS", "PROBLEM", 171, 175], ["CoV-2 infection", "PROBLEM", 176, 191], ["RMDs", "PROBLEM", 212, 216], ["usual rheumatological treatments", "TREATMENT", 237, 269], ["SARS", "PROBLEM", 293, 297], ["CoV", "PROBLEM", 298, 301], ["2 infection", "PROBLEM", 302, 313], ["RMDs", "TREATMENT", 354, 358], ["COVID", "TEST", 391, 396], ["RMDs", "TREATMENT", 431, 435], ["SARS", "PROBLEM", 462, 466], ["infected", "OBSERVATION", 448, 456]]], ["The subgroup leads were given the mandate to nominate the membership of their subgroups which were to be drawn from all five regions of the continent.", [["continent", "OBSERVATION", 140, 149]]], ["In conjunction with other paediatric rheumatologists on the task force, the PAFLAR executive on the CWC led an independent review and representation of the paediatric-specific recommendations to the CWC.Timeline ::: MethodsThe CWC was set up on June 8, and the first virtual meeting was held on June 10 by video conferencing.", [["CWC", "DISEASE", 199, 202], ["CWC", "CANCER", 199, 202], ["CWC", "CANCER", 227, 230], ["Methods", "TREATMENT", 216, 223], ["The CWC", "TEST", 223, 230]]], ["Harmonization of statements and approval of final statements were completed on June 29.Background guideline review ::: MethodsPublished guidelines and recommendations of international rheumatology bodies outside Africa on management of RMDs in the context of COVID-19 were reviewed.", [["RMDs", "DISEASE", 236, 240], ["RMDs", "CANCER", 236, 240], ["RMDs", "TREATMENT", 236, 240], ["COVID", "TEST", 259, 264]]], ["This includes the recently published guidelines of the European League Against Rheumatism (EULAR), American College of Rheumatology (ACR), the Australian Rheumatology Association (ARA), the Asia Pacific League of Associations for Rheumatology (APLAR) and the National institute for Health and Care Excellence (NICE) of the UK [2\u20136].", [["Rheumatism", "DISEASE", 79, 89]]], ["A second arm was designated \u2018Africa-Specific\u2019, and it includes clinical questions and recommendations that are specific to the settings and prevailing situations in Africa.", [["arm", "ANATOMY", 9, 12]]], ["Each subgroup was tasked with developing their clinical questions and recommendations along these two broad divisions.Target audience ::: MethodsThe primary target audience are practicing rheumatologists in Africa.", [["Methods", "TREATMENT", 138, 145]]], ["This includes rheumatologists managing adult, paediatric or both categories of patients.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]], ["The focus excludes patients, other physicians or policy-makers.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["However, recommendations covering advice to patients which are to be delivered by the rheumatologist are included.Literature review ::: MethodsIt was agreed that there is currently an insufficient body of evidence to conduct a meaningful systematic literature review.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["Methods", "TREATMENT", 136, 143]]], ["In addition, the short working timeline available to the task force precluded further delays.", [["further delays", "PROBLEM", 78, 92]]], ["However, a limited non-systematic literature review was undertaken to support the largely expert opinion-based process.", [["a limited non-systematic literature review", "TEST", 9, 51]]], ["Overlaps, duplication and out-of-scope recommendations were removed or amended, and the first list for the first round of voting was agreed upon by the CWC.", [["duplication", "PROBLEM", 10, 21], ["duplication", "OBSERVATION_MODIFIER", 10, 21]]], ["All members of the task force were invited to participate and were pre-informed of the time of opening and closure of each round of votes.", [["closure", "TREATMENT", 107, 114]]], ["Unique access links were sent out, and anonymous votes were gathered and processed.", [["Unique access links", "TEST", 0, 19]]], ["Only the members of the task force who treat either both adults and children or children only voted on the statements that are specific to paediatric rheumatology.Rating ::: MethodsEach statement was rated between 1 and 9 with 1 being \u2018complete disagreement\u2019 and 9 being \u2018complete agreement\u2019.", [["children", "ORGANISM", 68, 76], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 68, 76], ["children", "SPECIES", 80, 88]]], ["There was no requirement to vote on all statements, and the members were encouraged to abstain if they felt that a statement fell outside their area of expertise.", [["no", "UNCERTAINTY", 10, 12]]], ["This enabled the panel to identify an instance of misinterpretation of statement and invalidate the vote on that statement.Predefined parameters ::: MethodsThe levels of agreement on each statement of recommendation were defined as \u2018high\u2019 if after the second round of votes, all votes on a statement fell into the agreement bracket; \u2018low\u2019 if at least one vote fell into each of the disagreement and uncertainty bracket or two or more fell into disagreement bracket; and \u2018moderate\u2019 for all other combinations.", [["the panel", "TEST", 13, 22], ["Methods", "TREATMENT", 149, 156]]], ["A statement was retired if it had a mean vote below 7 or a \u2018low\u2019 level of agreement.Statement 1 ::: ResultsThere is currently no evidence to say that patients with RMDs or on DMARDs are more prone to contracting SARS-CoV-2; therefore, the normal medications for various rheumatic diseases should be continued as indicated.Statement 1 ::: ResultsThe risk factors for getting infected with the novel coronavirus are similar for patients with RMDs as for the general populace, and these include older age and co-morbidities such as hypertension and diabetes [2, 7].", [["RMDs", "DISEASE", 164, 168], ["SARS", "DISEASE", 212, 216], ["rheumatic diseases", "DISEASE", 270, 288], ["coronavirus", "DISEASE", 398, 409], ["RMDs", "DISEASE", 440, 444], ["hypertension", "DISEASE", 529, 541], ["diabetes", "DISEASE", 546, 554], ["patients", "ORGANISM", 150, 158], ["coronavirus", "ORGANISM", 398, 409], ["patients", "ORGANISM", 426, 434], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 426, 434], ["SARS-CoV", "SPECIES", 212, 220], ["RMDs", "PROBLEM", 164, 168], ["DMARDs", "TREATMENT", 175, 181], ["CoV", "TEST", 217, 220], ["the normal medications", "TREATMENT", 235, 257], ["various rheumatic diseases", "PROBLEM", 262, 288], ["The risk factors", "PROBLEM", 345, 361], ["the novel coronavirus", "PROBLEM", 388, 409], ["RMDs", "PROBLEM", 440, 444], ["co-morbidities", "PROBLEM", 506, 520], ["hypertension", "PROBLEM", 529, 541], ["diabetes", "PROBLEM", 546, 554], ["no evidence to", "UNCERTAINTY", 126, 140], ["rheumatic diseases", "OBSERVATION", 270, 288], ["hypertension", "OBSERVATION", 529, 541]]], ["Patients with RMDs have not been identified to be more prone to developing COVID-19 than people without RMDs, and this seems to be similar for the previous outbreaks of earlier corona viruses such as the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) [8, 9].", [["COVID", "DISEASE", 75, 80], ["RMDs", "DISEASE", 104, 108], ["acute respiratory syndrome coronavirus", "DISEASE", 211, 249], ["SARS-CoV)", "DISEASE", 251, 260], ["Middle East respiratory syndrome coronavirus", "DISEASE", 269, 313], ["Patients", "ORGANISM", 0, 8], ["people", "ORGANISM", 89, 95], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 204, 249], ["SARS-CoV", "ORGANISM", 251, 259], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 269, 313], ["MERS-CoV", "ORGANISM", 315, 323], ["Patients", "SPECIES", 0, 8], ["people", "SPECIES", 89, 95], ["severe acute respiratory syndrome coronavirus", "SPECIES", 204, 249], ["SARS-CoV", "SPECIES", 251, 259], ["Middle East respiratory syndrome coronavirus", "SPECIES", 269, 313], ["MERS-CoV", "SPECIES", 315, 323], ["RMDs", "PROBLEM", 14, 18], ["COVID", "TEST", 75, 80], ["RMDs", "PROBLEM", 104, 108], ["earlier corona viruses", "PROBLEM", 169, 191], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 200, 249], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 265, 313], ["corona viruses", "OBSERVATION", 177, 191], ["severe", "OBSERVATION_MODIFIER", 204, 210], ["acute", "OBSERVATION_MODIFIER", 211, 216], ["respiratory syndrome coronavirus", "OBSERVATION", 217, 249], ["Middle", "ANATOMY_MODIFIER", 269, 275], ["respiratory syndrome", "OBSERVATION", 281, 301]]], ["Mixed results have been reported with patients on prednisolone of more than 10 mg per day as well as disease-modifying agents such as anti-TNF and other biologics.", [["prednisolone", "CHEMICAL", 50, 62], ["prednisolone", "CHEMICAL", 50, 62], ["patients", "ORGANISM", 38, 46], ["prednisolone", "SIMPLE_CHEMICAL", 50, 62], ["anti-TNF", "SIMPLE_CHEMICAL", 134, 142], ["anti-TNF", "PROTEIN", 134, 142], ["patients", "SPECIES", 38, 46], ["prednisolone", "TREATMENT", 50, 62], ["disease-modifying agents", "TREATMENT", 101, 125], ["anti-TNF", "TREATMENT", 134, 142], ["other biologics", "TREATMENT", 147, 162]]], ["Also, conventional DMARDs and NSAIDs have not been identified to increase the odds of infection or hospitalization [10].", [["NSAIDs", "CHEMICAL", 30, 36], ["infection", "DISEASE", 86, 95], ["NSAIDs", "SIMPLE_CHEMICAL", 30, 36], ["conventional DMARDs", "TREATMENT", 6, 25], ["NSAIDs", "TREATMENT", 30, 36], ["infection", "PROBLEM", 86, 95], ["infection", "OBSERVATION", 86, 95]]], ["So far, it would appear that there is no definite evidence to date that ongoing treatments for RMDs confer added risks of infection with SARS-CoV-2 [11, 12].Statement 2 ::: ResultsPatients should be routinely advised to observe regular infection-prevention practices against SARS-CoV-2 such as social distancing, frequent hand washing and wearing of face covering in public places.Statement 2 ::: ResultsStandard infection-prevention practices should be frequently communicated and reinforced at every opportunity to the patients according to the recommendations in each member country of AFLAR [2, 3].", [["hand", "ANATOMY", 322, 326], ["RMDs", "DISEASE", 95, 99], ["infection", "DISEASE", 122, 131], ["SARS", "DISEASE", 137, 141], ["infection", "DISEASE", 236, 245], ["SARS", "DISEASE", 275, 279], ["infection", "DISEASE", 413, 422], ["hand", "ORGANISM_SUBDIVISION", 322, 326], ["patients", "ORGANISM", 521, 529], ["patients", "SPECIES", 521, 529], ["SARS-CoV", "SPECIES", 137, 145], ["ongoing treatments", "TREATMENT", 72, 90], ["RMDs", "TREATMENT", 95, 99], ["infection", "PROBLEM", 122, 131], ["CoV", "TEST", 142, 145], ["regular infection", "PROBLEM", 228, 245], ["SARS", "PROBLEM", 275, 279], ["frequent hand washing", "TREATMENT", 313, 334], ["no definite", "UNCERTAINTY", 38, 49], ["infection", "OBSERVATION", 122, 131], ["infection", "OBSERVATION", 236, 245], ["infection", "OBSERVATION", 413, 422]]], ["Components of the rheumatologist\u2019s advice should include regular and adequate hand washing, social distancing, avoiding touching the face and coughing into the elbow [13].", [["hand", "ANATOMY", 78, 82], ["face", "ANATOMY", 133, 137], ["hand", "ORGANISM_SUBDIVISION", 78, 82], ["face", "ANATOMY", 133, 137], ["elbow", "ANATOMY", 160, 165]]], ["Other specific infection-prevention advice may be relevant to the individual patient scenario or the prevailing local guidelines.Statement 3 ::: ResultsPatients should be advised to avoid using medicinal products with unproven efficacy against COVID-19.", [["infection", "DISEASE", 15, 24], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["Other specific infection", "PROBLEM", 0, 24], ["medicinal products", "TREATMENT", 194, 212], ["COVID", "TEST", 244, 249], ["infection", "OBSERVATION", 15, 24]]], ["Such products could include herbal preparations, orthodox medicines, various supplements and complementary medications.Statement 3 ::: ResultsIt was recognized that a long list can be made of various unproven remedies which have attained different levels of fame in the media since the onset of COVID-19 pandemic.", [["Such products", "TREATMENT", 0, 13], ["herbal preparations", "TREATMENT", 28, 47], ["orthodox medicines", "TREATMENT", 49, 67], ["various supplements", "TREATMENT", 69, 88], ["complementary medications", "TREATMENT", 93, 118], ["COVID", "TEST", 295, 300], ["pandemic", "PROBLEM", 304, 312]]], ["While this is not limited to Africa, the continent certainly has its fair share of promoted orthodox, herbal and complementary medicines of unproven efficacy against COVID-19.", [["Africa", "PROBLEM", 29, 35], ["herbal", "TREATMENT", 102, 108], ["complementary medicines", "TREATMENT", 113, 136], ["COVID", "TEST", 166, 171]]], ["Some of these have been shown to be associated with some risks in earlier reports [14, 15].Statement 4 ::: ResultsIn a patient without COVID-19, it is safe to initiate or maintain the use of NSAIDs for RMDs where indicated.Statement 4 ::: ResultsFor many patients who depend on regular NSAID use for managing their RMDs, routine withdrawal of such treatment may be counterproductive to the goal of care.", [["RMDs", "DISEASE", 202, 206], ["RMDs", "DISEASE", 315, 319], ["patient", "ORGANISM", 119, 126], ["NSAIDs", "SIMPLE_CHEMICAL", 191, 197], ["patients", "ORGANISM", 255, 263], ["NSAID", "SIMPLE_CHEMICAL", 286, 291], ["patient", "SPECIES", 119, 126], ["patients", "SPECIES", 255, 263], ["COVID", "TEST", 135, 140], ["NSAIDs", "TREATMENT", 191, 197], ["RMDs", "TREATMENT", 202, 206], ["regular NSAID use", "TREATMENT", 278, 295], ["managing their RMDs", "PROBLEM", 300, 319], ["such treatment", "TREATMENT", 343, 357]]], ["This is particularly noteworthy as exposure to NSAIDs has not been shown to increase the risk of infection with SARS-CoV-2.", [["NSAIDs", "CHEMICAL", 47, 53], ["infection", "DISEASE", 97, 106], ["SARS", "DISEASE", 112, 116], ["NSAIDs", "SIMPLE_CHEMICAL", 47, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 112, 122], ["SARS-CoV", "SPECIES", 112, 120], ["NSAIDs", "TREATMENT", 47, 53], ["infection", "PROBLEM", 97, 106], ["infection", "OBSERVATION", 97, 106]]], ["Whereas NSAIDs should generally be used in the lowest effective dose, the use in patients who go on to develop COVID-19 should be based on a favourable risk-benefit ratio [3, 16].", [["NSAIDs", "CHEMICAL", 8, 14], ["COVID-19", "CHEMICAL", 111, 119], ["NSAIDs", "SIMPLE_CHEMICAL", 8, 14], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["NSAIDs", "TREATMENT", 8, 14], ["COVID", "TEST", 111, 116]]], ["Certainly, there is currently no evidence-backed contraindication to the use of NSAIDs in the patient who is at risk of COVID19 [17].Statement 5 ::: ResultsIn a patient without COVID-19, oral or parenteral glucocorticoids may be used as indicated at the appropriate dose including pulse doses where necessary.Statement 5 ::: ResultsIt is recognized that the fear of glucocorticoid use in the era of COVID-19 may expose patients with organ-threatening diseases such as the vasculitides and aggressive connective tissue diseases to greater risks if appropriate interventions using the required immunosuppressive agents are not promptly adopted.", [["oral", "ANATOMY", 187, 191], ["parenteral", "ANATOMY", 195, 205], ["organ", "ANATOMY", 433, 438], ["connective tissue", "ANATOMY", 500, 517], ["NSAIDs", "CHEMICAL", 80, 86], ["COVID-19", "CHEMICAL", 177, 185], ["glucocorticoids", "CHEMICAL", 206, 221], ["COVID-19", "CHEMICAL", 399, 407], ["organ-threatening diseases", "DISEASE", 433, 459], ["vasculitides", "DISEASE", 472, 484], ["connective tissue diseases", "DISEASE", 500, 526], ["COVID-19", "CHEMICAL", 177, 185], ["COVID-19", "CHEMICAL", 399, 407], ["NSAIDs", "SIMPLE_CHEMICAL", 80, 86], ["patient", "ORGANISM", 94, 101], ["patient", "ORGANISM", 161, 168], ["oral", "ORGANISM_SUBDIVISION", 187, 191], ["patients", "ORGANISM", 419, 427], ["organ", "ORGAN", 433, 438], ["connective tissue", "TISSUE", 500, 517], ["patient", "SPECIES", 94, 101], ["patient", "SPECIES", 161, 168], ["patients", "SPECIES", 419, 427], ["NSAIDs", "TREATMENT", 80, 86], ["COVID", "TEST", 177, 182], ["oral or parenteral glucocorticoids", "TREATMENT", 187, 221], ["pulse doses", "TREATMENT", 281, 292], ["glucocorticoid use", "TREATMENT", 366, 384], ["COVID", "TEST", 399, 404], ["organ-threatening diseases", "PROBLEM", 433, 459], ["the vasculitides", "PROBLEM", 468, 484], ["aggressive connective tissue diseases", "PROBLEM", 489, 526], ["appropriate interventions", "TREATMENT", 547, 572], ["immunosuppressive agents", "TREATMENT", 592, 616], ["no evidence", "UNCERTAINTY", 30, 41], ["threatening diseases", "OBSERVATION", 439, 459], ["vasculitides", "OBSERVATION", 472, 484], ["aggressive", "OBSERVATION_MODIFIER", 489, 499], ["connective tissue diseases", "OBSERVATION", 500, 526]]], ["Undoubtedly, patients with these conditions may face short-term risks of major organ damage or mortality without appropriate treatment [18].", [["organ", "ANATOMY", 79, 84], ["organ damage", "DISEASE", 79, 91], ["patients", "ORGANISM", 13, 21], ["organ", "ORGAN", 79, 84], ["patients", "SPECIES", 13, 21], ["these conditions", "PROBLEM", 27, 43], ["major organ damage", "PROBLEM", 73, 91], ["appropriate treatment", "TREATMENT", 113, 134]]], ["Therefore, in the context of these severe diseases, the appropriate dose of glucocorticoids including high and pulse doses may be unavoidable [3].Statement 6 ::: ResultsAnti-malarials such as HCQ and CQ do not protect against SARSCoV-2, and as such, patients on HCQ or CQ for RMDs should be advised to observe necessary precautions to prevent infection.Statement 6 ::: ResultsDespite the in vitro anti-viral activities of HCQ and CQ which have been reported in various studies, these anti-malaria drugs have not been shown to prevent SAS-CoV-2 infection and patients with SLE on long-term treatment with anti-malarial drugs have not been shown to be spared from the infection or developing severe diseases [19].", [["glucocorticoids", "CHEMICAL", 76, 91], ["HCQ", "CHEMICAL", 192, 195], ["CQ", "CHEMICAL", 200, 202], ["HCQ", "CHEMICAL", 262, 265], ["CQ", "CHEMICAL", 269, 271], ["RMDs", "DISEASE", 276, 280], ["infection", "DISEASE", 343, 352], ["HCQ", "CHEMICAL", 422, 425], ["CQ", "CHEMICAL", 430, 432], ["infection", "DISEASE", 544, 553], ["SLE", "DISEASE", 572, 575], ["infection", "DISEASE", 666, 675], ["HCQ", "CHEMICAL", 192, 195], ["CQ", "CHEMICAL", 200, 202], ["HCQ", "CHEMICAL", 262, 265], ["HCQ", "CHEMICAL", 422, 425], ["CQ", "CHEMICAL", 430, 432], ["HCQ", "SIMPLE_CHEMICAL", 192, 195], ["CQ", "SIMPLE_CHEMICAL", 200, 202], ["patients", "ORGANISM", 250, 258], ["HCQ", "SIMPLE_CHEMICAL", 262, 265], ["CQ", "SIMPLE_CHEMICAL", 269, 271], ["HCQ", "SIMPLE_CHEMICAL", 422, 425], ["CQ", "SIMPLE_CHEMICAL", 430, 432], ["SAS-CoV-2", "ORGANISM", 534, 543], ["patients", "ORGANISM", 558, 566], ["patients", "SPECIES", 250, 258], ["CoV-", "SPECIES", 538, 542], ["patients", "SPECIES", 558, 566], ["these severe diseases", "PROBLEM", 29, 50], ["glucocorticoids", "TREATMENT", 76, 91], ["high and pulse doses", "TREATMENT", 102, 122], ["Anti-malarials", "TREATMENT", 169, 183], ["HCQ and CQ", "TREATMENT", 192, 202], ["HCQ", "TREATMENT", 262, 265], ["CQ", "TREATMENT", 269, 271], ["RMDs", "TREATMENT", 276, 280], ["necessary precautions", "TREATMENT", 310, 331], ["infection", "PROBLEM", 343, 352], ["HCQ", "TREATMENT", 422, 425], ["CQ", "PROBLEM", 430, 432], ["these anti-malaria drugs", "TREATMENT", 478, 502], ["SAS", "PROBLEM", 534, 537], ["CoV-2 infection", "PROBLEM", 538, 553], ["SLE", "PROBLEM", 572, 575], ["long-term treatment", "TREATMENT", 579, 598], ["anti-malarial drugs", "TREATMENT", 604, 623], ["the infection", "PROBLEM", 662, 675], ["developing severe diseases", "PROBLEM", 679, 705], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["diseases", "OBSERVATION", 42, 50], ["infection", "OBSERVATION", 343, 352], ["infection", "OBSERVATION", 544, 553], ["infection", "OBSERVATION", 666, 675], ["severe", "OBSERVATION_MODIFIER", 690, 696], ["diseases", "OBSERVATION", 697, 705]]], ["The task force recognized that there have been unsubstantiated suggestions at the beginning of the pandemic that the widespread use of anti-malarial drugs in Africa may be contributing to the delayed spread of the virus on the continent.Statement 7 ::: ResultsWhere HCQ scarcity is being experienced, rheumatologists may consider using alternative csDMARDs for patients with rheumatoid arthritis.Statement 7 ::: ResultsThe recent pan-African survey through the network of the COVID-19 African Rheumatology Study Group has shown that shortage of HCQ was being experienced in more than 60% of rheumatologists\u2019 services across the continent [1].", [["HCQ", "CHEMICAL", 266, 269], ["rheumatoid arthritis", "DISEASE", 375, 395], ["HCQ", "CHEMICAL", 545, 548], ["HCQ", "CHEMICAL", 266, 269], ["HCQ", "CHEMICAL", 545, 548], ["HCQ", "SIMPLE_CHEMICAL", 266, 269], ["patients", "ORGANISM", 361, 369], ["HCQ", "SIMPLE_CHEMICAL", 545, 548], ["patients", "SPECIES", 361, 369], ["anti-malarial drugs", "TREATMENT", 135, 154], ["the delayed spread of the virus", "PROBLEM", 188, 219], ["HCQ scarcity", "PROBLEM", 266, 278], ["alternative csDMARDs", "TREATMENT", 336, 356], ["rheumatoid arthritis", "PROBLEM", 375, 395], ["the COVID", "TEST", 472, 481], ["HCQ", "TREATMENT", 545, 548], ["widespread", "OBSERVATION_MODIFIER", 117, 127], ["anti-malarial drugs", "OBSERVATION", 135, 154], ["rheumatoid arthritis", "OBSERVATION", 375, 395]]], ["Therefore, for patients with rheumatoid arthritis, it was agreed that alternative DMARDs may be considered where appropriate.", [["rheumatoid arthritis", "DISEASE", 29, 49], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["rheumatoid arthritis", "PROBLEM", 29, 49], ["alternative DMARDs", "TREATMENT", 70, 88], ["rheumatoid", "OBSERVATION_MODIFIER", 29, 39], ["arthritis", "OBSERVATION", 40, 49]]], ["The task force recognized that some patients on triple therapy with stable disease may be able to continue with two csDMARDs without suffering flare ups.Statement 8 ::: ResultsWhere possible, the use of subcutaneous formulations of bDMARDs and bsDMARDs should be considered instead of IV infusions to limit patients\u2019 attendance to the hospital.Statement 8 ::: ResultsThe availability of biologic and biosimilar agents is highly varied across the continent of Africa.", [["subcutaneous", "ANATOMY", 203, 215], ["bDMARDs", "CHEMICAL", 232, 239], ["bsDMARDs", "CHEMICAL", 244, 252], ["patients", "ORGANISM", 36, 44], ["bDMARDs", "SIMPLE_CHEMICAL", 232, 239], ["bsDMARDs", "SIMPLE_CHEMICAL", 244, 252], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 307, 315], ["triple therapy", "TREATMENT", 48, 62], ["stable disease", "PROBLEM", 68, 82], ["suffering flare ups", "PROBLEM", 133, 152], ["subcutaneous formulations", "TREATMENT", 203, 228], ["bDMARDs", "TREATMENT", 232, 239], ["bsDMARDs", "TREATMENT", 244, 252], ["IV infusions", "TREATMENT", 285, 297], ["biologic and biosimilar agents", "TREATMENT", 387, 417]]], ["Many countries do not have access to any biosimilar drugs, and in others, the subcutaneous formulations of existing specific intravenously administered biologics are not available.", [["subcutaneous", "ANATOMY", 78, 90], ["intravenously", "ANATOMY", 125, 138], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["any biosimilar drugs", "TREATMENT", 37, 57], ["the subcutaneous formulations", "TREATMENT", 74, 103], ["existing specific intravenously administered biologics", "TREATMENT", 107, 161], ["subcutaneous", "ANATOMY", 78, 90]]], ["However, the driving goal of limiting in-patient hospital visits for infusion administration should be pursued wherever possible.Statement 9 ::: ResultsACEIs and ARBs should not be routinely discontinued in patients with RMDs at risk of COVID-19.Statement 9 ::: ResultsWhereas there is no evidence to suggest that ACEIs or ARBs increase the risk of SARS-CoV-2 infection, a large population-based study has revealed that the prevalence of use of these agents among patients with COVID19 is higher than in the general populace [20].", [["RMDs", "DISEASE", 221, 225], ["ACEIs", "CHEMICAL", 314, 319], ["ARBs", "CHEMICAL", 323, 327], ["SARS-CoV-2 infection", "DISEASE", 349, 369], ["COVID19", "CHEMICAL", 478, 485], ["COVID-19", "CHEMICAL", 237, 245], ["patient", "ORGANISM", 41, 48], ["ARBs", "SIMPLE_CHEMICAL", 162, 166], ["patients", "ORGANISM", 207, 215], ["ACEIs", "SIMPLE_CHEMICAL", 314, 319], ["ARBs", "SIMPLE_CHEMICAL", 323, 327], ["SARS-CoV-2", "ORGANISM", 349, 359], ["patients", "ORGANISM", 464, 472], ["patient", "SPECIES", 41, 48], ["patients", "SPECIES", 207, 215], ["patients", "SPECIES", 464, 472], ["SARS-CoV-2", "SPECIES", 349, 359], ["infusion administration", "TREATMENT", 69, 92], ["ResultsACEIs", "TEST", 145, 157], ["ARBs", "TREATMENT", 162, 166], ["COVID", "TEST", 237, 242], ["ACEIs", "TREATMENT", 314, 319], ["ARBs", "TREATMENT", 323, 327], ["SARS", "PROBLEM", 349, 353], ["CoV", "PROBLEM", 354, 357], ["2 infection", "PROBLEM", 358, 369], ["based study", "TEST", 390, 401], ["these agents", "TREATMENT", 445, 457], ["COVID19", "TREATMENT", 478, 485], ["no evidence to suggest", "UNCERTAINTY", 286, 308], ["large", "OBSERVATION_MODIFIER", 373, 378], ["higher", "OBSERVATION_MODIFIER", 489, 495]]], ["This is probably indicative of a higher prevalence of cardiovascular co-morbidities such as hypertension among patients with clinical and severe COVID-19, and this category of patients is also more likely to be on treatment with these drugs [20].", [["cardiovascular", "ANATOMY", 54, 68], ["cardiovascular co-morbidities", "DISEASE", 54, 83], ["hypertension", "DISEASE", 92, 104], ["cardiovascular", "ANATOMICAL_SYSTEM", 54, 68], ["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 176, 184], ["cardiovascular co-morbidities", "PROBLEM", 54, 83], ["hypertension", "PROBLEM", 92, 104], ["clinical and severe COVID", "PROBLEM", 125, 150], ["these drugs", "TREATMENT", 229, 240], ["probably indicative of", "UNCERTAINTY", 8, 30], ["higher", "OBSERVATION_MODIFIER", 33, 39], ["hypertension", "OBSERVATION", 92, 104]]], ["However, a study from the USA showed an almost 40% reduction in the risk of hospitalization among elderly patients with hypertension treated with ACEIs but not among those treated with ARBs [21].", [["hypertension", "DISEASE", 120, 132], ["ACEIs", "CHEMICAL", 146, 151], ["ARBs", "CHEMICAL", 185, 189], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["a study", "TEST", 9, 16], ["the USA", "TEST", 22, 29], ["hypertension", "PROBLEM", 120, 132], ["ACEIs", "TREATMENT", 146, 151], ["ARBs", "TREATMENT", 185, 189], ["hypertension", "OBSERVATION", 120, 132]]], ["The recommendation of both the American Heart Association and the European Society for Cardiology is to sustain treatment with these drugs in patients on them [22, 23].", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["these drugs", "TREATMENT", 127, 138]]], ["This is also the recommendation of the French Society of Rheumatology [17].Statement 10 ::: ResultsPatients with stable RMDs should have their vaccination against influenza and pneumococci updated.Statement 10 ::: ResultsThe administration of influenza and pneumococcal vaccines to stable patients without COVID-19 was generally agreed upon.", [["RMDs", "DISEASE", 120, 124], ["influenza", "DISEASE", 163, 172], ["influenza", "DISEASE", 243, 252], ["RMDs", "CANCER", 120, 124], ["influenza", "ORGANISM", 243, 252], ["pneumococcal", "ORGANISM", 257, 269], ["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 289, 297], ["pneumococcal", "SPECIES", 257, 269], ["their vaccination", "TREATMENT", 137, 154], ["influenza", "PROBLEM", 163, 172], ["pneumococci", "PROBLEM", 177, 188], ["influenza", "TREATMENT", 243, 252], ["pneumococcal vaccines", "TREATMENT", 257, 278], ["COVID", "TEST", 306, 311]]], ["While it is not known if being vaccinated against influenza could reduce the severity of COVID-19, certainly, reducing this risk may cut down the potential confusion with COVID-19 among some patients [2, 24].", [["influenza", "DISEASE", 50, 59], ["confusion", "DISEASE", 156, 165], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["influenza", "PROBLEM", 50, 59], ["COVID", "TEST", 89, 94], ["the potential confusion", "PROBLEM", 142, 165], ["COVID", "TEST", 171, 176]]], ["The task force recognized that national policies on vaccination differ among the member countries of AFLAR; members however agree that the ongoing pandemic should not reduce the use and administration of these vaccines for eligible patients.Statement 11 ::: ResultsRheumatologists should reduce patients\u2019 hospital attendances by considering less frequent blood monitoring for DMARDs among stable patients, longer prescription periods and virtual clinics.Statement 11 ::: ResultsWherever routine blood monitoring for DMARDs requires the attendance of patients to the hospital, reducing the frequency of laboratory investigations among stable patients will likely be of benefit [3].", [["blood", "ANATOMY", 355, 360], ["blood", "ANATOMY", 495, 500], ["patients", "ORGANISM", 232, 240], ["patients", "ORGANISM", 295, 303], ["blood", "ORGANISM_SUBSTANCE", 355, 360], ["patients", "ORGANISM", 396, 404], ["blood", "ORGANISM_SUBSTANCE", 495, 500], ["patients", "ORGANISM", 550, 558], ["patients", "ORGANISM", 641, 649], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 295, 303], ["patients", "SPECIES", 396, 404], ["patients", "SPECIES", 550, 558], ["patients", "SPECIES", 641, 649], ["vaccination", "TREATMENT", 52, 63], ["these vaccines", "TREATMENT", 204, 218], ["blood monitoring", "TEST", 355, 371], ["DMARDs", "TREATMENT", 376, 382], ["routine blood monitoring", "TEST", 487, 511], ["DMARDs", "TREATMENT", 516, 522], ["laboratory investigations", "TEST", 602, 627]]], ["This may imply re-organizing services and optimizing the line of communication between the healthcare service and the patient.", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125]]], ["Due to the increasing recognition of in-hospital transmission of SARS-CoV-2, limiting attendance will likely serve to reduce the anxiety of the healthcare workers and the patients [18].", [["SARS", "DISEASE", 65, 69], ["anxiety", "DISEASE", 129, 136], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["SARS-CoV", "SPECIES", 65, 73], ["SARS", "PROBLEM", 65, 69]]], ["As many patients with RMDs also have co-morbidities that put them at higher risk of severe COVID-19 such as metabolic syndrome, cardiovascular diseases and advanced age, it is important to explain this risk to patients and help them understand the purpose of reducing face-to-face interactions [25].Statement 12 ::: ResultsRMD patients on glucocorticoids who have been exposed to SARS-CoV-2 should continue their glucocorticoids at the lowest effective dose for maintaining disease control.Statement 12 ::: ResultsRecognizing the risk of adrenal suppression and the uncertain benefit of aggressive steroid tapering or withdrawal led to the task force agreeing on sustaining glucocorticoid treatments albeit at doses not more than required to keep treated conditions controlled.", [["cardiovascular", "ANATOMY", 128, 142], ["adrenal", "ANATOMY", 538, 545], ["RMDs", "DISEASE", 22, 26], ["COVID", "DISEASE", 91, 96], ["metabolic syndrome", "DISEASE", 108, 126], ["cardiovascular diseases", "DISEASE", 128, 151], ["glucocorticoids", "CHEMICAL", 339, 354], ["SARS", "DISEASE", 380, 384], ["glucocorticoids", "CHEMICAL", 413, 428], ["adrenal suppression", "DISEASE", 538, 557], ["steroid", "CHEMICAL", 598, 605], ["steroid", "CHEMICAL", 598, 605], ["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 210, 218], ["patients", "ORGANISM", 327, 335], ["SARS-CoV-2", "ORGANISM", 380, 390], ["adrenal", "ORGAN", 538, 545], ["steroid", "SIMPLE_CHEMICAL", 598, 605], ["glucocorticoid", "SIMPLE_CHEMICAL", 674, 688], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 327, 335], ["co-morbidities", "PROBLEM", 37, 51], ["severe COVID", "PROBLEM", 84, 96], ["metabolic syndrome", "PROBLEM", 108, 126], ["cardiovascular diseases", "PROBLEM", 128, 151], ["glucocorticoids", "TREATMENT", 339, 354], ["SARS", "PROBLEM", 380, 384], ["CoV", "TEST", 385, 388], ["their glucocorticoids", "TREATMENT", 407, 428], ["disease control", "TREATMENT", 474, 489], ["adrenal suppression", "PROBLEM", 538, 557], ["aggressive steroid tapering", "TREATMENT", 587, 614], ["withdrawal", "PROBLEM", 618, 628], ["sustaining glucocorticoid treatments", "TREATMENT", 663, 699], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["metabolic syndrome", "OBSERVATION", 108, 126], ["disease", "OBSERVATION", 474, 481], ["adrenal", "ANATOMY", 538, 545], ["suppression", "OBSERVATION", 546, 557]]], ["This seems to align with the recommendations of other international associations of rheumatology [2\u20134, 17].Statement 13 ::: ResultsIn patients who have been exposed to SARS-CoV-2 but are asymptomatic, continue anti-osteoporosis treatments including vitamin D and calcium supplementation.Statement 13 ::: ResultsThe task force noted that the widespread disruption of service may put osteoporosis service on a lower rung of priority than usual.", [["SARS", "DISEASE", 168, 172], ["vitamin D", "CHEMICAL", 249, 258], ["calcium", "CHEMICAL", 263, 270], ["osteoporosis", "DISEASE", 382, 394], ["vitamin D", "CHEMICAL", 249, 258], ["calcium", "CHEMICAL", 263, 270], ["patients", "ORGANISM", 134, 142], ["vitamin D", "SIMPLE_CHEMICAL", 249, 258], ["calcium", "SIMPLE_CHEMICAL", 263, 270], ["patients", "SPECIES", 134, 142], ["SARS-CoV", "SPECIES", 168, 176], ["asymptomatic", "PROBLEM", 187, 199], ["anti-osteoporosis treatments", "TREATMENT", 210, 238], ["vitamin D", "TREATMENT", 249, 258], ["calcium supplementation", "TREATMENT", 263, 286], ["osteoporosis service", "TREATMENT", 382, 402]]], ["In situations like this, efforts should be made, and patients are advised to sustain the ongoing use of osteoporosis prophylaxis or treatment in order to prevent the potentially devastating impacts of fragility fractures [26].", [["osteoporosis", "DISEASE", 104, 116], ["fragility fractures", "DISEASE", 201, 220], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["osteoporosis prophylaxis", "TREATMENT", 104, 128], ["treatment", "TREATMENT", 132, 141], ["fragility fractures", "PROBLEM", 201, 220], ["osteoporosis", "OBSERVATION", 104, 116], ["fragility", "OBSERVATION_MODIFIER", 201, 210], ["fractures", "OBSERVATION", 211, 220]]], ["While COVID-19 poses a veritable threat to the African population, the management of other chronic health conditions should not suffer unintended consequences such as prolonged neglect resulting in mounting morbidity and mortality [27].", [["COVID-19", "CHEMICAL", 6, 14], ["neglect", "DISEASE", 177, 184], ["other chronic health conditions", "PROBLEM", 85, 116], ["unintended consequences", "PROBLEM", 135, 158], ["prolonged neglect", "PROBLEM", 167, 184], ["mounting morbidity", "PROBLEM", 198, 216]]], ["Hospital-administered treatments such as intravenous zolendronate and the training of self-injection of subcutaneous agents such as denosumab and teriparatide may face delays.", [["intravenous", "ANATOMY", 41, 52], ["subcutaneous", "ANATOMY", 104, 116], ["zolendronate", "CHEMICAL", 53, 65], ["denosumab", "CHEMICAL", 132, 141], ["teriparatide", "CHEMICAL", 146, 158], ["zolendronate", "CHEMICAL", 53, 65], ["denosumab", "CHEMICAL", 132, 141], ["teriparatide", "CHEMICAL", 146, 158], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 52], ["zolendronate", "SIMPLE_CHEMICAL", 53, 65], ["denosumab", "SIMPLE_CHEMICAL", 132, 141], ["teriparatide", "SIMPLE_CHEMICAL", 146, 158], ["treatments", "TREATMENT", 22, 32], ["intravenous zolendronate", "TREATMENT", 41, 65], ["self-injection of subcutaneous agents", "TREATMENT", 86, 123], ["denosumab", "TREATMENT", 132, 141], ["teriparatide", "TREATMENT", 146, 158], ["face delays", "PROBLEM", 163, 174]]], ["It is not known for certain how long a delay of each agent is acceptable, but rheumatologists should assist the patients in preventing long treatment gaps wherever possible.Statement 14 ::: ResultsFollowing exposure to SARS-CoV-2 infection, continue Pneumocystis jirovecii pneumonia (PJP) prophylaxis in a patient who is already on it.Statement 14 ::: ResultsThe appropriate use of PJP prophylaxis before the advent of the novel SARS-CoV-2 should not stop in the current pandemic.", [["SARS-CoV-2 infection", "DISEASE", 219, 239], ["Pneumocystis jirovecii pneumonia", "DISEASE", 250, 282], ["PJP", "DISEASE", 284, 287], ["PJP", "CHEMICAL", 382, 385], ["SARS", "DISEASE", 429, 433], ["PJP", "CHEMICAL", 382, 385], ["patients", "ORGANISM", 112, 120], ["SARS-CoV-2", "ORGANISM", 219, 229], ["Pneumocystis jirovecii", "ORGANISM", 250, 272], ["patient", "ORGANISM", 306, 313], ["SARS-CoV-2", "ORGANISM", 429, 439], ["patients", "SPECIES", 112, 120], ["Pneumocystis jirovecii", "SPECIES", 250, 272], ["patient", "SPECIES", 306, 313], ["SARS-CoV-2", "SPECIES", 219, 229], ["Pneumocystis jirovecii", "SPECIES", 250, 272], ["SARS-CoV", "SPECIES", 429, 437], ["long treatment gaps", "PROBLEM", 135, 154], ["SARS", "PROBLEM", 219, 223], ["CoV", "PROBLEM", 224, 227], ["2 infection", "PROBLEM", 228, 239], ["Pneumocystis jirovecii pneumonia", "PROBLEM", 250, 282], ["PJP) prophylaxis", "TREATMENT", 284, 300], ["PJP prophylaxis", "TREATMENT", 382, 397], ["not known for", "UNCERTAINTY", 6, 19], ["infection", "OBSERVATION", 230, 239], ["Pneumocystis jirovecii", "OBSERVATION", 250, 272]]], ["It is agreed that the potential confusion that may result from the presentations of both diseases can lead to avoidable clinical dilemmas especially as the impact of superimposed PJP on COVID-19 has not been determined.", [["confusion", "DISEASE", 32, 41], ["COVID-19", "CHEMICAL", 186, 194], ["COVID-19", "CHEMICAL", 186, 194], ["COVID-19", "GENE_OR_GENE_PRODUCT", 186, 194], ["the potential confusion", "PROBLEM", 18, 41], ["both diseases", "PROBLEM", 84, 97], ["avoidable clinical dilemmas", "PROBLEM", 110, 137], ["superimposed PJP", "PROBLEM", 166, 182], ["COVID", "TEST", 186, 191], ["superimposed", "OBSERVATION_MODIFIER", 166, 178], ["PJP", "OBSERVATION", 179, 182]]], ["Anecdotal reports have now shown PJP pneumonia mimicking COVID-19, and recent guidelines have advocated the sustenance of PJP prophylaxis [2, 28].Statement 15 ::: ResultsRegardless of recent exposure to SARS-CoV-2, ACEIs and ARBs may be initiated or increased in a patient with RMD if indicated.Statement 15 ::: ResultsDespite the fear that has been associated with the use of ACEIs and ARBs regarding SARS-CoV-2 infection, there has not been any evidence that the use of these drugs makes proven infection worse.", [["pneumonia", "DISEASE", 37, 46], ["PJP", "CHEMICAL", 122, 125], ["SARS", "DISEASE", 203, 207], ["ARBs", "CHEMICAL", 225, 229], ["RMD", "DISEASE", 278, 281], ["SARS-CoV-2 infection", "DISEASE", 402, 422], ["infection", "DISEASE", 497, 506], ["PJP", "CHEMICAL", 122, 125], ["PJP", "SIMPLE_CHEMICAL", 122, 125], ["CoV-2", "ORGANISM", 208, 213], ["ACEIs", "SIMPLE_CHEMICAL", 215, 220], ["ARBs", "SIMPLE_CHEMICAL", 225, 229], ["patient", "ORGANISM", 265, 272], ["RMD", "CANCER", 278, 281], ["ACEIs", "SIMPLE_CHEMICAL", 377, 382], ["ARBs", "SIMPLE_CHEMICAL", 387, 391], ["SARS-CoV-2", "ORGANISM", 402, 412], ["patient", "SPECIES", 265, 272], ["SARS-CoV", "SPECIES", 402, 410], ["PJP pneumonia", "PROBLEM", 33, 46], ["PJP prophylaxis", "TREATMENT", 122, 137], ["SARS", "PROBLEM", 203, 207], ["ACEIs", "TREATMENT", 215, 220], ["ARBs", "TREATMENT", 225, 229], ["ACEIs", "TREATMENT", 377, 382], ["ARBs", "TREATMENT", 387, 391], ["SARS", "PROBLEM", 402, 406], ["CoV-2 infection", "PROBLEM", 407, 422], ["these drugs", "TREATMENT", 472, 483], ["infection", "PROBLEM", 497, 506], ["PJP", "OBSERVATION_MODIFIER", 33, 36], ["pneumonia", "OBSERVATION", 37, 46], ["PJP", "OBSERVATION", 122, 125], ["increased", "OBSERVATION_MODIFIER", 250, 259], ["infection", "OBSERVATION", 413, 422], ["infection", "OBSERVATION", 497, 506]]], ["The task force agrees that it is logical to sustain treatment with these drugs among patients who have ongoing indications for their use except if there are other clinical reasons for discontinuation.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["these drugs", "TREATMENT", 67, 78]]], ["This is similar to the position of other professional rheumatology bodies in Europe and America [3, 17].Statement 16 ::: ResultsRegardless of recent exposure to SARS-CoV-2, intra-articular steroid administration may be undertaken if indicated with the use of appropriate personal protective equipment (PPE).Statement 16 ::: ResultsWhere indicated, there is no evidence to avoid administering intra-articular steroids for patients where this is the best option of care after weighing the risk of hospital attendance.", [["intra-articular", "ANATOMY", 173, 188], ["intra-articular", "ANATOMY", 392, 407], ["SARS", "DISEASE", 161, 165], ["steroid", "CHEMICAL", 189, 196], ["steroids", "CHEMICAL", 408, 416], ["steroid", "CHEMICAL", 189, 196], ["steroids", "CHEMICAL", 408, 416], ["intra-articular", "IMMATERIAL_ANATOMICAL_ENTITY", 173, 188], ["steroid", "SIMPLE_CHEMICAL", 189, 196], ["intra-articular", "IMMATERIAL_ANATOMICAL_ENTITY", 392, 407], ["steroids", "SIMPLE_CHEMICAL", 408, 416], ["patients", "ORGANISM", 421, 429], ["patients", "SPECIES", 421, 429], ["SARS-CoV", "SPECIES", 161, 169], ["SARS", "PROBLEM", 161, 165], ["intra-articular steroid administration", "TREATMENT", 173, 211], ["intra-articular steroids", "TREATMENT", 392, 416], ["no evidence to", "UNCERTAINTY", 357, 371]]], ["However, standard procedures regarding the use of personal protective equipment should be observed to limit the risk of transmission of SARS-CoV-2 infection between healthcare professionals and patients where such procedures are deemed justified [18].Statement 17 ::: ResultsIn an RMD patient with confirmed or presumed COVID-19, ongoing glucocorticoid treatment should not be stopped but should be maintained at the lowest effective dose.Statement 17 ::: ResultsIt is agreed that the abrupt cessation of ongoing long-term glucocorticoid treatment in patients who have been on it in the long term before developing COVID-19 serves to cause more problems than prevent unproven worse outcome.", [["SARS", "DISEASE", 136, 140], ["infection", "DISEASE", 147, 156], ["COVID-19", "CHEMICAL", 615, 623], ["SARS-CoV-2", "ORGANISM", 136, 146], ["patients", "ORGANISM", 194, 202], ["patient", "ORGANISM", 285, 292], ["glucocorticoid", "SIMPLE_CHEMICAL", 338, 352], ["patients", "ORGANISM", 551, 559], ["patients", "SPECIES", 194, 202], ["patient", "SPECIES", 285, 292], ["patients", "SPECIES", 551, 559], ["SARS-CoV", "SPECIES", 136, 144], ["personal protective equipment", "TREATMENT", 50, 79], ["SARS", "PROBLEM", 136, 140], ["CoV-2 infection", "PROBLEM", 141, 156], ["COVID", "TEST", 320, 325], ["ongoing glucocorticoid treatment", "TREATMENT", 330, 362], ["ongoing long-term glucocorticoid treatment", "TREATMENT", 505, 547], ["long-term glucocorticoid", "OBSERVATION_MODIFIER", 513, 537]]], ["This is similar to the recommendation of the ACR and EULAR, and it was agreed that advising the patient in advance regarding the use of glucocorticoids in the event of developing COVID-19 will help to prepare them properly [2\u20134].", [["glucocorticoids", "CHEMICAL", 136, 151], ["COVID-19", "CHEMICAL", 179, 187], ["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["glucocorticoids", "TREATMENT", 136, 151]]], ["In addition, a new trial has shown that dexamethasone reduces 28-day mortality among patients receiving oxygen or on mechanical ventilation [29].Statement 18 ::: ResultsIn an RMD patient with confirmed or presumed COVID-19, unless specifically indicated, routine stoppage of NSAIDs, analgesics, ACEIs or ARB is not required.Statement 18 ::: ResultsStrictly speaking, the new diagnosis of COVID-19 should not be taken as an indication for discontinuation of analgesics, NSAIDs, ACEIs or ARBs.", [["dexamethasone", "CHEMICAL", 40, 53], ["oxygen", "CHEMICAL", 104, 110], ["NSAIDs", "CHEMICAL", 275, 281], ["ACEIs", "CHEMICAL", 295, 300], ["ARB", "CHEMICAL", 304, 307], ["ACEIs", "CHEMICAL", 477, 482], ["dexamethasone", "CHEMICAL", 40, 53], ["oxygen", "CHEMICAL", 104, 110], ["COVID-19", "CHEMICAL", 388, 396], ["dexamethasone", "SIMPLE_CHEMICAL", 40, 53], ["patients", "ORGANISM", 85, 93], ["oxygen", "SIMPLE_CHEMICAL", 104, 110], ["patient", "ORGANISM", 179, 186], ["NSAIDs", "SIMPLE_CHEMICAL", 275, 281], ["ACEIs", "SIMPLE_CHEMICAL", 295, 300], ["ARB", "SIMPLE_CHEMICAL", 304, 307], ["NSAIDs", "SIMPLE_CHEMICAL", 469, 475], ["ACEIs", "SIMPLE_CHEMICAL", 477, 482], ["ARBs", "SIMPLE_CHEMICAL", 486, 490], ["patients", "SPECIES", 85, 93], ["patient", "SPECIES", 179, 186], ["dexamethasone", "TREATMENT", 40, 53], ["oxygen", "TREATMENT", 104, 110], ["mechanical ventilation", "TREATMENT", 117, 139], ["COVID", "TEST", 214, 219], ["NSAIDs", "TREATMENT", 275, 281], ["analgesics", "TREATMENT", 283, 293], ["ACEIs", "TREATMENT", 295, 300], ["ARB", "TREATMENT", 304, 307], ["COVID", "TEST", 388, 393], ["analgesics", "TREATMENT", 457, 467], ["NSAIDs", "TREATMENT", 469, 475], ["ACEIs", "TREATMENT", 477, 482], ["ARBs", "TREATMENT", 486, 490]]], ["This recommendation is based on the lack of evidence of a worse outcome among patients on these treatments, where they are sustained throughout the management of their COVID-19 symptoms.Statement 19 ::: ResultsEach rheumatology service should consider providing a helpline number to patients to use or for their doctors to use to seek rheumatological advice should they develop COVID-19.Statement 19 ::: ResultsVarious patterns of anxieties have been shown in the recent African survey of rheumatologists and their perception of their patients [1].", [["COVID-19", "CHEMICAL", 378, 386], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 283, 291], ["patients", "ORGANISM", 535, 543], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 283, 291], ["patients", "SPECIES", 535, 543], ["these treatments", "TREATMENT", 90, 106], ["their COVID-19 symptoms", "PROBLEM", 162, 185], ["COVID", "TEST", 378, 383], ["anxieties", "PROBLEM", 431, 440]]], ["Some of these can be allayed in the patient by keeping an open line of communication and maintaining easy and rapid access to reaching the rheumatologist helpline for advice.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["an open line of communication", "TREATMENT", 55, 84]]], ["In this period, it will not be unexpected for patients to be unusually anxious, and this state may be helped by having reliable access to guidance regarding the management of their RMD treatments and queries around their RMDs [18].Statement 20 ::: ResultsThere is currently no proof that SARS-CoV-2 infection is transmitted through breastfeeding; thus, breastfeeding may be continued while observing personal hygiene precautions if a lactating woman has tested positive for SARS-CoV-2 infection.Statement 20 ::: ResultsThe nucleic acid of the SARS-CoV-2 virus has not been detected in breast milk, and it stands reasonable that the unlikely risk of transmission is much lower than the known benefits of continued breastfeeding.", [["breast milk", "ANATOMY", 585, 596], ["RMD", "DISEASE", 181, 184], ["SARS", "DISEASE", 288, 292], ["infection", "DISEASE", 299, 308], ["SARS-CoV-2 infection", "DISEASE", 474, 494], ["nucleic acid", "CHEMICAL", 523, 535], ["SARS", "DISEASE", 543, 547], ["patients", "ORGANISM", 46, 54], ["SARS-CoV-2", "ORGANISM", 288, 298], ["woman", "ORGANISM", 444, 449], ["SARS-CoV-2", "ORGANISM", 474, 484], ["SARS-CoV-2 virus", "ORGANISM", 543, 559], ["breast milk", "ORGANISM_SUBSTANCE", 585, 596], ["patients", "SPECIES", 46, 54], ["woman", "SPECIES", 444, 449], ["CoV-2 virus", "SPECIES", 548, 559], ["SARS-CoV-2", "SPECIES", 288, 298], ["SARS-CoV-2", "SPECIES", 474, 484], ["SARS-CoV-2 virus", "SPECIES", 543, 559], ["unusually anxious", "PROBLEM", 61, 78], ["the management", "TREATMENT", 157, 171], ["their RMD treatments", "TREATMENT", 175, 195], ["CoV", "PROBLEM", 293, 296], ["2 infection", "PROBLEM", 297, 308], ["personal hygiene precautions", "TREATMENT", 400, 428], ["SARS", "PROBLEM", 474, 478], ["CoV", "PROBLEM", 479, 482], ["2 infection", "PROBLEM", 483, 494], ["The nucleic acid", "TEST", 519, 535], ["the SARS", "TEST", 539, 547], ["CoV", "TEST", 548, 551], ["virus", "PROBLEM", 554, 559], ["infection", "OBSERVATION", 299, 308], ["infection", "OBSERVATION", 485, 494]]], ["However, observation of standard infection-prevention practices should be advised [30].", [["infection", "DISEASE", 33, 42], ["standard infection", "PROBLEM", 24, 42], ["infection", "OBSERVATION", 33, 42]]], ["Rooming-in may be feasible, and direct breastfeeding is advisable in a woman with suspected or confirmed COVID-19 [31].", [["woman", "ORGANISM", 71, 76], ["woman", "SPECIES", 71, 76], ["COVID", "TEST", 105, 110]]], ["The World Health Organization recommends continuing breastfeeding for as long as possible regardless of a mother\u2019s COVID-19 status while practicing standard hygiene methods and taking respiratory precautions including wearing a mask [13].Statement 21 ::: ResultsIn the event that a lactating mother with COVID-19 is too unwell to breastfeed the child, expressed breast milk or formula feeds should be considered, and these should be prepared using hygienic practices as recommended by government and regulatory bodies of the given region.Statement 21 ::: ResultsWhere the clinical status of the mother will make direct breastfeeding impractical, expressed breast milk is agreed on as an ideal feeding option, and this will not require pasteurization [31].", [["respiratory", "ANATOMY", 184, 195], ["breast milk", "ANATOMY", 362, 373], ["breast milk", "ANATOMY", 656, 667], ["breast milk", "DISEASE", 656, 667], ["child", "ORGANISM", 345, 350], ["breast", "ORGANISM_SUBDIVISION", 362, 368], ["milk", "ORGANISM_SUBSTANCE", 369, 373], ["breast", "ORGANISM", 656, 662], ["milk", "ORGANISM_SUBSTANCE", 663, 667], ["respiratory precautions", "TREATMENT", 184, 207], ["a mask", "TREATMENT", 226, 232], ["formula feeds", "TREATMENT", 377, 390], ["hygienic practices", "TREATMENT", 448, 466], ["an ideal feeding option", "TREATMENT", 684, 707], ["breast", "ANATOMY", 362, 368]]], ["Formula feeding is an acceptable alternative if breastfeeding is not possible.", [["Formula feeding", "TREATMENT", 0, 15]]], ["It was recognized that preventing women in rural Africa from breastfeeding their children is likely to be associated with significant deleterious economic and health impacts and there is currently no evidence to advise exercising caution in this regard as long as hygienic practices are followed.Statement 22 ::: ResultsAmong paediatric patients with suspected SARS-CoV-2 infection who have negative nasopharyngeal PCR test, PCR test on stool samples should be considered to help confirm the diagnosis.Statement 22 ::: ResultsIt may well be that relying only on the nasopharyngeal swab test for the diagnosis of COVID-19 in children will potentially lead to significant under-diagnosis, and, as such, it is agreed that faecal PCR test may be an additional screening method.", [["nasopharyngeal", "ANATOMY", 400, 414], ["stool samples", "ANATOMY", 437, 450], ["nasopharyngeal swab", "ANATOMY", 566, 585], ["faecal", "ANATOMY", 719, 725], ["SARS-CoV-2 infection", "DISEASE", 361, 381], ["COVID-19", "CHEMICAL", 612, 620], ["women", "ORGANISM", 34, 39], ["children", "ORGANISM", 81, 89], ["patients", "ORGANISM", 337, 345], ["SARS-CoV-2", "ORGANISM", 361, 371], ["nasopharyngeal", "ORGAN", 400, 414], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 566, 585], ["children", "ORGANISM", 624, 632], ["faecal", "ORGANISM_SUBSTANCE", 719, 725], ["women", "SPECIES", 34, 39], ["children", "SPECIES", 81, 89], ["patients", "SPECIES", 337, 345], ["children", "SPECIES", 624, 632], ["SARS-CoV-2", "SPECIES", 361, 371], ["significant deleterious economic and health impacts", "PROBLEM", 122, 173], ["SARS", "PROBLEM", 361, 365], ["CoV-2 infection", "PROBLEM", 366, 381], ["nasopharyngeal PCR test", "TEST", 400, 423], ["PCR test", "TEST", 425, 433], ["stool samples", "TEST", 437, 450], ["the nasopharyngeal swab test", "TEST", 562, 590], ["COVID", "TEST", 612, 617], ["faecal PCR test", "TEST", 719, 734], ["an additional screening method", "TEST", 742, 772], ["nasopharyngeal", "ANATOMY", 400, 414]]], ["Indeed, emerging data seem to suggest the possibility of faecal transmission as an additional route [32].", [["faecal", "ANATOMY", 57, 63], ["faecal", "ORGANISM_SUBSTANCE", 57, 63], ["faecal transmission", "PROBLEM", 57, 76]]], ["This may be from environmental contamination, a risk that is likely higher in both rural African communities and in urban slums.", [["environmental contamination", "PROBLEM", 17, 44], ["may be", "UNCERTAINTY", 5, 11], ["environmental", "OBSERVATION_MODIFIER", 17, 30], ["contamination", "OBSERVATION", 31, 44], ["is likely", "UNCERTAINTY", 58, 67], ["higher", "OBSERVATION_MODIFIER", 68, 74]]], ["As children of all ages have been shown to develop COVID-19 without any gender disparity, healthcare professionals would do well to not exercise prolonged inertia in embarking upon appropriate testing of these patients, but it is advisable to limit the number of parents or family members attending with the patient to the barest minimum [18].DiscussionIn the unprecedented experience of a world grappling with COVID-19, the task force was faced with a need to deliver a project backed by a limited amount of high-quality evidence.", [["children", "ORGANISM", 3, 11], ["patients", "ORGANISM", 210, 218], ["patient", "ORGANISM", 308, 315], ["children", "SPECIES", 3, 11], ["patients", "SPECIES", 210, 218], ["patient", "SPECIES", 308, 315], ["COVID", "TREATMENT", 411, 416]]], ["It soon became clear that the scanty amount and low quality of existing evidence on various relevant clinical questions as well as the lengthy duration needed for its execution made it an unworthy venture to proceed with.", [["clear", "OBSERVATION", 15, 20], ["scanty", "OBSERVATION_MODIFIER", 30, 36], ["amount", "OBSERVATION_MODIFIER", 37, 43], ["low quality", "OBSERVATION_MODIFIER", 48, 59]]], ["However, the structure of AFLAR and the gradually growing membership of the PAFLAR usefully identified the need to work together to produce a common document in view of potential substantial overlaps in the relevant aspects of recommendation for adults and children in the era of COVID-19.", [["adults", "ORGANISM", 246, 252], ["children", "ORGANISM", 257, 265], ["AFLAR", "PROTEIN", 26, 31], ["PAFLAR", "PROTEIN", 76, 82], ["children", "SPECIES", 257, 265], ["AFLAR", "OBSERVATION", 26, 31], ["gradually", "OBSERVATION_MODIFIER", 40, 49], ["growing", "OBSERVATION_MODIFIER", 50, 57], ["substantial", "OBSERVATION_MODIFIER", 179, 190], ["overlaps", "OBSERVATION", 191, 199]]], ["The other peculiarity is the wide disparity in the structures of rheumatology and the entire healthcare services of the various countries covered by AFLAR.DiscussionA recognition of these variations meant that some flexibility is required with interpretation of some of these recommendations in the context of the prevailing local policies.", [["wide", "OBSERVATION_MODIFIER", 29, 33], ["disparity", "OBSERVATION_MODIFIER", 34, 43]]], ["Similarly, the relevance of some of the recommendations may succumb to the limit of available options of DMARDs and their formulations in some countries.", [["DMARDs", "TREATMENT", 105, 111], ["their formulations", "TREATMENT", 116, 134]]], ["Furthermore, the standard vaccination practices in some countries may dictate a contextual interpretation of the recommendation on influenza and pneumococcal vaccinations as provided in this document.", [["influenza", "DISEASE", 131, 140], ["pneumococcal", "ORGANISM", 145, 157], ["pneumococcal", "SPECIES", 145, 157], ["the standard vaccination practices", "TREATMENT", 13, 47], ["influenza", "TREATMENT", 131, 140], ["pneumococcal vaccinations", "TREATMENT", 145, 170]]], ["The virtual convening, execution and delivery of the project with seamless efficacy within the limit of resources and published evidence, however, signal a future of more possibilities in executing daunting tasks under difficult circumstances and tight schedules.", [["delivery", "TREATMENT", 37, 45], ["tight schedules", "TREATMENT", 247, 262]]], ["Whereas there are still unanswered questions about the management of RMDs in the world of COVID-19, we identify that there are endless needs for research and service improvement to deliver the best care to the African patients.", [["RMDs", "DISEASE", 69, 73], ["RMDs", "CANCER", 69, 73], ["patients", "ORGANISM", 218, 226], ["patients", "SPECIES", 218, 226], ["RMDs", "TREATMENT", 69, 73]]], ["The task force agreed to target rheumatologists and not policy-makers, other physicians or patients directly.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["However, relevant aspects of advice suitable for patients are directed towards the rheumatologist for delivery to the African patients.DiscussionCertainly, patient education is crucial in the proper delivery of the safety practices and best approaches to dealing with RMDs in this precarious time of the pandemic.", [["RMDs", "DISEASE", 268, 272], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 126, 134], ["patient", "ORGANISM", 156, 163], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 126, 134], ["patient", "SPECIES", 156, 163], ["delivery", "TREATMENT", 102, 110]]], ["The coalition of national rheumatology societies within AFLAR will be a cornerstone in cascading the preliminary recommendations through their networks and working together to deliver subsequent updates with even more answers to clinical questions of wider pan-African spread.", [["wider pan-African spread", "PROBLEM", 251, 275], ["coalition", "OBSERVATION_MODIFIER", 4, 13]]], ["The immediate future calls for a continuation of seeking answers to various questions around the care for RMDs in the world of COVID-19, and it has become imperative that the lessons learnt so far be thoughtfully processed going forward.", [["RMDs", "DISEASE", 106, 110]]]], "PMC7308044": [["IntroductionHydraulic fracturing, also called fracking, is a significant technological advance for the oil and gas industry.", [["oil", "ANATOMY", 103, 106], ["oil", "ORGANISM_SUBSTANCE", 103, 106], ["IntroductionHydraulic fracturing", "TREATMENT", 0, 32], ["Hydraulic fracturing", "OBSERVATION", 12, 32]]], ["In a context of historically low interest rates due to unconventional monetary policies, this advance has encouraged the US and some large foreign banks to invest massively in the shale industry, a sector expected to offer a strong profitability potential.2As a result, the extraction of shale oil in the US has grown dramatically over the last few years and is expected to further increase.", [["shale oil", "ANATOMY", 288, 297], ["2As", "SIMPLE_CHEMICAL", 256, 259], ["oil", "ORGANISM_SUBSTANCE", 294, 297], ["historically low interest rates", "PROBLEM", 16, 47], ["the US", "TEST", 117, 123], ["some large foreign banks", "PROBLEM", 128, 152], ["the extraction of shale oil", "TREATMENT", 270, 297], ["large", "OBSERVATION_MODIFIER", 133, 138], ["foreign banks", "OBSERVATION", 139, 152], ["shale oil", "OBSERVATION", 288, 297], ["grown", "OBSERVATION_MODIFIER", 312, 317], ["dramatically", "OBSERVATION_MODIFIER", 318, 330], ["increase", "OBSERVATION_MODIFIER", 382, 390]]], ["Estimates from the US Energy Information Administration suggested that, in 2013, the US produced approximately 3.5 million barrels per day (Mb/d) of shale oil (Neff and Coleman, 2014), three times higher than the amount produced in 2010.", [["oil", "ORGANISM_SUBSTANCE", 155, 158], ["the US", "TEST", 81, 87]]], ["By 2020, the US shale oil production is estimated to reach 4.8 Mb/d, which is approximately one-third of the total US oil supply.", [["oil", "ANATOMY", 118, 121], ["oil", "ORGANISM_SUBSTANCE", 22, 25], ["oil", "ORGANISM_SUBSTANCE", 118, 121], ["the US shale oil production", "TEST", 9, 36]]], ["Nevertheless, fracking technology has also added new costs to the oil extraction process.", [["oil", "ANATOMY", 66, 69], ["oil", "ORGANISM_SUBSTANCE", 66, 69], ["the oil extraction process", "TREATMENT", 62, 88]]], ["Compared to conventional oil, shale oil drilling and extraction are far more labour and capital-intensive, making the process necessarily costlier.3Thus, US shale production requires significant investments.", [["oil", "ANATOMY", 25, 28], ["oil", "ORGANISM_SUBSTANCE", 25, 28], ["conventional oil", "TREATMENT", 12, 28], ["shale oil drilling", "TREATMENT", 30, 48], ["extraction", "TREATMENT", 53, 63], ["US shale production", "TEST", 154, 173]]], ["The funding requirement, coupled with easy access to low-cost debt, has lead shale companies to rely extensively upon borrowing mostly from banks.", [["The funding requirement", "PROBLEM", 0, 23], ["easy access to low-cost debt", "TREATMENT", 38, 66], ["lead shale companies", "TREATMENT", 72, 92], ["shale", "OBSERVATION", 77, 82]]], ["Loans to oil and gas (O&G hereafter) companies have almost tripled in recent years.", [["oil", "ANATOMY", 9, 12], ["oil", "ORGANISM_SUBSTANCE", 9, 12]]], ["Many of these loans were extended to smaller oil companies, in particular, those engaged in shale oil exploration and production.", [["loans", "OBSERVATION", 14, 19], ["smaller", "OBSERVATION_MODIFIER", 37, 44], ["oil companies", "OBSERVATION", 45, 58], ["shale", "OBSERVATION", 92, 97], ["oil exploration", "OBSERVATION", 98, 113]]], ["By 2014, the aggregate net debt of O&G companies had already exceeded $175 billion, an approximately 250% increase from its 2005 level (Azar, 2017).IntroductionUnsurprisingly, the oil price collapse of 2014\u20132015 worsened the financial health of the US shale industry.", [["oil", "ANATOMY", 180, 183], ["oil", "ORGANISM_SUBSTANCE", 180, 183], ["increase", "OBSERVATION_MODIFIER", 106, 114]]], ["In fact, shale oil has a shorter lead time between drilling and production relative to conventional oil, making it more responsive to oil price fluctuations.", [["shale oil", "ANATOMY", 9, 18], ["oil", "ANATOMY", 100, 103], ["oil", "ANATOMY", 134, 137], ["oil", "ORGANISM_SUBSTANCE", 15, 18], ["oil", "ORGANISM_SUBSTANCE", 100, 103], ["oil", "ORGANISM_SUBSTANCE", 134, 137], ["conventional oil", "TREATMENT", 87, 103], ["shale oil", "OBSERVATION", 9, 18]]], ["Lower oil prices have reduced the revenues and cash flow generated by the latter, which creates difficulties servicing their loans.", [["oil", "ANATOMY", 6, 9], ["oil", "ORGANISM_SUBSTANCE", 6, 9], ["Lower oil prices", "TREATMENT", 0, 16], ["oil prices", "OBSERVATION", 6, 16]]], ["While some drilling companies have shown resilience in this lower price environment, there has been a substantial increase in the number of bankruptcies, from 0 in June 2014 to 82 in May 2016 (Baumeister and Kilian, 2016).IntroductionSimultaneously, there were growing concerns about US bank reserves capacity to face non-performing loans to the O&G sector, even though these loans accounted for at most 5% of total loans at the major US banks (Baumeister and Kilian, 2016).", [["substantial", "OBSERVATION_MODIFIER", 102, 113], ["increase", "OBSERVATION_MODIFIER", 114, 122]]], ["Baumeister and Kilian (2016) documented that the values of major US banks' stocks, which initially appreciated amid falling oil prices, sharply decreased to a trough by early 2016, before rebounding following the partial recovery of oil prices.", [["oil", "ANATOMY", 233, 236], ["oil", "ORGANISM_SUBSTANCE", 124, 127], ["oil", "ORGANISM_SUBSTANCE", 233, 236], ["oil prices", "TREATMENT", 233, 243], ["oil prices", "OBSERVATION", 233, 243]]], ["While many major US banks have attempted to allay fears of non-performing O&G loans by increasing their reserves, investors worry that conditions could deteriorate even more in the event of an oil market crisis, resulting in a further decline in oil prices.", [["oil", "ANATOMY", 246, 249], ["oil", "ORGANISM_SUBSTANCE", 193, 196], ["oil", "ORGANISM_SUBSTANCE", 246, 249], ["a further decline in oil prices", "PROBLEM", 225, 256], ["oil prices", "OBSERVATION", 246, 256]]], ["First, the coronavirus pandemic has caused demand for oil to decline so rapidly that the US has seen its oil storage capacity fill up.", [["oil", "ANATOMY", 54, 57], ["oil", "ANATOMY", 105, 108], ["coronavirus pandemic", "DISEASE", 11, 31], ["coronavirus", "ORGANISM", 11, 22], ["oil", "ORGANISM_SUBSTANCE", 54, 57], ["oil", "ORGANISM_SUBSTANCE", 105, 108], ["the coronavirus pandemic", "PROBLEM", 7, 31], ["the US", "TEST", 85, 91], ["coronavirus", "OBSERVATION", 11, 22]]], ["Consequently, oil prices have collapsed to critical levels, turning the US oil market on its head.", [["oil", "ANATOMY", 14, 17], ["head", "ANATOMY", 93, 97], ["oil", "ORGANISM_SUBSTANCE", 14, 17], ["head", "ORGANISM_SUBDIVISION", 93, 97], ["oil prices", "TREATMENT", 14, 24], ["head", "ANATOMY", 93, 97]]], ["For the first time, the benchmark for US oil prices, the West Texas Intermediate (WTI) crude oil futures contract, traded at negative prices, spreading fears beyond the US banking sector to the broader stock market.IntroductionOne question that emerged from both analysts and investors is whether the strengthening of the link between the banking sector and the oil market alongside the development of this industry could lead to higher instability in both oil and financial markets.", [["oil", "ANATOMY", 457, 460], ["oil", "ORGANISM_SUBSTANCE", 41, 44], ["oil", "ORGANISM_SUBSTANCE", 362, 365], ["oil", "ORGANISM_SUBSTANCE", 457, 460], ["US oil prices", "TREATMENT", 38, 51], ["the West Texas Intermediate (WTI) crude oil futures", "TREATMENT", 53, 104], ["spreading fears", "PROBLEM", 142, 157], ["higher instability in both oil and financial markets", "PROBLEM", 430, 482], ["stock market", "OBSERVATION", 202, 214], ["higher", "OBSERVATION_MODIFIER", 430, 436], ["instability", "OBSERVATION", 437, 448]]], ["As previously stated, the decline in the price of oil is synonymous with more challenges for oil companies to honour their debt obligations, with potentially adverse effects on US banks' asset quality.", [["oil", "ORGANISM_SUBSTANCE", 50, 53], ["oil", "ORGANISM_SUBSTANCE", 93, 96]]], ["However, if banks cut off their loans to O&G industries, turbulence in the oil market would be unavoidable given the financial fragility of the US shale industry.IntroductionAgainst this background, this study assesses whether the closer link between the banking and O&G sectors in the US could represent a potential new driver of banking and/or oil crises.", [["oil", "ANATOMY", 75, 78], ["oil", "ANATOMY", 346, 349], ["oil", "ORGANISM_SUBSTANCE", 75, 78], ["oil", "ORGANISM_SUBSTANCE", 346, 349], ["turbulence in the oil market", "TREATMENT", 57, 85], ["this study", "TEST", 199, 209], ["oil crises", "PROBLEM", 346, 356], ["new", "OBSERVATION_MODIFIER", 317, 320]]], ["In particular, to evaluate this potential risk transmission, we investigate the existence of volatility spillovers between stock returns of the four major US banks and oil prices.", [["oil", "ANATOMY", 168, 171], ["oil", "ORGANISM_SUBSTANCE", 168, 171], ["oil prices", "OBSERVATION", 168, 178]]], ["To the best of our knowledge, this is the first study to address this issue, which has remained unexplored to date.", [["the first study", "TEST", 38, 53]]], ["However, it is of critical importance as such volatility spillovers could reflect the potential existence of new crisis transmission channels driven by the interactions between these two sectors.IntroductionTo conduct our analysis, we use intraday data (1-min spot prices) of stock market indexes of the four major US banks (Bank of America, Citigroup, JP Morgan Chase, and Wells Fargo) and the West Texas Intermediate (WTI) oil price from January 2006 to June 2016.", [["such volatility spillovers", "PROBLEM", 41, 67], ["new crisis transmission channels", "PROBLEM", 109, 141], ["our analysis", "TEST", 218, 230], ["intraday data", "TEST", 239, 252], ["new", "OBSERVATION_MODIFIER", 109, 112], ["crisis", "OBSERVATION", 113, 119], ["JP", "ANATOMY", 353, 355]]], ["To assess volatility spillovers, we then use Vector AutoRegressive Fractionally Integrated Moving Average (VARFIMA) models introduced by Chiriac and Voev (2011).", [["volatility spillovers", "PROBLEM", 10, 31], ["Moving Average (VARFIMA) models", "TREATMENT", 91, 122]]], ["These models provide a suitable framework for capturing long memory dynamics of stock and oil price volatilities and identifying the interrelationship between them.", [["oil", "ANATOMY", 90, 93], ["oil", "ORGANISM_SUBSTANCE", 90, 93]]], ["Finally, to provide a comprehensive picture of volatility spillovers between the oil market and US banking sector, we also estimate volatility impulse response functions, following the methodology proposed by Chung (2001).IntroductionOur empirical results provide evidence of volatility spillovers between the oil market and US banking sector.", [["oil", "ANATOMY", 81, 84], ["oil", "ANATOMY", 310, 313], ["oil", "ORGANISM_SUBSTANCE", 81, 84], ["oil", "ORGANISM_SUBSTANCE", 310, 313], ["volatility spillovers", "PROBLEM", 276, 297], ["volatility spillovers", "OBSERVATION", 276, 297]]], ["Impulse response functions show that a standard positive shock in the volatility of oil prices has a positive impact on the volatility of US banks' stock prices.", [["oil", "ANATOMY", 84, 87], ["shock", "DISEASE", 57, 62], ["oil", "ORGANISM_SUBSTANCE", 84, 87], ["a standard positive shock", "PROBLEM", 37, 62]]], ["Responses of oil price volatility to a shock in the volatility of US banks' stock prices are also significant.", [["oil", "ANATOMY", 13, 16], ["shock", "DISEASE", 39, 44], ["oil", "ORGANISM_SUBSTANCE", 13, 16], ["a shock", "PROBLEM", 37, 44], ["shock", "OBSERVATION", 39, 44], ["significant", "OBSERVATION_MODIFIER", 98, 109]]], ["Interestingly, these responses are more pronounced during the period when US banks have become more involved in O&G industries, supporting the potential contribution of shale oil revolution in developing new linkages between oil prices and the US banking sector.", [["oil", "ANATOMY", 225, 228], ["oil", "ORGANISM_SUBSTANCE", 175, 178], ["oil", "ORGANISM_SUBSTANCE", 225, 228], ["US banks", "TEST", 74, 82], ["shale oil revolution", "TREATMENT", 169, 189], ["oil prices", "TREATMENT", 225, 235], ["pronounced", "OBSERVATION_MODIFIER", 40, 50], ["shale oil", "OBSERVATION", 169, 178], ["new", "OBSERVATION_MODIFIER", 204, 207], ["linkages", "OBSERVATION_MODIFIER", 208, 216], ["oil prices", "OBSERVATION", 225, 235]]], ["These results are robust to the use of an alternative model of volatility transmission.IntroductionOur study contributes to the ongoing debate regarding the sustainability of the US fracking industry by highlighting its potential role as a key driver of oil and financial instabilities in the future.", [["oil", "ANATOMY", 254, 257], ["oil", "ORGANISM_SUBSTANCE", 254, 257], ["IntroductionOur study", "TEST", 87, 108], ["financial instabilities", "PROBLEM", 262, 285]]], ["Firstly, we extend the existing studies assessing volatility spillovers between oil and stock markets,4by highlighting the volatility interaction between oil prices and US banks' stock prices.", [["oil", "ANATOMY", 80, 83], ["oil", "ANATOMY", 154, 157], ["oil", "ORGANISM_SUBSTANCE", 80, 83], ["oil", "ORGANISM_SUBSTANCE", 154, 157], ["the existing studies", "TEST", 19, 39]]], ["We provide new insights into the dynamic link between oil prices and the US banking system through two main channels.", [["oil", "ANATOMY", 54, 57], ["oil", "ORGANISM_SUBSTANCE", 54, 57]]], ["Following a strand of the literature (see for example Narayan and Sharma, 2014; Broadstock and Filis, 2014), we emphasise the crucial role that oil prices could play in worsening the financial health of the banking sector through the deterioration of the creditworthiness of borrowers (here O&G industries).", [["oil", "ANATOMY", 144, 147], ["oil", "ORGANISM_SUBSTANCE", 144, 147], ["Narayan", "TEST", 54, 61], ["Sharma", "TEST", 66, 72], ["Broadstock", "TEST", 80, 90]]], ["Unlike the existing literature that only documents the existence of volatility spillovers from oil prices to the banking sector, we go further by suggesting the underlying mechanisms channelled through the shale oil industry.", [["oil", "ANATOMY", 95, 98], ["oil", "ORGANISM_SUBSTANCE", 95, 98], ["volatility spillovers", "OBSERVATION", 68, 89]]], ["More importantly, we highlight the critical role that the US banking sector could play in triggering turmoil in oil markets by disrupting the supply side of the oil market through decreasing the amount of available credit to O&G industries.IntroductionWe also contribute to the recent literature assessing the link between the oil sector and the US economy (Baumeister and Kilian, 2016; Bj\u00f8rnland and Zhulanova, 2019).", [["oil", "ANATOMY", 161, 164], ["oil", "ORGANISM_SUBSTANCE", 161, 164]]], ["Bj\u00f8rnland and Zhulanova (2019) provide evidence of positive spillovers from an increase in the real oil price to non-oil investment, employment, and production in the US - effects that were not present before the shale revolution.", [["oil", "ANATOMY", 100, 103], ["oil", "ORGANISM_SUBSTANCE", 100, 103], ["positive spillovers", "PROBLEM", 51, 70], ["non-oil investment", "TREATMENT", 113, 131], ["positive spillovers", "OBSERVATION", 51, 70], ["increase", "OBSERVATION_MODIFIER", 79, 87]]], ["Baumeister and Kilian (2016) explore the impact of the 2014\u20132016 oil price decline on the US real GDP growth and find evidence of a net effect close to zero.", [["GDP", "CHEMICAL", 98, 101], ["GDP", "CHEMICAL", 98, 101], ["oil", "ORGANISM_SUBSTANCE", 65, 68], ["GDP", "SIMPLE_CHEMICAL", 98, 101], ["the US", "TEST", 86, 92], ["a net effect", "PROBLEM", 130, 142]]], ["In particular, their results suggested that this decline positively affected the US economy by increasing real private consumption and non-oil-related business investment, a positive effect counterbalanced by a substantial reduction in real investment by the oil sector.", [["oil", "ORGANISM_SUBSTANCE", 259, 262], ["this decline", "PROBLEM", 44, 56], ["a positive effect counterbalanced", "PROBLEM", 172, 205], ["a substantial reduction", "TREATMENT", 209, 232], ["increasing", "OBSERVATION_MODIFIER", 95, 105], ["positive effect", "OBSERVATION_MODIFIER", 174, 189], ["substantial", "OBSERVATION_MODIFIER", 211, 222], ["reduction", "OBSERVATION_MODIFIER", 223, 232]]], ["By addressing the volatility interactions of oil prices and the US banking sector, we explored the relationship between the oil sector and the US economy through financial spillovers.", [["oil", "ANATOMY", 45, 48], ["oil", "ORGANISM_SUBSTANCE", 45, 48], ["oil", "ORGANISM_SUBSTANCE", 124, 127], ["oil prices", "TREATMENT", 45, 55]]], ["For instance, significant spillovers from a decline in oil prices to the major US banks' stocks may decelerate the US economy by affecting some key sectors of the latter.", [["oil", "ANATOMY", 55, 58], ["oil", "ORGANISM_SUBSTANCE", 55, 58], ["significant spillovers", "PROBLEM", 14, 36], ["oil prices", "TREATMENT", 55, 65], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["spillovers", "OBSERVATION", 26, 36]]], ["However, because the US shale industry remains financially fragile and depends mainly on banks to finance its activity, one would expect a decline in real investment in the oil sector following a decrease of loans to O&G companies.", [["oil", "ORGANISM_SUBSTANCE", 173, 176], ["financially fragile", "PROBLEM", 47, 66], ["fragile", "OBSERVATION", 59, 66]]], ["This situation could demonstrate adverse consequences on the US economy.IntroductionThe rest of the paper is structured as follows.", [["adverse consequences", "PROBLEM", 33, 53], ["the US economy", "TEST", 57, 71]]], ["Section 2 provides empirical evidence on the increased link between the oil market and US banking sector.", [["oil", "ANATOMY", 72, 75], ["oil", "ORGANISM_SUBSTANCE", 72, 75], ["increased", "OBSERVATION_MODIFIER", 45, 54]]], ["Section 3 presents the data and methodology used in this study.", [["this study", "TEST", 52, 62]]], ["Section 6 provides some concluding remarks.Study motivation: stylized factsThe US has started extracting shale oil on a large scale from 2006, although the existence of a vital shale oil resource has been known for decades.", [["shale oil", "ANATOMY", 105, 114], ["oil", "ORGANISM_SUBSTANCE", 111, 114], ["oil", "ORGANISM_SUBSTANCE", 183, 186], ["The US", "TEST", 75, 81], ["a vital shale oil resource", "TREATMENT", 169, 195]]], ["With a slight slowdown due to the 2008 financial crisis,5it is only after 2010 that the U.S shale oil production increased, creating a boom in domestic crude oil production.", [["oil", "ANATOMY", 98, 101], ["oil", "ANATOMY", 158, 161], ["oil", "ORGANISM_SUBSTANCE", 98, 101], ["oil", "ORGANISM_SUBSTANCE", 158, 161], ["a slight slowdown", "PROBLEM", 5, 22], ["slight", "OBSERVATION_MODIFIER", 7, 13], ["slowdown", "OBSERVATION", 14, 22], ["increased", "OBSERVATION_MODIFIER", 113, 122], ["oil production", "OBSERVATION", 158, 172]]]], "40886cbc7d15ef110d144a22a3a25750f6e132cd": [["INTRODUCTIONAs the COVID-19 pandemic sweeps across the globe, early diagnosis is one of the main ways to combat the infection.", [["infection", "DISEASE", 116, 125], ["the COVID", "TREATMENT", 15, 24], ["the infection", "PROBLEM", 112, 125], ["globe", "ANATOMY", 55, 60], ["infection", "OBSERVATION", 116, 125]]], ["The reverse-transcription polymerase chain reaction (RT-PCR) taken from nasopharyngeal swab samples has become the gold-standard in making the diagnosis.", [["nasopharyngeal swab samples", "ANATOMY", 72, 99], ["nasopharyngeal swab samples", "CANCER", 72, 99], ["The reverse-transcription polymerase chain reaction", "PROBLEM", 0, 51], ["RT-PCR", "TEST", 53, 59], ["nasopharyngeal swab samples", "TEST", 72, 99], ["nasopharyngeal", "ANATOMY", 72, 86]]], ["However, it is well-known that although the RT-PCR assay is highly specific, it has a low sensitivity.", [["the RT-PCR assay", "TEST", 40, 56], ["a low sensitivity", "PROBLEM", 84, 101], ["low sensitivity", "OBSERVATION_MODIFIER", 86, 101]]], ["1,2 Chest CT is not a replacement for RT-PCR, but it could be used in highly suspicious cases of COVID-19 pneumonia who are severely ill or when RT-PCR is not readily available.", [["pneumonia", "DISEASE", 106, 115], ["COVID-19", "SPECIES", 97, 105], ["Chest CT", "TEST", 4, 12], ["a replacement", "TREATMENT", 20, 33], ["RT-PCR", "TEST", 38, 44], ["COVID-19 pneumonia", "PROBLEM", 97, 115], ["severely ill", "PROBLEM", 124, 136], ["RT-PCR", "TEST", 145, 151], ["Chest", "ANATOMY", 4, 9], ["pneumonia", "OBSERVATION", 106, 115]]], ["3 There is also increasing evidence that chest CT is a more sensitive diagnostic tool compared to the RT-PCR assay.", [["chest", "ANATOMY", 41, 46], ["chest", "ORGAN", 41, 46], ["chest CT", "TEST", 41, 49], ["the RT-PCR assay", "TEST", 98, 114], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["chest", "ANATOMY", 41, 46]]], ["But, the main limitation of chest CT is its low specificity.", [["chest", "ANATOMY", 28, 33], ["chest", "ORGAN", 28, 33], ["chest CT", "TEST", 28, 36], ["main", "OBSERVATION_MODIFIER", 9, 13], ["chest", "ANATOMY", 28, 33]]], ["The imaging diagnosis is simple when the pattern of disease on the chest CT is classic of the COVID-19 pneumonia.", [["chest", "ANATOMY", 67, 72], ["pneumonia", "DISEASE", 103, 112], ["chest", "ORGAN", 67, 72], ["The imaging diagnosis", "TEST", 0, 21], ["disease", "PROBLEM", 52, 59], ["the chest CT", "TEST", 63, 75], ["the COVID", "TEST", 90, 99], ["pneumonia", "PROBLEM", 103, 112], ["disease", "OBSERVATION", 52, 59], ["chest", "ANATOMY", 67, 72], ["pneumonia", "OBSERVATION", 103, 112]]], ["In situations, patients with pre-existing thoracic diseases which is often the case in the at-risk elderly population, then the appearances may no longer be as classical.", [["thoracic", "ANATOMY", 42, 50], ["thoracic diseases", "DISEASE", 42, 59], ["patients", "ORGANISM", 15, 23], ["thoracic", "ORGAN", 42, 50], ["patients", "SPECIES", 15, 23], ["pre-existing thoracic diseases", "PROBLEM", 29, 59], ["thoracic", "ANATOMY", 42, 50], ["diseases", "OBSERVATION", 51, 59], ["may no longer", "UNCERTAINTY", 140, 153]]], ["In this case series, we present clinical scenarios in which the diagnosis is challenging and use imaging clues available to the radiologist to either make the diagnosis or at least reduce the differential diagnoses.", [["imaging clues", "TEST", 97, 110]]], ["All the CT positive/negative cases included in this review are supported by corresponding RT-PCR test results unless specifically indicated in individual cases.INTRODUCTIONClassic and probable COVID-19 CT patterns Using the British Society of Thoracic Imaging (BSTI) guidelines for reporting CT scans in COVID-19 pneumonia, the classic CT manifestation of the disease is lower lobe or peripheral predominant with multiple, bilateral foci of ground glass opacification; probable pattern consists of lower lobe predominant mix of bronchocentric and peripheral consolidation with limited ground glass opacification; and indeterminate cases occurs in the context when the clinical information suggests an alternative diagnosis.", [["lower lobe", "ANATOMY", 371, 381], ["foci", "ANATOMY", 433, 437], ["lower lobe", "ANATOMY", 498, 508], ["bronchocentric", "ANATOMY", 528, 542], ["pneumonia", "DISEASE", 313, 322], ["lobe", "CANCER", 377, 381], ["bronchocentric", "CANCER", 528, 542], ["All the CT", "TEST", 0, 10], ["corresponding RT-PCR test", "TEST", 76, 101], ["INTRODUCTIONClassic", "TREATMENT", 160, 179], ["COVID", "TEST", 193, 198], ["Thoracic Imaging", "TEST", 243, 259], ["CT scans", "TEST", 292, 300], ["COVID", "TEST", 304, 309], ["pneumonia", "PROBLEM", 313, 322], ["the classic CT", "TEST", 324, 338], ["the disease", "PROBLEM", 356, 367], ["ground glass opacification", "PROBLEM", 441, 467], ["lower lobe predominant mix of bronchocentric and peripheral consolidation", "PROBLEM", 498, 571], ["limited ground glass opacification", "PROBLEM", 577, 611], ["Thoracic", "ANATOMY", 243, 251], ["pneumonia", "OBSERVATION", 313, 322], ["disease", "OBSERVATION", 360, 367], ["lower lobe", "ANATOMY", 371, 381], ["peripheral", "ANATOMY_MODIFIER", 385, 395], ["predominant", "OBSERVATION_MODIFIER", 396, 407], ["multiple", "OBSERVATION_MODIFIER", 413, 421], ["bilateral", "ANATOMY_MODIFIER", 423, 432], ["foci", "OBSERVATION", 433, 437], ["ground glass opacification", "OBSERVATION", 441, 467], ["probable", "UNCERTAINTY", 469, 477], ["lower lobe", "ANATOMY", 498, 508], ["predominant", "OBSERVATION_MODIFIER", 509, 520], ["mix", "OBSERVATION_MODIFIER", 521, 524], ["bronchocentric", "OBSERVATION_MODIFIER", 528, 542], ["peripheral", "ANATOMY_MODIFIER", 547, 557], ["consolidation", "OBSERVATION", 558, 571], ["limited", "OBSERVATION_MODIFIER", 577, 584], ["ground glass opacification", "OBSERVATION", 585, 611], ["indeterminate", "OBSERVATION_MODIFIER", 617, 630]]], ["3 From our experience, the bilateral multifocal ground glass opacification may range from minor small foci (Figure 1a ), ill-defined ground glass patches (Figure 1b) , to dense ground glass foci in a random distribution (Figure 1c ).", [["foci", "ANATOMY", 102, 106], ["the bilateral multifocal ground glass opacification", "PROBLEM", 23, 74], ["minor small foci", "PROBLEM", 90, 106], ["ill-defined ground glass patches", "PROBLEM", 121, 153], ["dense ground glass foci", "PROBLEM", 171, 194], ["bilateral", "ANATOMY_MODIFIER", 27, 36], ["multifocal", "OBSERVATION_MODIFIER", 37, 47], ["ground glass opacification", "OBSERVATION", 48, 74], ["range", "OBSERVATION_MODIFIER", 79, 84], ["minor", "OBSERVATION_MODIFIER", 90, 95], ["small", "OBSERVATION_MODIFIER", 96, 101], ["foci", "OBSERVATION", 102, 106], ["ill-defined", "OBSERVATION_MODIFIER", 121, 132], ["ground glass patches", "OBSERVATION", 133, 153], ["dense", "OBSERVATION_MODIFIER", 171, 176], ["ground glass foci", "OBSERVATION", 177, 194], ["random distribution", "OBSERVATION_MODIFIER", 200, 219]]], ["The diagnosis may also be made with confidence when there are patterns that mimic organising pneumonia such as peripheral perilobular ground glass opacification (Figure 2a and b), and the reverse halo sign (Figure 2c and d) .", [["pneumonia", "DISEASE", 93, 102], ["pneumonia", "PROBLEM", 93, 102], ["peripheral perilobular ground glass opacification", "PROBLEM", 111, 160], ["the reverse halo sign", "PROBLEM", 184, 205], ["pneumonia", "OBSERVATION", 93, 102], ["peripheral", "ANATOMY_MODIFIER", 111, 121], ["perilobular", "ANATOMY", 122, 133], ["ground glass opacification", "OBSERVATION", 134, 160]]], ["These imaging patterns along with the clinical history, signs and symptoms provide the reporting radiologist with a high degree of confidence in making the diagnosis of COVID-19 pneumonia in the absence of a RT-PCR test result.The diagnostic challengesThe level of diagnostic certainty is significantly reduced in the absence of characteristic CT features.", [["COVID", "DISEASE", 169, 174], ["pneumonia", "DISEASE", 178, 187], ["These imaging patterns", "TEST", 0, 22], ["symptoms", "PROBLEM", 66, 74], ["COVID-19 pneumonia", "PROBLEM", 169, 187], ["a RT-PCR test", "TEST", 206, 219], ["pneumonia", "OBSERVATION", 178, 187], ["significantly", "OBSERVATION_MODIFIER", 289, 302], ["reduced", "OBSERVATION_MODIFIER", 303, 310]]], ["This is further complicated by three commonly encountered clinical scenarios -heart failure, other types of infection particularly in patients with immunosuppression, and trauma.", [["heart", "ANATOMY", 78, 83], ["heart failure", "DISEASE", 78, 91], ["infection", "DISEASE", 108, 117], ["trauma", "DISEASE", 171, 177], ["heart", "ORGAN", 78, 83], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["heart failure", "PROBLEM", 78, 91], ["infection", "PROBLEM", 108, 117], ["immunosuppression", "TREATMENT", 148, 165], ["trauma", "PROBLEM", 171, 177], ["heart", "ANATOMY", 78, 83], ["failure", "OBSERVATION", 84, 91], ["infection", "OBSERVATION", 108, 117]]], ["These cases all have the potential to cause, contribute to or mask the ground glass opacification seen in COVID-19 pneumonia.", [["pneumonia", "DISEASE", 115, 124], ["mask the ground glass opacification", "PROBLEM", 62, 97], ["COVID", "TEST", 106, 111], ["pneumonia", "PROBLEM", 115, 124], ["ground glass opacification", "OBSERVATION", 71, 97], ["pneumonia", "OBSERVATION", 115, 124]]], ["The following cases illustrate the subtle features that may aid the reporting radiologist to identify the suspicious COVID-19 pneumonia from diseases that masquerade.The diagnostic challengesCOVID-19 and heart failure Existing heart disease is found known to be one of the main risk factors for developing COVID-19 pneumonia.", [["heart", "ANATOMY", 204, 209], ["heart", "ANATOMY", 227, 232], ["pneumonia", "DISEASE", 126, 135], ["heart failure", "DISEASE", 204, 217], ["heart disease", "DISEASE", 227, 240], ["COVID", "DISEASE", 306, 311], ["pneumonia", "DISEASE", 315, 324], ["heart", "ORGAN", 204, 209], ["heart", "ORGAN", 227, 232], ["the suspicious COVID", "PROBLEM", 102, 122], ["pneumonia", "PROBLEM", 126, 135], ["diseases", "PROBLEM", 141, 149], ["The diagnostic challengesCOVID", "TEST", 166, 196], ["heart failure Existing heart disease", "PROBLEM", 204, 240], ["developing COVID-19 pneumonia", "PROBLEM", 295, 324], ["pneumonia", "OBSERVATION", 126, 135], ["heart", "ANATOMY", 204, 209], ["failure", "OBSERVATION", 210, 217], ["heart", "ANATOMY", 227, 232], ["disease", "OBSERVATION", 233, 240], ["pneumonia", "OBSERVATION", 315, 324]]], ["5 Heart failure with fluid overloading may produce symptoms and CT features that are difficult to distinguish from COVID-19 pneumonia.", [["Heart", "ANATOMY", 2, 7], ["fluid", "ANATOMY", 21, 26], ["Heart failure", "DISEASE", 2, 15], ["fluid overloading", "DISEASE", 21, 38], ["pneumonia", "DISEASE", 124, 133], ["Heart failure", "PROBLEM", 2, 15], ["fluid overloading", "PROBLEM", 21, 38], ["symptoms", "PROBLEM", 51, 59], ["CT features", "TEST", 64, 75], ["COVID", "TEST", 115, 120], ["pneumonia", "PROBLEM", 124, 133], ["Heart", "ANATOMY", 2, 7], ["failure", "OBSERVATION", 8, 15], ["fluid overloading", "OBSERVATION", 21, 38], ["pneumonia", "OBSERVATION", 124, 133]]], ["In this clinical scenario, three elderly patients with known heart failure presented with a history of a worsening of cough and shortness of breath without convincing COVID-19 contact.", [["heart", "ANATOMY", 61, 66], ["heart failure", "DISEASE", 61, 74], ["cough", "DISEASE", 118, 123], ["shortness of breath", "DISEASE", 128, 147], ["patients", "ORGANISM", 41, 49], ["heart", "ORGAN", 61, 66], ["patients", "SPECIES", 41, 49], ["known heart failure", "PROBLEM", 55, 74], ["a worsening of cough", "PROBLEM", 103, 123], ["shortness of breath", "PROBLEM", 128, 147], ["heart", "ANATOMY", 61, 66], ["failure", "OBSERVATION", 67, 74], ["worsening", "OBSERVATION_MODIFIER", 105, 114], ["cough", "OBSERVATION", 118, 123]]], ["All three patients had CT pulmonary angiograms (CTPA) to exclude pulmonary embolism.", [["pulmonary", "ANATOMY", 26, 35], ["pulmonary", "ANATOMY", 65, 74], ["pulmonary embolism", "DISEASE", 65, 83], ["patients", "ORGANISM", 10, 18], ["pulmonary", "ORGAN", 26, 35], ["pulmonary", "ORGAN", 65, 74], ["patients", "SPECIES", 10, 18], ["CT pulmonary angiograms", "TEST", 23, 46], ["CTPA", "TEST", 48, 52], ["pulmonary embolism", "PROBLEM", 65, 83], ["pulmonary", "ANATOMY", 26, 35], ["pulmonary", "ANATOMY", 65, 74], ["embolism", "OBSERVATION", 75, 83]]], ["The CT scans of the patients demonstrated bilateral pleural effusions with smooth interlobular septal thickening and ground glass opacification.", [["pleural effusions", "ANATOMY", 52, 69], ["interlobular septal", "ANATOMY", 82, 101], ["pleural effusions", "DISEASE", 52, 69], ["patients", "ORGANISM", 20, 28], ["pleural effusions", "PATHOLOGICAL_FORMATION", 52, 69], ["smooth interlobular septal", "TISSUE", 75, 101], ["patients", "SPECIES", 20, 28], ["The CT scans", "TEST", 0, 12], ["bilateral pleural effusions", "PROBLEM", 42, 69], ["smooth interlobular septal thickening", "PROBLEM", 75, 112], ["ground glass opacification", "PROBLEM", 117, 143], ["bilateral", "ANATOMY_MODIFIER", 42, 51], ["pleural", "ANATOMY", 52, 59], ["effusions", "OBSERVATION", 60, 69], ["smooth", "OBSERVATION_MODIFIER", 75, 81], ["interlobular", "ANATOMY_MODIFIER", 82, 94], ["septal", "ANATOMY_MODIFIER", 95, 101], ["thickening", "OBSERVATION", 102, 112], ["ground glass opacification", "OBSERVATION", 117, 143]]], ["Patient A ( Figure 3a ) and Patient B (Figure 3b ) demonstrated different degree of interlobular septal thickening and the associated ground glass opacification is located mainly in the dependent positions.", [["interlobular septal", "ANATOMY", 84, 103], ["interlobular septal", "MULTI-TISSUE_STRUCTURE", 84, 103], ["Patient", "SPECIES", 0, 7], ["Patient", "SPECIES", 28, 35], ["Patient B (Figure 3b )", "TEST", 28, 50], ["interlobular septal thickening", "PROBLEM", 84, 114], ["the associated ground glass opacification", "PROBLEM", 119, 160], ["different", "OBSERVATION_MODIFIER", 64, 73], ["degree", "OBSERVATION_MODIFIER", 74, 80], ["interlobular", "ANATOMY_MODIFIER", 84, 96], ["septal", "ANATOMY_MODIFIER", 97, 103], ["thickening", "OBSERVATION", 104, 114], ["ground glass opacification", "OBSERVATION", 134, 160], ["dependent", "OBSERVATION_MODIFIER", 186, 195], ["positions", "OBSERVATION_MODIFIER", 196, 205]]], ["In comparison, in Patient C ( Figure 3c ) the ground glass opacification is more uniformly distributed within the areas of smooth interlobular thickening resulting in the crazypaving sign, which in the right clinical context it is a supportive feature of COVID-19 pneumonia, 3,6,7 and further supported by a positive RT-PCR test in Patient C only.The diagnostic challengesThe defining clinical and CT features between COVID-19 pneumonia and heart failure become further complicated when there is possible superadded infection from other types of organisms.", [["smooth interlobular", "ANATOMY", 123, 142], ["heart", "ANATOMY", 441, 446], ["pneumonia", "DISEASE", 264, 273], ["pneumonia", "DISEASE", 427, 436], ["heart failure", "DISEASE", 441, 454], ["infection", "DISEASE", 516, 525], ["smooth interlobular", "TISSUE", 123, 142], ["heart", "ORGAN", 441, 446], ["Patient", "SPECIES", 18, 25], ["the ground glass opacification", "PROBLEM", 42, 72], ["smooth interlobular thickening", "PROBLEM", 123, 153], ["the crazypaving sign", "PROBLEM", 167, 187], ["COVID-19 pneumonia", "PROBLEM", 255, 273], ["a positive RT-PCR test", "TEST", 306, 328], ["CT features", "TEST", 398, 409], ["COVID", "TEST", 418, 423], ["pneumonia", "PROBLEM", 427, 436], ["heart failure", "PROBLEM", 441, 454], ["superadded infection", "PROBLEM", 505, 525], ["organisms", "PROBLEM", 546, 555], ["ground glass opacification", "OBSERVATION", 46, 72], ["more uniformly", "OBSERVATION_MODIFIER", 76, 90], ["areas", "OBSERVATION_MODIFIER", 114, 119], ["smooth", "OBSERVATION_MODIFIER", 123, 129], ["interlobular", "ANATOMY_MODIFIER", 130, 142], ["thickening", "OBSERVATION", 143, 153], ["crazypaving sign", "OBSERVATION", 171, 187], ["right", "ANATOMY_MODIFIER", 202, 207], ["pneumonia", "OBSERVATION", 264, 273], ["pneumonia", "OBSERVATION", 427, 436], ["heart", "ANATOMY", 441, 446], ["failure", "OBSERVATION", 447, 454], ["possible", "UNCERTAINTY", 496, 504], ["superadded", "OBSERVATION_MODIFIER", 505, 515], ["infection", "OBSERVATION", 516, 525]]], ["The next two patients both presented with signs and symptoms of shortness of breath and fever.", [["shortness of breath", "DISEASE", 64, 83], ["fever", "DISEASE", 88, 93], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["signs", "PROBLEM", 42, 47], ["symptoms", "PROBLEM", 52, 60], ["shortness of breath", "PROBLEM", 64, 83], ["fever", "PROBLEM", 88, 93], ["fever", "OBSERVATION", 88, 93]]], ["Patient D's CT demonstrated bilateral pleural effusions with patchy ground glass and ground glass nodularity (Figure 4a ), which is more common in bacterial infections, or fungal infection if they are immunocompromised.", [["pleural effusions", "ANATOMY", 38, 55], ["pleural effusions", "DISEASE", 38, 55], ["bacterial infections", "DISEASE", 147, 167], ["fungal infection", "DISEASE", 172, 188], ["pleural effusions", "PATHOLOGICAL_FORMATION", 38, 55], ["Patient", "SPECIES", 0, 7], ["Patient D's CT", "TEST", 0, 14], ["bilateral pleural effusions", "PROBLEM", 28, 55], ["patchy ground glass", "PROBLEM", 61, 80], ["ground glass nodularity", "PROBLEM", 85, 108], ["bacterial infections", "PROBLEM", 147, 167], ["fungal infection", "PROBLEM", 172, 188], ["immunocompromised", "PROBLEM", 201, 218], ["bilateral", "ANATOMY_MODIFIER", 28, 37], ["pleural", "ANATOMY", 38, 45], ["effusions", "OBSERVATION", 46, 55], ["patchy", "OBSERVATION_MODIFIER", 61, 67], ["ground glass", "OBSERVATION", 68, 80], ["ground glass nodularity", "OBSERVATION", 85, 108], ["more common", "OBSERVATION_MODIFIER", 132, 143], ["bacterial", "OBSERVATION_MODIFIER", 147, 156], ["infections", "OBSERVATION", 157, 167], ["fungal", "OBSERVATION_MODIFIER", 172, 178], ["infection", "OBSERVATION", 179, 188], ["immunocompromised", "OBSERVATION", 201, 218]]], ["In contrast, Patient E's CT ( Figure 4b ) showed bilateral small pleural effusions with bronchocentric ground glass opacification.", [["pleural effusions", "ANATOMY", 65, 82], ["pleural effusions", "DISEASE", 65, 82], ["pleural effusions", "PATHOLOGICAL_FORMATION", 65, 82], ["Patient", "SPECIES", 13, 20], ["Patient E's CT ( Figure 4b )", "TEST", 13, 41], ["bilateral small pleural effusions", "PROBLEM", 49, 82], ["bronchocentric ground glass opacification", "PROBLEM", 88, 129], ["bilateral", "ANATOMY_MODIFIER", 49, 58], ["small", "OBSERVATION_MODIFIER", 59, 64], ["pleural", "ANATOMY", 65, 72], ["effusions", "OBSERVATION", 73, 82], ["bronchocentric", "OBSERVATION_MODIFIER", 88, 102], ["ground glass opacification", "OBSERVATION", 103, 129]]], ["Based on recent reports, in the right clinical context bronchocentric ground glass opacification could be one of the supportive CT features of COVID-19 pneumonia.", [["pneumonia", "DISEASE", 152, 161], ["bronchocentric ground glass opacification", "PROBLEM", 55, 96], ["the supportive CT features", "TEST", 113, 139], ["COVID", "TEST", 143, 148], ["pneumonia", "PROBLEM", 152, 161], ["right", "ANATOMY_MODIFIER", 32, 37], ["bronchocentric", "OBSERVATION_MODIFIER", 55, 69], ["ground glass opacification", "OBSERVATION", 70, 96], ["pneumonia", "OBSERVATION", 152, 161]]], ["3, 6, 7 This patient was also had a positive RT-PCR test.The diagnostic challengesPatient F is known to have heart failure and already has a diagnosis of COVID-19 infection from a recent RT-PCR test.", [["heart", "ANATOMY", 109, 114], ["heart failure", "DISEASE", 109, 122], ["infection", "DISEASE", 163, 172], ["patient", "ORGANISM", 13, 20], ["heart", "ORGAN", 109, 114], ["patient", "SPECIES", 13, 20], ["a positive RT-PCR test", "PROBLEM", 34, 56], ["heart failure", "PROBLEM", 109, 122], ["COVID-19 infection", "PROBLEM", 154, 172], ["a recent RT-PCR test", "TEST", 178, 198], ["heart", "ANATOMY", 109, 114], ["failure", "OBSERVATION", 115, 122], ["infection", "OBSERVATION", 163, 172]]], ["He has a persistent fever and a sudden increase in his oxygen requirement.", [["fever", "DISEASE", 20, 25], ["oxygen", "CHEMICAL", 55, 61], ["oxygen", "CHEMICAL", 55, 61], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["a persistent fever", "PROBLEM", 7, 25], ["a sudden increase", "PROBLEM", 30, 47], ["his oxygen requirement", "PROBLEM", 51, 73], ["persistent", "OBSERVATION_MODIFIER", 9, 19], ["fever", "OBSERVATION", 20, 25], ["sudden", "OBSERVATION_MODIFIER", 32, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["oxygen requirement", "OBSERVATION", 55, 73]]], ["A CTPA was performed to exclude pulmonary emboli as the cause of his hypoxia, because COVID-19 infection increases the risk of thromboembolism.", [["pulmonary emboli", "ANATOMY", 32, 48], ["pulmonary emboli", "DISEASE", 32, 48], ["hypoxia", "DISEASE", 69, 76], ["COVID-19", "CHEMICAL", 86, 94], ["infection", "DISEASE", 95, 104], ["thromboembolism", "DISEASE", 127, 142], ["pulmonary", "ORGAN", 32, 41], ["A CTPA", "TEST", 0, 6], ["pulmonary emboli", "PROBLEM", 32, 48], ["his hypoxia", "PROBLEM", 65, 76], ["COVID", "TEST", 86, 91], ["infection", "PROBLEM", 95, 104], ["thromboembolism", "PROBLEM", 127, 142], ["pulmonary", "ANATOMY", 32, 41], ["emboli", "OBSERVATION", 42, 48], ["hypoxia", "OBSERVATION", 69, 76], ["infection", "OBSERVATION", 95, 104], ["thromboembolism", "OBSERVATION", 127, 142]]], ["8, 9 The CTPA showed predominately bronchocentric ground glass opacification in the right upper lobe and middle lobe, bilateral pleural effusions and dense consolidation on the left (Figure 5a-c) .", [["right upper lobe", "ANATOMY", 84, 100], ["middle lobe", "ANATOMY", 105, 116], ["pleural effusions", "ANATOMY", 128, 145], ["pleural effusions", "DISEASE", 128, 145], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 90, 100], ["lobe", "ORGAN", 112, 116], ["pleural effusions", "PATHOLOGICAL_FORMATION", 128, 145], ["The CTPA", "TEST", 5, 13], ["predominately bronchocentric ground glass opacification in the right upper lobe and middle lobe", "PROBLEM", 21, 116], ["bilateral pleural effusions", "PROBLEM", 118, 145], ["dense consolidation on the left", "PROBLEM", 150, 181], ["predominately", "OBSERVATION_MODIFIER", 21, 34], ["bronchocentric", "OBSERVATION_MODIFIER", 35, 49], ["ground glass opacification", "OBSERVATION", 50, 76], ["right upper lobe", "ANATOMY", 84, 100], ["middle lobe", "ANATOMY", 105, 116], ["bilateral", "ANATOMY_MODIFIER", 118, 127], ["pleural", "ANATOMY", 128, 135], ["effusions", "OBSERVATION", 136, 145], ["dense", "OBSERVATION_MODIFIER", 150, 155], ["consolidation", "OBSERVATION", 156, 169], ["left", "ANATOMY_MODIFIER", 177, 181]]], ["The upper zone predominance of the bronchocentric ground glass alone is indeterminant for the disease, which again emphasizes the importance of any relevant clinical information.", [["the disease", "PROBLEM", 90, 101], ["upper", "ANATOMY_MODIFIER", 4, 9], ["zone", "OBSERVATION_MODIFIER", 10, 14], ["predominance", "OBSERVATION_MODIFIER", 15, 27], ["bronchocentric", "OBSERVATION_MODIFIER", 35, 49], ["ground glass", "OBSERVATION", 50, 62], ["indeterminant", "OBSERVATION_MODIFIER", 72, 85], ["disease", "OBSERVATION", 94, 101]]], ["The dense consolidation is central and unilateral affecting the left lung only, which makes it more likely to be bacterial infection than COVID-19 infection.", [["left lung", "ANATOMY", 64, 73], ["infection", "DISEASE", 123, 132], ["COVID-19", "CHEMICAL", 138, 146], ["infection", "DISEASE", 147, 156], ["lung", "ORGAN", 69, 73], ["COVID-19", "ORGANISM", 138, 146], ["COVID-19", "SPECIES", 138, 146], ["The dense consolidation", "PROBLEM", 0, 23], ["bacterial infection", "PROBLEM", 113, 132], ["COVID-19 infection", "PROBLEM", 138, 156], ["dense", "OBSERVATION_MODIFIER", 4, 9], ["consolidation", "OBSERVATION", 10, 23], ["central", "OBSERVATION_MODIFIER", 27, 34], ["unilateral", "OBSERVATION_MODIFIER", 39, 49], ["left lung", "ANATOMY", 64, 73], ["makes it more likely to be", "UNCERTAINTY", 86, 112], ["bacterial", "OBSERVATION_MODIFIER", 113, 122], ["infection", "OBSERVATION", 123, 132], ["infection", "OBSERVATION", 147, 156]]], ["No pulmonary embolus was present.", [["pulmonary embolus", "ANATOMY", 3, 20], ["pulmonary embolus", "DISEASE", 3, 20], ["pulmonary", "ORGAN", 3, 12], ["pulmonary embolus", "PROBLEM", 3, 20], ["pulmonary", "ANATOMY", 3, 12], ["embolus", "OBSERVATION", 13, 20]]], ["This patient had COVID-19 and bacterial infections with fluid overload.The diagnostic challengesThese cases demonstrate the complexity of separating features of concurrent COVID-19 pneumonia with heart failure and the possibility of additional infection.", [["fluid", "ANATOMY", 56, 61], ["heart", "ANATOMY", 196, 201], ["bacterial infections", "DISEASE", 30, 50], ["fluid overload", "DISEASE", 56, 70], ["pneumonia", "DISEASE", 181, 190], ["heart failure", "DISEASE", 196, 209], ["infection", "DISEASE", 244, 253], ["patient", "ORGANISM", 5, 12], ["fluid", "ORGANISM_SUBSTANCE", 56, 61], ["heart", "ORGAN", 196, 201], ["patient", "SPECIES", 5, 12], ["COVID", "TEST", 17, 22], ["bacterial infections", "PROBLEM", 30, 50], ["fluid overload", "PROBLEM", 56, 70], ["concurrent COVID-19 pneumonia", "PROBLEM", 161, 190], ["heart failure", "PROBLEM", 196, 209], ["additional infection", "PROBLEM", 233, 253], ["bacterial", "OBSERVATION_MODIFIER", 30, 39], ["infections", "OBSERVATION", 40, 50], ["fluid overload", "OBSERVATION", 56, 70], ["pneumonia", "OBSERVATION", 181, 190], ["heart", "ANATOMY", 196, 201], ["failure", "OBSERVATION", 202, 209], ["possibility of", "UNCERTAINTY", 218, 232], ["additional", "OBSERVATION_MODIFIER", 233, 243], ["infection", "OBSERVATION", 244, 253]]], ["It is important for the radiologist to identify from the multitude of abnormalities, the individual features of each co-existing condition to help determine the diagnoses and to guide their management.COVID-19 and other infectionsDuring the pandemic, almost every request for chest imaging includes the possibility of COVID-19 infection.", [["chest", "ANATOMY", 276, 281], ["infections", "DISEASE", 220, 230], ["infection", "DISEASE", 327, 336], ["chest", "ORGAN", 276, 281], ["COVID-19", "GENE_OR_GENE_PRODUCT", 318, 326], ["abnormalities", "PROBLEM", 70, 83], ["their management", "TREATMENT", 184, 200], ["COVID", "TEST", 201, 206], ["other infections", "PROBLEM", 214, 230], ["chest imaging", "TEST", 276, 289], ["COVID-19 infection", "PROBLEM", 318, 336], ["abnormalities", "OBSERVATION", 70, 83], ["infections", "OBSERVATION", 220, 230], ["chest", "ANATOMY", 276, 281], ["infection", "OBSERVATION", 327, 336]]], ["However, radiologists still need to remain vigilant in identifying other types of infection that could be misinterpreted as COVID-19.", [["infection", "DISEASE", 82, 91], ["infection", "PROBLEM", 82, 91], ["COVID", "TEST", 124, 129], ["infection", "OBSERVATION", 82, 91]]], ["Patient G presented with cough and fever.", [["cough", "DISEASE", 25, 30], ["fever", "DISEASE", 35, 40], ["Patient", "SPECIES", 0, 7], ["cough", "PROBLEM", 25, 30], ["fever", "PROBLEM", 35, 40], ["cough", "OBSERVATION", 25, 30], ["fever", "OBSERVATION", 35, 40]]], ["The CT scan showed predominantly left upper lobe central ground glass opacification (Figure 6a ).", [["left upper lobe", "ANATOMY", 33, 48], ["The CT scan", "TEST", 0, 11], ["predominantly left upper lobe central ground glass opacification", "PROBLEM", 19, 83], ["predominantly", "OBSERVATION_MODIFIER", 19, 32], ["left upper lobe", "ANATOMY", 33, 48], ["central", "ANATOMY_MODIFIER", 49, 56], ["ground glass opacification", "OBSERVATION", 57, 83]]], ["This feature would favour lobar pneumonia, but COVID-19 infection is not completely excluded since it can also produce upper zone central ground glass opacification.", [["lobar", "ANATOMY", 26, 31], ["pneumonia", "DISEASE", 32, 41], ["COVID-19", "CHEMICAL", 47, 55], ["infection", "DISEASE", 56, 65], ["lobar pneumonia", "PROBLEM", 26, 41], ["COVID", "TEST", 47, 52], ["19 infection", "PROBLEM", 53, 65], ["upper zone central ground glass opacification", "PROBLEM", 119, 164], ["lobar", "OBSERVATION_MODIFIER", 26, 31], ["pneumonia", "OBSERVATION", 32, 41], ["infection", "OBSERVATION", 56, 65], ["not completely excluded", "UNCERTAINTY", 69, 92], ["upper", "ANATOMY_MODIFIER", 119, 124], ["zone", "ANATOMY_MODIFIER", 125, 129], ["central", "ANATOMY_MODIFIER", 130, 137], ["ground glass opacification", "OBSERVATION", 138, 164]]], ["This requires detailed inspection of the rest of the CT for features of lymphadenopathy, bronchiectasis, bronchial wall thickening, and mucus plugging in the area of ground glass (Figure 6b .", [["bronchial wall", "ANATOMY", 105, 119], ["mucus", "ANATOMY", 136, 141], ["lymphadenopathy", "DISEASE", 72, 87], ["bronchiectasis", "DISEASE", 89, 103], ["lymphadenopathy", "PATHOLOGICAL_FORMATION", 72, 87], ["mucus", "PATHOLOGICAL_FORMATION", 136, 141], ["the CT", "TEST", 49, 55], ["lymphadenopathy", "PROBLEM", 72, 87], ["bronchiectasis", "PROBLEM", 89, 103], ["bronchial wall thickening", "PROBLEM", 105, 130], ["mucus plugging", "PROBLEM", 136, 150], ["lymphadenopathy", "OBSERVATION", 72, 87], ["bronchiectasis", "OBSERVATION", 89, 103], ["bronchial", "ANATOMY", 105, 114], ["wall", "ANATOMY_MODIFIER", 115, 119], ["thickening", "OBSERVATION", 120, 130], ["mucus plugging", "OBSERVATION", 136, 150], ["area", "OBSERVATION_MODIFIER", 158, 162], ["ground glass", "OBSERVATION", 166, 178]]], ["Patient D's CT (4a) showed bilateral pleural effusions with patchy ground glass and ground glass nodularity (arrows), which is more common in bacterial infections, or if someone is immunocompromised, fungal infection is also a possibility.", [["pleural effusions", "ANATOMY", 37, 54], ["pleural effusions", "DISEASE", 37, 54], ["bacterial infections", "DISEASE", 142, 162], ["fungal infection", "DISEASE", 200, 216], ["pleural effusions", "PATHOLOGICAL_FORMATION", 37, 54], ["Patient", "SPECIES", 0, 7], ["Patient D's CT (4a)", "TEST", 0, 19], ["bilateral pleural effusions", "PROBLEM", 27, 54], ["patchy ground glass", "PROBLEM", 60, 79], ["ground glass nodularity", "PROBLEM", 84, 107], ["bacterial infections", "PROBLEM", 142, 162], ["immunocompromised", "PROBLEM", 181, 198], ["fungal infection", "PROBLEM", 200, 216], ["bilateral", "ANATOMY_MODIFIER", 27, 36], ["pleural", "ANATOMY", 37, 44], ["effusions", "OBSERVATION", 45, 54], ["patchy", "OBSERVATION_MODIFIER", 60, 66], ["ground glass", "OBSERVATION", 67, 79], ["ground glass nodularity", "OBSERVATION", 84, 107], ["more common", "OBSERVATION_MODIFIER", 127, 138], ["bacterial", "OBSERVATION_MODIFIER", 142, 151], ["infections", "OBSERVATION", 152, 162], ["fungal", "OBSERVATION_MODIFIER", 200, 206], ["infection", "OBSERVATION", 207, 216], ["also a possibility", "UNCERTAINTY", 220, 238]]], ["Patient E's CT (4b) showed bilateral small pleural effusions with bronchocentric ground glass opacification, which in the right clinical context it could be supportive of COVID-19 pneumonia. sepsis and cough.", [["pleural effusions", "ANATOMY", 43, 60], ["pleural effusions", "DISEASE", 43, 60], ["pneumonia", "DISEASE", 180, 189], ["sepsis", "DISEASE", 191, 197], ["cough", "DISEASE", 202, 207], ["pleural effusions", "PATHOLOGICAL_FORMATION", 43, 60], ["Patient", "SPECIES", 0, 7], ["Patient E's CT (4b)", "TEST", 0, 19], ["bilateral small pleural effusions", "PROBLEM", 27, 60], ["bronchocentric ground glass opacification", "PROBLEM", 66, 107], ["COVID-19 pneumonia", "PROBLEM", 171, 189], ["sepsis", "PROBLEM", 191, 197], ["cough", "PROBLEM", 202, 207], ["bilateral", "ANATOMY_MODIFIER", 27, 36], ["small", "OBSERVATION_MODIFIER", 37, 42], ["pleural", "ANATOMY", 43, 50], ["effusions", "OBSERVATION", 51, 60], ["bronchocentric", "OBSERVATION_MODIFIER", 66, 80], ["ground glass opacification", "OBSERVATION", 81, 107], ["right", "ANATOMY_MODIFIER", 122, 127], ["pneumonia", "OBSERVATION", 180, 189], ["cough", "OBSERVATION", 202, 207]]], ["His CT showed mucus plugging and nodular ground glass in the left lung apex (Figure 7a) , which is most likely due to bacterial infection.", [["mucus", "ANATOMY", 14, 19], ["left lung apex", "ANATOMY", 61, 75], ["bacterial infection", "DISEASE", 118, 137], ["mucus", "TISSUE", 14, 19], ["lung apex", "MULTI-TISSUE_STRUCTURE", 66, 75], ["His CT", "TEST", 0, 6], ["mucus plugging", "PROBLEM", 14, 28], ["nodular ground glass in the left lung apex", "PROBLEM", 33, 75], ["bacterial infection", "PROBLEM", 118, 137], ["mucus plugging", "OBSERVATION", 14, 28], ["nodular", "OBSERVATION_MODIFIER", 33, 40], ["ground glass", "OBSERVATION", 41, 53], ["left", "ANATOMY_MODIFIER", 61, 65], ["lung", "ANATOMY", 66, 70], ["apex", "ANATOMY_MODIFIER", 71, 75], ["most likely due to", "UNCERTAINTY", 99, 117], ["bacterial", "OBSERVATION_MODIFIER", 118, 127], ["infection", "OBSERVATION", 128, 137]]], ["Furthermore, there were mass-like consolidation in the rest of the lungs (Figure 7b There are also situations in which it is not possible to distinguish COVID-19 infection from other infections.", [["lungs", "ANATOMY", 67, 72], ["infection", "DISEASE", 162, 171], ["infections", "DISEASE", 183, 193], ["lungs", "ORGAN", 67, 72], ["COVID-19", "CELL", 153, 161], ["COVID-19", "SPECIES", 153, 161], ["mass-like consolidation", "PROBLEM", 24, 47], ["COVID-19 infection", "PROBLEM", 153, 171], ["other infections", "PROBLEM", 177, 193], ["mass", "OBSERVATION", 24, 28], ["like", "OBSERVATION_MODIFIER", 29, 33], ["consolidation", "OBSERVATION", 34, 47], ["rest of", "ANATOMY_MODIFIER", 55, 62], ["lungs", "ANATOMY", 67, 72], ["not possible", "UNCERTAINTY", 125, 137], ["infection", "OBSERVATION", 162, 171], ["infections", "OBSERVATION", 183, 193]]], ["Patient J was newly diagnosed with HIV and presented with fever and cough.", [["fever", "DISEASE", 58, 63], ["cough", "DISEASE", 68, 73], ["HIV", "ORGANISM", 35, 38], ["Patient", "SPECIES", 0, 7], ["HIV", "SPECIES", 35, 38], ["HIV", "SPECIES", 35, 38], ["HIV", "PROBLEM", 35, 38], ["fever", "PROBLEM", 58, 63], ["cough", "PROBLEM", 68, 73], ["HIV", "OBSERVATION", 35, 38], ["fever", "OBSERVATION", 58, 63], ["cough", "OBSERVATION", 68, 73]]], ["The chest CT showed bilateral apical to basal patchy ground glass opacification, slightly worse in the lower lobes (Figure 9a-c) .", [["chest", "ANATOMY", 4, 9], ["lower lobes", "ANATOMY", 103, 114], ["The chest CT", "TEST", 0, 12], ["bilateral apical to basal patchy ground glass opacification", "PROBLEM", 20, 79], ["chest", "ANATOMY", 4, 9], ["bilateral", "ANATOMY_MODIFIER", 20, 29], ["apical", "ANATOMY_MODIFIER", 30, 36], ["basal", "ANATOMY_MODIFIER", 40, 45], ["patchy", "OBSERVATION_MODIFIER", 46, 52], ["ground glass opacification", "OBSERVATION", 53, 79], ["slightly", "OBSERVATION_MODIFIER", 81, 89], ["worse", "OBSERVATION_MODIFIER", 90, 95], ["lower lobes", "ANATOMY", 103, 114]]], ["The pattern is non-specific and may be due to various opportunistic organisms especially other viruses.", [["various opportunistic organisms", "PROBLEM", 46, 77], ["other viruses", "PROBLEM", 89, 102], ["non-specific", "OBSERVATION_MODIFIER", 15, 27], ["may be due to", "UNCERTAINTY", 32, 45]]], ["His blood results revealed a low haemoglobin (73 g l \u22121 ), low platelets (5 \u00d7 10 9 /L), and neutropaenia (non-detectable level).", [["blood", "ANATOMY", 4, 9], ["platelets", "ANATOMY", 63, 72], ["neutropaenia", "DISEASE", 92, 104], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["platelets", "CELL", 63, 72], ["platelets", "CELL_TYPE", 63, 72], ["His blood", "TEST", 0, 9], ["a low haemoglobin", "PROBLEM", 27, 44], ["low platelets", "PROBLEM", 59, 72], ["neutropaenia", "PROBLEM", 92, 104], ["low haemoglobin", "OBSERVATION_MODIFIER", 29, 44], ["low platelets", "OBSERVATION_MODIFIER", 59, 72]]], ["The cytopaenic pattern was suggestive of haemophagocytic lymphohistiocytosis (HLH).", [["haemophagocytic lymphohistiocytosis", "DISEASE", 41, 76], ["HLH", "DISEASE", 78, 81], ["haemophagocytic lymphohistiocytosis", "CANCER", 41, 76], ["The cytopaenic pattern", "TEST", 0, 22], ["haemophagocytic lymphohistiocytosis", "PROBLEM", 41, 76], ["HLH", "PROBLEM", 78, 81], ["suggestive of", "UNCERTAINTY", 27, 40], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 41, 76]]], ["Later, he was confirmed to have Epstein-Barr viral infection, which is one of the secondary causes of HLH.", [["Epstein-Barr viral infection", "DISEASE", 32, 60], ["HLH", "DISEASE", 102, 105], ["Epstein-Barr viral", "ORGANISM", 32, 50], ["Epstein", "PROBLEM", 32, 39], ["Barr viral infection", "PROBLEM", 40, 60], ["HLH", "PROBLEM", 102, 105], ["Epstein", "OBSERVATION", 32, 39], ["Barr viral infection", "OBSERVATION", 40, 60], ["HLH", "OBSERVATION", 102, 105]]], ["10 He had multiple negative RT-PCR test results.", [["PCR test", "TEST", 31, 39]]], ["This case illustrates the importance of radiologists keeping an open mind for other infections during the COVID-19 pandemic.", [["infections", "DISEASE", 84, 94], ["other infections", "PROBLEM", 78, 94], ["the COVID", "TEST", 102, 111], ["pandemic", "PROBLEM", 115, 123], ["infections", "OBSERVATION", 84, 94]]], ["Chest CT showed predominately bronchocentric ground glass opacification in the right upper lobe and middle lobe with bilateral pleural effusions and dense consolidation on the left (5a-c).", [["right upper lobe", "ANATOMY", 79, 95], ["middle lobe", "ANATOMY", 100, 111], ["pleural effusions", "ANATOMY", 127, 144], ["pleural effusions", "DISEASE", 127, 144], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 85, 95], ["lobe", "ORGAN", 107, 111], ["pleural effusions", "PATHOLOGICAL_FORMATION", 127, 144], ["Chest CT", "TEST", 0, 8], ["predominately bronchocentric ground glass opacification in the right upper lobe and middle lobe", "PROBLEM", 16, 111], ["bilateral pleural effusions", "PROBLEM", 117, 144], ["dense consolidation on the left", "PROBLEM", 149, 180], ["predominately", "OBSERVATION_MODIFIER", 16, 29], ["bronchocentric", "OBSERVATION_MODIFIER", 30, 44], ["ground glass opacification", "OBSERVATION", 45, 71], ["right upper lobe", "ANATOMY", 79, 95], ["middle lobe", "ANATOMY", 100, 111], ["bilateral", "ANATOMY_MODIFIER", 117, 126], ["pleural", "ANATOMY", 127, 134], ["effusions", "OBSERVATION", 135, 144], ["dense", "OBSERVATION_MODIFIER", 149, 154], ["consolidation", "OBSERVATION", 155, 168], ["left", "ANATOMY_MODIFIER", 176, 180]]], ["The CT showed predominantly left upper lobe central ground glass opacification (6a), which would favour lobar pneumonia, but COVID-19 infection is not completely excluded since it can also produce upper zone central ground glass opacification.", [["left upper lobe", "ANATOMY", 28, 43], ["lobar", "ANATOMY", 104, 109], ["pneumonia", "DISEASE", 110, 119], ["infection", "DISEASE", 134, 143], ["The CT", "TEST", 0, 6], ["predominantly left upper lobe central ground glass opacification", "PROBLEM", 14, 78], ["lobar pneumonia", "PROBLEM", 104, 119], ["COVID", "TEST", 125, 130], ["19 infection", "PROBLEM", 131, 143], ["upper zone central ground glass opacification", "PROBLEM", 197, 242], ["predominantly", "OBSERVATION_MODIFIER", 14, 27], ["left upper lobe", "ANATOMY", 28, 43], ["central", "ANATOMY_MODIFIER", 44, 51], ["ground glass opacification", "OBSERVATION", 52, 78], ["favour", "UNCERTAINTY", 97, 103], ["lobar", "OBSERVATION_MODIFIER", 104, 109], ["pneumonia", "OBSERVATION", 110, 119], ["infection", "OBSERVATION", 134, 143], ["not completely excluded", "UNCERTAINTY", 147, 170], ["upper", "ANATOMY_MODIFIER", 197, 202], ["zone", "ANATOMY_MODIFIER", 203, 207], ["central", "ANATOMY_MODIFIER", 208, 215], ["ground glass opacification", "OBSERVATION", 216, 242]]], ["Detailed inspection of the rest of the CT showed mucus plugging in the area of ground glass (Fig b, arrow) , which would be consistent with bacterial infection.COVID-19 and traumaAcute thoracic injury, especially direct impact can produce a combination of pulmonary consolidation and ground glass opacification.", [["mucus", "ANATOMY", 49, 54], ["thoracic", "ANATOMY", 185, 193], ["pulmonary", "ANATOMY", 256, 265], ["bacterial infection", "DISEASE", 140, 159], ["COVID-19", "CHEMICAL", 160, 168], ["thoracic injury", "DISEASE", 185, 200], ["mucus", "TISSUE", 49, 54], ["thoracic", "ORGAN", 185, 193], ["pulmonary", "ORGAN", 256, 265], ["Detailed inspection", "TEST", 0, 19], ["the CT", "TEST", 35, 41], ["mucus plugging", "PROBLEM", 49, 63], ["ground glass (Fig b, arrow)", "PROBLEM", 79, 106], ["bacterial infection", "PROBLEM", 140, 159], ["COVID", "TEST", 160, 165], ["traumaAcute thoracic injury", "PROBLEM", 173, 200], ["pulmonary consolidation", "PROBLEM", 256, 279], ["ground glass opacification", "PROBLEM", 284, 310], ["mucus plugging", "OBSERVATION", 49, 63], ["area", "OBSERVATION_MODIFIER", 71, 75], ["ground glass", "OBSERVATION", 79, 91], ["would be consistent with", "UNCERTAINTY", 115, 139], ["bacterial", "OBSERVATION_MODIFIER", 140, 149], ["infection", "OBSERVATION", 150, 159], ["thoracic", "ANATOMY", 185, 193], ["injury", "OBSERVATION", 194, 200], ["pulmonary", "ANATOMY", 256, 265], ["consolidation", "OBSERVATION", 266, 279], ["ground glass opacification", "OBSERVATION", 284, 310]]], ["As a result, traumatic injuries can make the diagnosis of COVID-19 infection challenging.", [["traumatic injuries", "DISEASE", 13, 31], ["COVID-19", "CHEMICAL", 58, 66], ["infection", "DISEASE", 67, 76], ["traumatic injuries", "PROBLEM", 13, 31], ["COVID-19 infection challenging", "PROBLEM", 58, 88], ["infection", "OBSERVATION", 67, 76]]], ["Patient K presented after a fall at a standing height with left-sided chest pain and shortness of breath.", [["chest", "ANATOMY", 70, 75], ["K", "CHEMICAL", 8, 9], ["chest pain", "DISEASE", 70, 80], ["shortness of breath", "DISEASE", 85, 104], ["chest", "ORGANISM_SUBDIVISION", 70, 75], ["Patient", "SPECIES", 0, 7], ["a fall", "PROBLEM", 26, 32], ["left-sided chest pain", "PROBLEM", 59, 80], ["shortness of breath", "PROBLEM", 85, 104], ["left", "ANATOMY_MODIFIER", 59, 63], ["sided", "ANATOMY_MODIFIER", 64, 69], ["chest", "ANATOMY", 70, 75], ["pain", "OBSERVATION", 76, 80]]], ["His trauma CT showed a left-sided pneumothorax with associated left-sided rib fractures (Figure 10a-b) .", [["trauma", "DISEASE", 4, 10], ["pneumothorax", "DISEASE", 34, 46], ["fractures", "DISEASE", 78, 87], ["rib", "ORGAN", 74, 77], ["His trauma CT", "TEST", 0, 13], ["a left-sided pneumothorax", "PROBLEM", 21, 46], ["associated left-sided rib fractures", "PROBLEM", 52, 87], ["left", "ANATOMY_MODIFIER", 23, 27], ["sided", "ANATOMY_MODIFIER", 28, 33], ["pneumothorax", "OBSERVATION", 34, 46], ["left", "ANATOMY_MODIFIER", 63, 67], ["sided", "ANATOMY_MODIFIER", 68, 73], ["rib", "ANATOMY", 74, 77], ["fractures", "OBSERVATION", 78, 87]]], ["There were also bilateral small areas of ground glass opacification and consolidation in the apicoposterior segment of the left upper lobe.", [["apicoposterior segment", "ANATOMY", 93, 115], ["left upper lobe", "ANATOMY", 123, 138], ["apicoposterior segment", "MULTI-TISSUE_STRUCTURE", 93, 115], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 128, 138], ["bilateral small areas of ground glass opacification", "PROBLEM", 16, 67], ["consolidation", "PROBLEM", 72, 85], ["bilateral", "OBSERVATION_MODIFIER", 16, 25], ["small", "OBSERVATION_MODIFIER", 26, 31], ["areas", "OBSERVATION_MODIFIER", 32, 37], ["ground glass opacification", "OBSERVATION", 41, 67], ["consolidation", "OBSERVATION", 72, 85], ["apicoposterior", "ANATOMY_MODIFIER", 93, 107], ["segment", "ANATOMY_MODIFIER", 108, 115], ["left upper lobe", "ANATOMY", 123, 138]]], ["It was possible that the peripherally affected areas were related to the trauma, but the centrally affected areas particularly those in the right lung were incompatible with the acute injuries.", [["right lung", "ANATOMY", 140, 150], ["trauma", "DISEASE", 73, 79], ["acute injuries", "DISEASE", 178, 192], ["lung", "ORGAN", 146, 150], ["the peripherally affected areas", "PROBLEM", 21, 52], ["the trauma", "PROBLEM", 69, 79], ["the centrally affected areas", "PROBLEM", 85, 113], ["the acute injuries", "PROBLEM", 174, 192], ["peripherally", "OBSERVATION_MODIFIER", 25, 37], ["affected", "OBSERVATION_MODIFIER", 38, 46], ["areas", "OBSERVATION", 47, 52], ["trauma", "OBSERVATION", 73, 79], ["centrally", "OBSERVATION_MODIFIER", 89, 98], ["affected", "OBSERVATION_MODIFIER", 99, 107], ["areas", "OBSERVATION", 108, 113], ["right", "ANATOMY_MODIFIER", 140, 145], ["lung", "ANATOMY", 146, 150], ["incompatible with", "UNCERTAINTY", 156, 173], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["injuries", "OBSERVATION", 184, 192]]], ["There was the exception of the right posterior peripheral consolidation (Figure 10b, arrow) .", [["right posterior peripheral", "ANATOMY", 31, 57], ["the right posterior peripheral consolidation", "PROBLEM", 27, 71], ["right", "ANATOMY_MODIFIER", 31, 36], ["posterior", "ANATOMY_MODIFIER", 37, 46], ["peripheral", "ANATOMY_MODIFIER", 47, 57], ["consolidation", "OBSERVATION", 58, 71]]], ["In the context of the traumatic history, contre-coup thoracic injury was the most likely explanation but the absence of subpleural sparing was atypical for acute contusion.", [["thoracic", "ANATOMY", 53, 61], ["subpleural", "ANATOMY", 120, 130], ["traumatic", "DISEASE", 22, 31], ["thoracic injury", "DISEASE", 53, 68], ["contusion", "DISEASE", 162, 171], ["thoracic", "ORGAN", 53, 61], ["subpleural", "PATHOLOGICAL_FORMATION", 120, 130], ["the traumatic history", "PROBLEM", 18, 39], ["contre-coup thoracic injury", "PROBLEM", 41, 68], ["subpleural sparing", "PROBLEM", 120, 138], ["acute contusion", "PROBLEM", 156, 171], ["traumatic", "OBSERVATION_MODIFIER", 22, 31], ["thoracic", "ANATOMY", 53, 61], ["injury", "OBSERVATION", 62, 68], ["most likely explanation", "UNCERTAINTY", 77, 100], ["subpleural", "ANATOMY", 120, 130], ["sparing", "OBSERVATION", 131, 138], ["atypical for", "UNCERTAINTY", 143, 155], ["acute", "OBSERVATION_MODIFIER", 156, 161], ["contusion", "OBSERVATION", 162, 171]]], ["COVID pneumonia or bacterial infection were possibilities.", [["pneumonia", "DISEASE", 6, 15], ["bacterial infection", "DISEASE", 19, 38], ["COVID pneumonia", "PROBLEM", 0, 15], ["bacterial infection", "PROBLEM", 19, 38], ["pneumonia", "OBSERVATION", 6, 15], ["bacterial", "OBSERVATION_MODIFIER", 19, 28], ["infection", "OBSERVATION", 29, 38]]], ["Further questioning revealed that the patient had a fever for the last 14 days, and he later tested positive for COVID-19 infection only.", [["fever", "DISEASE", 52, 57], ["COVID-19", "CHEMICAL", 113, 121], ["infection", "DISEASE", 122, 131], ["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["a fever", "PROBLEM", 50, 57], ["COVID", "TEST", 113, 118], ["19 infection", "PROBLEM", 119, 131], ["fever", "OBSERVATION", 52, 57], ["infection", "OBSERVATION", 122, 131]]], ["No other organism was isolated.", [["other organism", "PROBLEM", 3, 17], ["organism", "OBSERVATION", 9, 17]]], ["A summary of the findings from Patient A to K have been presented in Table 1 .CONCLUSIONThe classic CT patterns of COVID-19 pneumonia have been well-reported and are now more readily recognised by radiologists.", [["pneumonia", "DISEASE", 124, 133], ["classic CT patterns", "TEST", 92, 111], ["COVID", "TEST", 115, 120], ["pneumonia", "PROBLEM", 124, 133], ["pneumonia", "OBSERVATION", 124, 133]]], ["However, a confident diagnosis of COVID-19 pneumonia can become difficult when there are concurrent conditions which may result in similar patterns of disease.", [["COVID", "DISEASE", 34, 39], ["pneumonia", "DISEASE", 43, 52], ["COVID-19 pneumonia", "PROBLEM", 34, 52], ["concurrent conditions", "PROBLEM", 89, 110], ["disease", "PROBLEM", 151, 158], ["pneumonia", "OBSERVATION", 43, 52], ["disease", "OBSERVATION", 151, 158]]], ["In these cases, the imaging must be scrutinised carefully.", [["the imaging", "TEST", 16, 27]]], ["During the peak and recovery phases of the pandemic, radiologists must remain vigilant to enable the correct diagnosis of COVID-19 pneumonia to be made and distinguished from its mimics.LEARNING POINTS1.", [["COVID", "DISEASE", 122, 127], ["pneumonia", "DISEASE", 131, 140], ["POINTS1", "PROTEIN", 195, 202], ["COVID", "TEST", 122, 127], ["pneumonia", "PROBLEM", 131, 140], ["pneumonia", "OBSERVATION", 131, 140]]], ["All radiologists should be aware of the typical and atypical CT patterns of COVID-19 pneumonia.", [["pneumonia", "DISEASE", 85, 94], ["COVID", "TEST", 76, 81], ["pneumonia", "PROBLEM", 85, 94], ["pneumonia", "OBSERVATION", 85, 94]]], ["Pre-existing conditions and traumatic thoracic injuries can make the diagnosis challenging.", [["thoracic", "ANATOMY", 38, 46], ["traumatic thoracic injuries", "DISEASE", 28, 55], ["thoracic", "ORGAN", 38, 46], ["Pre-existing conditions", "PROBLEM", 0, 23], ["traumatic thoracic injuries", "PROBLEM", 28, 55], ["traumatic", "OBSERVATION_MODIFIER", 28, 37], ["thoracic", "ANATOMY", 38, 46], ["injuries", "OBSERVATION", 47, 55]]], ["Other types of infection particularly viral can be difficult to distinguish from COVID-19 pneumonia.", [["infection", "DISEASE", 15, 24], ["pneumonia", "DISEASE", 90, 99], ["COVID-19", "SPECIES", 81, 89], ["infection", "PROBLEM", 15, 24], ["viral", "PROBLEM", 38, 43], ["COVID", "TEST", 81, 86], ["pneumonia", "PROBLEM", 90, 99], ["infection", "OBSERVATION", 15, 24], ["pneumonia", "OBSERVATION", 90, 99]]], ["Subtle imaging clues should be scrutinised carefully to identify the non-COVID-19 conditions that may mask or contribute to similar disease pattern.", [["Subtle imaging clues", "TEST", 0, 20], ["similar disease pattern", "PROBLEM", 124, 147], ["similar", "OBSERVATION_MODIFIER", 124, 131], ["disease", "OBSERVATION", 132, 139]]], ["Patient was newly diagnosed with HIV and presented with fever and cough.", [["fever", "DISEASE", 56, 61], ["cough", "DISEASE", 66, 71], ["HIV", "ORGANISM", 33, 36], ["Patient", "SPECIES", 0, 7], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 33, 36], ["HIV", "PROBLEM", 33, 36], ["fever", "PROBLEM", 56, 61], ["cough", "PROBLEM", 66, 71], ["HIV", "OBSERVATION", 33, 36], ["fever", "OBSERVATION", 56, 61], ["cough", "OBSERVATION", 66, 71]]], ["The chest CT showed bilateral patchy ground glass opacification and slightly worse in the lower lobes (9a-c).", [["chest", "ANATOMY", 4, 9], ["lower lobes", "ANATOMY", 90, 101], ["The chest CT", "TEST", 0, 12], ["bilateral patchy ground glass opacification", "PROBLEM", 20, 63], ["slightly worse in the lower lobes", "PROBLEM", 68, 101], ["chest", "ANATOMY", 4, 9], ["bilateral", "ANATOMY_MODIFIER", 20, 29], ["patchy", "OBSERVATION_MODIFIER", 30, 36], ["ground glass opacification", "OBSERVATION", 37, 63], ["slightly", "OBSERVATION_MODIFIER", 68, 76], ["worse", "OBSERVATION_MODIFIER", 77, 82], ["lower lobes", "ANATOMY", 90, 101]]], ["The pattern is non-specific and could be due to various opportunistic organisms.", [["various opportunistic organisms", "PROBLEM", 48, 79], ["non-specific", "OBSERVATION_MODIFIER", 15, 27], ["could be due to", "UNCERTAINTY", 32, 47], ["various", "OBSERVATION_MODIFIER", 48, 55], ["opportunistic organisms", "OBSERVATION", 56, 79]]], ["Later, he was confirmed to have Epstein-Barr viral infection, which induced HLH.", [["Epstein-Barr viral infection", "DISEASE", 32, 60], ["HLH", "DISEASE", 76, 79], ["Epstein-Barr viral", "ORGANISM", 32, 50], ["Epstein", "PROBLEM", 32, 39], ["Barr viral infection", "PROBLEM", 40, 60], ["HLH", "PROBLEM", 76, 79], ["Epstein", "OBSERVATION", 32, 39], ["Barr viral infection", "OBSERVATION", 40, 60], ["HLH", "OBSERVATION", 76, 79]]], ["HLH, haemophagocytic lymphohistiocytosis.", [["HLH", "DISEASE", 0, 3], ["haemophagocytic lymphohistiocytosis", "DISEASE", 5, 40], ["HLH", "PROBLEM", 0, 3], ["haemophagocytic lymphohistiocytosis", "PROBLEM", 5, 40], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 5, 40]]], ["Patient with fall onto left side and trauma CT showed left-sided pneumothorax with associated left-sided rib fractures (10a-b).", [["left side", "ANATOMY", 23, 32], ["trauma", "DISEASE", 37, 43], ["pneumothorax", "DISEASE", 65, 77], ["fractures", "DISEASE", 109, 118], ["rib", "ORGAN", 105, 108], ["Patient", "SPECIES", 0, 7], ["fall onto left side", "PROBLEM", 13, 32], ["trauma CT", "TEST", 37, 46], ["left-sided pneumothorax", "PROBLEM", 54, 77], ["associated left-sided rib fractures", "PROBLEM", 83, 118], ["left", "ANATOMY_MODIFIER", 54, 58], ["sided", "ANATOMY_MODIFIER", 59, 64], ["pneumothorax", "OBSERVATION", 65, 77], ["left", "ANATOMY_MODIFIER", 94, 98], ["sided", "ANATOMY_MODIFIER", 99, 104], ["rib", "ANATOMY", 105, 108], ["fractures", "OBSERVATION", 109, 118]]], ["The centrally affected areas particularly those in the right lung were most likely from COVID-19 infection.The right posterior peripheral consolidation (arrow) could be from contre-coup injury, but infective consolidation was also possible given the absence of subpleural sparing for acute contusion.", [["right lung", "ANATOMY", 55, 65], ["right posterior peripheral", "ANATOMY", 111, 137], ["subpleural", "ANATOMY", 261, 271], ["infection", "DISEASE", 97, 106], ["contusion", "DISEASE", 290, 299], ["lung", "ORGAN", 61, 65], ["posterior peripheral", "MULTI-TISSUE_STRUCTURE", 117, 137], ["subpleural", "TISSUE", 261, 271], ["The centrally affected areas", "PROBLEM", 0, 28], ["COVID-19 infection", "PROBLEM", 88, 106], ["The right posterior peripheral consolidation", "PROBLEM", 107, 151], ["contre-coup injury", "PROBLEM", 174, 192], ["infective consolidation", "PROBLEM", 198, 221], ["subpleural sparing", "PROBLEM", 261, 279], ["acute contusion", "PROBLEM", 284, 299], ["centrally", "OBSERVATION_MODIFIER", 4, 13], ["affected", "OBSERVATION_MODIFIER", 14, 22], ["areas", "OBSERVATION", 23, 28], ["right", "ANATOMY_MODIFIER", 55, 60], ["lung", "ANATOMY", 61, 65], ["most likely", "UNCERTAINTY", 71, 82], ["infection", "OBSERVATION", 97, 106], ["right", "ANATOMY_MODIFIER", 111, 116], ["posterior", "ANATOMY_MODIFIER", 117, 126], ["peripheral", "ANATOMY_MODIFIER", 127, 137], ["consolidation", "OBSERVATION", 138, 151], ["coup", "OBSERVATION_MODIFIER", 181, 185], ["injury", "OBSERVATION", 186, 192], ["infective", "OBSERVATION_MODIFIER", 198, 207], ["consolidation", "OBSERVATION", 208, 221], ["subpleural", "ANATOMY", 261, 271], ["acute", "OBSERVATION_MODIFIER", 284, 289], ["contusion", "OBSERVATION", 290, 299]]]], "b40159b406d4be046f9e60d3ed65d94ea46879fb": [["Looming threat of COVID-19 infection in Africa: act collectively, and fastBecause of the high volume of air traffic and trade between China and Africa, 1 Africa is at a high risk for the introduction and spread of the novel coronavirus disease 2019 (COVID-19); although only Egypt has reported the first case, from a non-national.", [["COVID-19", "CHEMICAL", 18, 26], ["infection", "DISEASE", 27, 36], ["coronavirus disease", "DISEASE", 224, 243], ["COVID-19", "ORGANISM", 18, 26], ["COVID", "TEST", 18, 23], ["the high volume of air traffic", "PROBLEM", 85, 115], ["the novel coronavirus disease", "PROBLEM", 214, 243], ["COVID", "TEST", 250, 255], ["infection", "OBSERVATION", 27, 36], ["air traffic", "OBSERVATION", 104, 115]]], ["2 The greatest concern for public health experts is whether COVID-19 will become a pandemic, with sustained year-round transmission, similar to influenza, as is now being observed in several countries.", [["influenza", "DISEASE", 144, 153], ["COVID", "TEST", 60, 65], ["a pandemic", "PROBLEM", 81, 91], ["influenza", "PROBLEM", 144, 153], ["greatest", "OBSERVATION_MODIFIER", 6, 14], ["influenza", "OBSERVATION", 144, 153]]], ["3 What might happen to Africa-where most countries have weak health-care systems, including inadequate surveillance and laboratory capacity, scarcity of public health human resources, and limited financial means-if a pandemic occurs?", [["human", "ORGANISM", 167, 172], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["laboratory capacity", "TEST", 120, 139]]], ["With neither treatment nor vaccines, and without pre-existing immunity, the effect might be devastating because of the multiple health challenges the continent already faces: rapid population growth and increased movement of people; existing endemic diseases, such as human immunodeficiency virus, tuberculosis, and malaria; remerging and emerging infectious pathogens such as Ebola virus disease, Lassa haemorrhagic fever, and others; and increasing incidence of non-communicable diseases.Looming threat of COVID-19 infection in Africa: act collectively, and fastModels that enable the continent to better allocate scarce resources to better prepare and respond to the COVID-19 epidemic are crucial.", [["human immunodeficiency virus", "DISEASE", 268, 296], ["tuberculosis", "DISEASE", 298, 310], ["malaria", "DISEASE", 316, 323], ["infectious pathogens", "DISEASE", 348, 368], ["Ebola virus disease", "DISEASE", 377, 396], ["Lassa haemorrhagic fever", "DISEASE", 398, 422], ["non-communicable diseases", "DISEASE", 464, 489], ["COVID-19", "CHEMICAL", 508, 516], ["infection", "DISEASE", 517, 526], ["people", "ORGANISM", 225, 231], ["human immunodeficiency virus", "ORGANISM", 268, 296], ["Ebola virus", "ORGANISM", 377, 388], ["COVID-19", "ORGANISM", 508, 516], ["people", "SPECIES", 225, 231], ["human immunodeficiency virus", "SPECIES", 268, 296], ["Ebola virus", "SPECIES", 377, 388], ["Lassa haemorrhagic fever", "SPECIES", 398, 422], ["human immunodeficiency virus", "SPECIES", 268, 296], ["Ebola virus", "SPECIES", 377, 388], ["neither treatment", "TREATMENT", 5, 22], ["vaccines", "TREATMENT", 27, 35], ["rapid population growth", "PROBLEM", 175, 198], ["increased movement of people", "PROBLEM", 203, 231], ["existing endemic diseases", "PROBLEM", 233, 258], ["human immunodeficiency virus", "PROBLEM", 268, 296], ["tuberculosis", "PROBLEM", 298, 310], ["malaria", "PROBLEM", 316, 323], ["remerging", "PROBLEM", 325, 334], ["emerging infectious pathogens", "PROBLEM", 339, 368], ["Ebola virus disease", "PROBLEM", 377, 396], ["Lassa haemorrhagic fever", "PROBLEM", 398, 422], ["non-communicable diseases", "PROBLEM", 464, 489], ["COVID", "TEST", 508, 513], ["the COVID", "TEST", 666, 675], ["increased", "OBSERVATION_MODIFIER", 203, 212], ["movement", "OBSERVATION_MODIFIER", 213, 221], ["endemic diseases", "OBSERVATION", 242, 258], ["tuberculosis", "OBSERVATION", 298, 310], ["malaria", "OBSERVATION", 316, 323], ["infectious", "OBSERVATION_MODIFIER", 348, 358], ["Ebola virus", "OBSERVATION", 377, 388], ["Lassa", "OBSERVATION_MODIFIER", 398, 403], ["increasing", "OBSERVATION_MODIFIER", 440, 450], ["non-communicable diseases", "OBSERVATION", 464, 489], ["infection", "OBSERVATION", 517, 526]]], ["The modelling study by Marius Gilbert and colleagues in The Lancet 4 identifies each African country's risk of importation of COVID-19 from China, using data on the volume of air travel from three airports in provinces in China to African countries.", [["The modelling study", "TEST", 0, 19], ["COVID", "TEST", 126, 131], ["air", "OBSERVATION", 175, 178]]], ["Gilbert and colleagues use two indicators to determine the capacity of countries to detect and respond to cases: preparedness, using the WHO International Health Regulations Moni toring and Evaluation Framework; and vulnerability, using the Infectious Disease Vulnerability Index.", [["Infectious Disease", "DISEASE", 241, 259], ["Infectious", "OBSERVATION", 241, 251]]], ["Based on their analysis, Egypt, Algeria, and South Africa had the highest importation risk, and a moderate to high capacity to respond to outbreaks.", [["their analysis", "TEST", 9, 23], ["a moderate to high capacity", "PROBLEM", 96, 123], ["moderate", "OBSERVATION_MODIFIER", 98, 106], ["high capacity", "OBSERVATION_MODIFIER", 110, 123]]], ["Nigeria, Ethiopia, Sudan, Angola, Tanzania, Ghana, and Kenya had moderate risk with variable capacity and high vulnerability.", [["variable capacity", "PROBLEM", 84, 101], ["high vulnerability", "PROBLEM", 106, 124], ["moderate", "OBSERVATION_MODIFIER", 65, 73], ["variable capacity", "OBSERVATION", 84, 101], ["high vulnerability", "OBSERVATION", 106, 124]]], ["The study provides a valuable tool that can help countries in Africa prioritise and allocate resources as they prepare to respond to the potential introduction and spread of COVID-19.Looming threat of COVID-19 infection in Africa: act collectively, and fastThe study should also be interpreted in light of the fast-evolving nature of the COVID-19 outbreak.", [["COVID-19", "CHEMICAL", 201, 209], ["infection", "DISEASE", 210, 219], ["COVID-19", "CHEMICAL", 174, 182], ["COVID-19", "ORGANISM", 201, 209], ["The study", "TEST", 0, 9], ["COVID", "TEST", 174, 179], ["COVID", "TEST", 201, 206], ["The study", "TEST", 257, 266], ["the COVID", "TEST", 334, 343], ["infection", "OBSERVATION", 210, 219]]], ["First, with the exception of Ethiopian airlines, all African airlines have suspended flights to China.", [["Ethiopian airlines", "OBSERVATION", 29, 47]]], ["Although these measures might delay, but not stop, 5 the importation risk of COVID-19 into Africa, their implementation is still worthwhile.", [["COVID-19", "CHEMICAL", 77, 85], ["COVID", "TEST", 77, 82]]], ["Second, although Beijing, Shanghai, and Fujian do not report the highest number of cases of COVID-19 in China, the volume of travel from these cities to Africa is high, which might increase the risk of exporting cases to Africa.", [["COVID", "TEST", 92, 97]]], ["Lastly, almost half of the flights from Africa to China are operated by Ethiopian Airlines, so it is possible that cases might pass through Ethiopia and affect destination countries.Looming threat of COVID-19 infection in Africa: act collectively, and fastThe report by Gilbert and colleagues 4 provides an important tool to map out the continental risk for the spread of COVID-19 in Africa, which should be used to inform a framework of action to prepare the continent for any potential importation and spread of COVID-19.", [["COVID-19", "CHEMICAL", 200, 208], ["infection", "DISEASE", 209, 218], ["COVID-19", "CHEMICAL", 514, 522], ["COVID-19", "ORGANISM", 200, 208], ["COVID", "TEST", 200, 205], ["COVID", "TEST", 372, 377], ["COVID", "TEST", 514, 519], ["infection", "OBSERVATION", 209, 218]]], ["The strategy must be comprehensive, and member states, donors, and partners should immediately commit to releasing financial resources to support country-customised implementation plans derived from the strategy.", [["donors", "ORGANISM", 55, 61]]], ["To help develop a common strategy that will allow for effective coordination, collaboration, and communication, the African Union Commission, Africa Centres for Disease Control and Prevention (Africa CDC), and WHO, in partnership with African countries, have established the Africa Taskforce for Coronavirus Preparedness and Response (AFTCOR).", [["Disease Control", "TREATMENT", 161, 176]]], ["The partnership has six work streams: laboratory diagnosis and subtyping; surveillance, including screening at points of entry and cross-border activities; infection prevention and control in healthcare facilities; clinical management of people with severe COVID-19; risk communication; and supply-chain management and stockpiles.", [["infection", "DISEASE", 156, 165], ["COVID", "DISEASE", 257, 262], ["people", "ORGANISM", 238, 244], ["people", "SPECIES", 238, 244], ["surveillance", "TEST", 74, 86], ["screening", "TEST", 98, 107], ["infection prevention", "TREATMENT", 156, 176], ["severe COVID", "PROBLEM", 250, 262], ["supply-chain management", "TREATMENT", 291, 314]]], ["Because mitigating the potential spread of COVID-19 in Africa will require rapid detection and containment, the laboratory work streams of AFTCOR, Africa CDC, and WHO are working closely to expeditiously scale up diagnostic testing capacity linked to enhanced surveillance and monitoring-eg, at the beginning of February, only two countries in Africa had the diagnostic capacity to test for COVID-19.", [["COVID-19", "CHEMICAL", 43, 51], ["COVID", "TEST", 43, 48], ["rapid detection", "TEST", 75, 90], ["diagnostic testing capacity", "TEST", 213, 240], ["enhanced surveillance", "TEST", 251, 272], ["monitoring", "TEST", 277, 287], ["COVID", "TEST", 391, 396]]], ["However, as of Feb 25, 2020, more than 40 countries would have been capacitated to accurately diagnose COVID-19 infection, thanks to the coordination efforts of AFTCOR.", [["infection", "DISEASE", 112, 121], ["AFTCOR", "PROTEIN", 161, 167], ["COVID-19", "SPECIES", 103, 111], ["infection", "PROBLEM", 112, 121], ["infection", "OBSERVATION", 112, 121]]], ["Second, any effective preparedness and response strategy for COVID-19 requires a committed political will; as such, the African Union Commission, Africa CDC, and WHO convened, on Feb 22, 2020, in Addis Ababa, Ethiopia, an emergency meeting of all ministers of health of 55 member states to commit to acting fast and collectively to develop and implement a coordinated continent-wide strategy.", [["COVID", "TEST", 61, 66]]], ["To prevent the occurrence of a social, health security, and economic tragedy, actions agreed at the emergency ministerial meeting will need to be acted on quickly, before any additional COVID-19 cases are introduced to the continent, and result in sustained human-tohuman transmission.", [["human", "ORGANISM", 258, 263], ["tohuman", "CELL", 264, 271], ["human", "SPECIES", 258, 263], ["human", "SPECIES", 258, 263]]], ["Third, commitment and release of financial resources from partners and donors before a crisis hits Africa will help anticipate demand and address supply chain management, mapping, and stockpiling of COVID-19 response needs, such as large quantities of personal protective equipment, gloves, surgical masks, coveralls, and hoods, and medical countermeasures like antiviral agents.", [["supply chain management", "TREATMENT", 146, 169], ["mapping", "TEST", 171, 178], ["COVID", "TREATMENT", 199, 204], ["personal protective equipment", "TREATMENT", 252, 281], ["gloves", "TREATMENT", 283, 289], ["surgical masks", "TREATMENT", 291, 305], ["coveralls", "TREATMENT", 307, 316], ["hoods", "TREATMENT", 322, 327], ["medical countermeasures", "TREATMENT", 333, 356], ["antiviral agents", "TREATMENT", 362, 378]]], ["Supplies of these items will be limited in Africa because of reduced manufacturing capacity.Looming threat of COVID-19 infection in Africa: act collectively, and fastFourth, national, regional, and international organisations need to cooperate and collaborate to optimise limited supplies, using a whole of government approach.", [["COVID-19", "CHEMICAL", 110, 118], ["infection", "DISEASE", 119, 128], ["COVID-19", "ORGANISM", 110, 118], ["reduced manufacturing capacity", "PROBLEM", 61, 91], ["COVID", "TEST", 110, 115], ["19 infection", "PROBLEM", 116, 128], ["a whole of government approach", "TREATMENT", 296, 326], ["infection", "OBSERVATION", 119, 128]]], ["Fifth, all member states will need to urgently develop and put in place proper quarantine and infection control protocols, including procedures for implementing social distancing (mass gathering and potential closure of public facilities).", [["infection", "DISEASE", 94, 103], ["infection control protocols", "TREATMENT", 94, 121], ["procedures", "TREATMENT", 133, 143], ["potential closure of public facilities", "TREATMENT", 199, 237], ["infection", "OBSERVATION", 94, 103]]], ["Medical staff at major hospitals must be trained in the proper protocols of quarantining individuals who are at-risk of COVID-19 infection, as well as isolation and safe treatment of patients who test positive.", [["infection", "DISEASE", 129, 138], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["COVID-19 infection", "PROBLEM", 120, 138], ["isolation", "TREATMENT", 151, 160], ["safe treatment", "TREATMENT", 165, 179], ["infection", "OBSERVATION", 129, 138]]], ["As the Director General of WHO has stated several times, the window of opportunity to act is narrowing.", [["narrowing", "PROBLEM", 93, 102], ["narrowing", "OBSERVATION", 93, 102]]], ["Africa needs to be supported to act now, and needs to act fast.Looming threat of COVID-19 infection in Africa: act collectively, and fastJNN is the director of the Africa CDC and a WHO special envoy on COVID-19.", [["COVID-19", "CHEMICAL", 81, 89], ["infection", "DISEASE", 90, 99], ["COVID-19", "ORGANISM", 81, 89], ["COVID-19", "DNA", 202, 210], ["COVID", "TEST", 81, 86], ["COVID", "TEST", 202, 207], ["infection", "OBSERVATION", 90, 99]]]]}